Immunotherapy in hematologic malignancies: achievements, challenges and future prospects.

Introduction

Cancer immunosurveillance is a process in which multiple innate and adaptive immune effector cells and molecules are involved in the recognition and killing of cancer cells. 1 Extrinsic immune stress can either prevent tumor growth, development and survival or promote tumor growth by both sculpting the immunogenicity of the tumor or inhibiting the anti-tumor immune response. 1 , 2 Immune editing is considered one of the key parts of why tumors could evade the surveillance and lie dormant in the host body for years before re-emerging through the “equilibrium” and “senescence”. 3 With the growth of poorly-immunogenic variants and the destruction of the host immune system, cancer cells ultimately evade immunosurveillance. 4 Cancer cells employ many strategies to suppress the immune system of the human body, so that they can survive in every stage of the anti-tumor immune responses. 5 The generation of anti-tumor immune response is a complicated and multi-step process and Chen et al. refer to these steps as the “Cancer-Immunity Cycle”. 6 As for cancer patients, the “Cancer-Immunity Cycle” does not perform optimally. Any abnormality in these steps can lead to the failure of the “Cancer-Immunity Cycle” and consequent cancer immune evasion. 7 Immunotherapies could fight against cancer by harnessing the immune system and restoring anti-tumor immunity. 8 Constructed over decades, immunotherapies have begun to demonstrate such promising results in treating cancer patients and have been selected as the “Breakthrough of the Year for 2013”. 8 – 10

Hematologic malignancies refer to malignant diseases originating from the lymphohematopoietic system and may involve all systems and organs throughout the body. Hematologic malignancies mainly include acute leukemia, chronic leukemia, lymphoma, multiple myeloma (MM), myelodysplastic syndrome (MDS), and myeloproliferative neoplasm (MPN). Acute lymphoblastic leukemia (ALL) is characterized by the abnormal proliferation of a huge number of immature lymphocytes. 11 Acute myeloid leukemia (AML) is the most commonly occurring acute leukemia in adults and its incidence increases with age. As a result of genetical mutations in hematopoietic stem/progenitor cells, AML is a highly heterogeneous disease. 12 , 13 Lymphomas are typically divided into two categories, Hodgkin lymphoma (HL, which accounts for about 10% of all lymphomas) and non-Hodgkin lymphoma (NHL). 14 NHL is the most prevalent kind of lymphoma arising from lymphocytes that are at various stages of development and the characteristics of the specific lymphoma subtype reflect those of the cell from which they originated. 14 Diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL) represent the most common types of NHL. HL, also known as Hodgkin’s disease, is a rare type of lymphoma with unique histologic, immunophenotypic and clinical features. 15 , 16 HL consists of two discrete disease entities: classical HL (cHL), which accounts for the majority of HL cases and nodular lymphocyte predominant HL. 16 MM, MDS and MPN are most common in elderly patients. MM accounts for about 10% of hematologic malignancies and cannot currently be cured. It typically begins as an asymptomatic precursor, either a monoclonal gammopathy of undetermined significance or smoldering multiple myeloma. 17 MDS is a clonal disorder characterized by ineffective hematopoiesis and a tendency to evolve into AML. 18 With increasing advances in chemotherapy, radiotherapy and targeted therapy, the overall response rate (ORR) of cancer patients has improved significantly. Historically, multi-drug chemotherapy has been the cornerstone of the treatment of both pediatric and adult patients with hematologic malignancies. However, over the past decade, many patients still face treatment failure due to relapse and resistance. The molecular characteristics of hematologic malignancies are highly heterogeneous, leading to considerable challenges in precision medicine and individualized treatment.

With the potential to induce long-term remission in patients with refractory or relapsed (R/R) hematologic malignancies, immunotherapy has already led to a paradigm shift in cancer therapy and tremendous success in the clinic. Furthermore, hematologic malignancies in this setting have some unique characteristics that make these cancers well-suited as targets for immunotherapy. 19 Immune cells and cancer cells are in constant interconnection with each other within the hematopoietic system, enabling an environment that is conducive to immune surveillance. Since the cellular origins of malignancies are the same as that of the immune system, the nature of these cancer cells is immunostimulatory. However, this may meanwhile lead to deficit and hindered immune responses. There has been accelerating advancement of cancer immunotherapies based on various strategies to harness the host immune system. Different immunotherapeutic approaches have their advantages but also shortcomings that need to be addressed. This review will provide perspectives on the applications and clinical considerations of immunotherapies so that clinicians can acquire timely information about such revolutionary therapeutic options. Here, we first outline the recent advances made toward understanding multiple categories of immunotherapies in the treatment of hematologic malignancies. We further discuss the specific mechanisms of action, summarize the clinical trials and outcomes of immunotherapies in hematologic malignancies, as well as the adverse effects (AEs) and toxicity management and then provide insights into future directions.

The history of immunotherapy in hematologic malignancies

As for the field of treating hematologic malignancies, immunotherapy mainly involves targeted antibodies, immune checkpoint inhibitors (ICIs), tumor vaccines, adoptive cell therapy (ACT), and stem cell transplantation (Fig. 1a ). The journey of the history of immunotherapy for hematologic malignancies is summarized in (Fig. 1b ). The allogeneic hematopoietic stem cell transplantation (allo-HSCT) is one of the oldest forms of cancer immunotherapy. 20 The allo-HSCT was first applied to disease treatment in 1968 by E. Donnall Thomas, who would later win the Nobel Prize for being a pioneer in this technology and is praised as “the father of stem cell transplantation”. 20 The allo-HSCT was primarily performed for treating leukemia in 1975 and lymphoma in 1978. Since then, HSCT has been used worldwide to treat serious blood disorders. Although it has been referred to as “the bluntest weapon of chemotherapists”, as it indeed aims to eradicate and restore the hematopoietic and immune systems, it still occupies a pivotal position and gives patients the possibility of a cure. It wasn’t until the end of the 20th century that new immunotherapy approaches emerged. Rituximab, a kind of anti-CD20 monoclonal antibody (mAb), was the first to be approved by the United States Food and Drug Administration (FDA) for the treatment of cancer in 1997 and since then has become the prototype for anti-CD20 mAbs and the backbone treatment regimen for B-cell malignancies, such as DLBCL, CLL (chronic lymphoblastic leukemia) and FL. 21 As well, the rituximab, combined with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen, has become the first-line therapy for patients with NHL. 22 Meanwhile, more types of mAbs have been developed, such as tafasitamab (anti-CD19 mAb) for DLBCL, 23 daratumumab (anti-CD38 mAb) for MM, 24 and lintuzumab (anti-CD33 mAb) for AML. 25 However, for R/R patients, mAbs often lose their clinical effectiveness and the development of bispecific antibodies (bsAbs) may allow for the continuation of treatment. Blinatumomab, an anti-CD3/CD19 BiTE (bispecific T cell engager), was the first FDA-approved BiTE for the treatment of R/R precursor B-cell ALL (pre-B-ALL) and has also achieved remarkable curative effects. 26 Over the past several decades, antibody-drug conjugates (ADCs) have been evaluated in a variety of clinical trials of hematologic malignancies. The brentuximab vedotin was approved by the FDA in 2011 for treating relapsed HL and systemic anaplastic large cell lymphoma (SALCL). 27 , 28 WT1 (Wilms’ tumor gene 1) peptide-based tumor vaccine was first used in patients with overt leukemia from MDS or MDS with myelofibrosis in the year 2002. 29 , 30 As another rising star in immunotherapy, ICIs have entered the field of treatment for hematologic malignancies due to their great success in solid tumors. PD-1/PD-L1 (programmed death receptor 1, programmed death receptor ligand 1) inhibitors play a notable clinical role in B-cell lymphoma, especially in HL. 31 CTLA-4 (cytotoxic T-lymphocyte antigen number 4) inhibitor also demonstrates certain curative effects in patients with HL and AML. 32 There’re lots of clinical trials of these drugs applied to different kinds of hematologic malignancies to overcome resistance and relapse. ACT is the most popular immunotherapy for patients with R/R hematologic malignancies, such as TCR-T (T cell receptor-engineered T) cell, γ/δ-T (gamma/delta T) cell, NK (nature killer) cell and CAR-NK (chimeric antigen receptor nature killer) cell and especially CAR-T (chimeric antigen receptor T) cell therapy. 33 – 35 Fred Hutchison Cancer Institute used CAR-T cells for the first time to treat B-cell lymphoma and proved its safety in the year 2008. And in the year 2010, two patients with CLL first received CAR-T transfusion and achieved CR (complete remission) and the CAR-T cells were still detected in vivo after 10 years of follow-up. 36 In 2012, Emily, an American patient with B-ALL, received CAR-T therapy and was cured. She has been disease-free for almost 11 years up to now. The development of CAR-T therapy has been greatly boosted due to the launch of large clinical trials, such as axicabtagene ciloleucel and tisagenlecleucel, as well as the FDA’s approval of the first commercialized CAR-T cell product in 2017. At present, CAR-T therapy has achieved remarkable results in R/R ALL, CLL, NHL, and MM. 37 There are many CAR targets for each malignant disease and the number of treatment lines is gradually advancing. In summary, immunotherapy has achieved rapid development in recent years, which provides more possibilities and hopes for the cure of hematologic malignancies. Fig. 1 The development of immunotherapy for hematologic malignancies. a Types of immunotherapies for treating hematologic malignancies. b The journey of the history of immunotherapy for hematologic malignancies

Overview of immunotherapies in hematologic malignancies

HSCT

HSCT is an effective means of curing a range of hematologic diseases. It is done by harvesting functional hematopoietic stem cells from the patients or a healthy donor and transplanting them to the patients to replace their dysfunctional blood system. Initially, bone marrow was considered as a source of stem cells for transplantation. However, within the last two decades, peripheral blood stem cells have replaced bone marrow stem cells and become the main stream. 38 The replacement indicates no impact on overall survival (OS) except a greater risk of graft-versus-host disease (GVHD). 38 Fortunately, the management of GVHD is strict and upgraded continuously. 39 The allo-HSCT is usually considered as a preferred choice for hematologic malignancies. 40 , 41 But due to the greater risk of GVHD, allo-HSCT is still restrictive to the patient’s own status. This led to the emergence of reduced-intensity stem cell transplantation (RIST), which is associated with less morbidity and mortality and can be performed in a wider range of patients. 42 , 43 Meanwhile, cord blood transplantation with a low relapse rate and chronic GVHD was also promoted but was later hampered by a high incidence of infection and transplant-related mortality. However, the safety and feasibility of HSCT using single UM171-expanded cord blood were validated in patients with malignant hematologic diseases who did not have a suitable HLA (human leukocyte antigen)-matched donor, indicating the potential to overcome the disadvantages of other cord blood transplantation while maintaining the benefits of low risk of chronic GVHD and relapse. 44 Haploidentical family donors, such as parents, children, or haploidentical siblings, offer the advantage of rapid donor availability. Currently, two methods are most commonly used for haploidentical hematopoietic stem cell transplantation (haplo-HSCT): (i) granulocyte colony-stimulating factor (G-CSF) plus anti-thymocyte globulin-based regimen with non-manipulated T-cell enriched grafts, which was originated by the Peking group in China; (ii) post-transplantation cyclophosphamide-based regimens with non-manipulated T-cell enriched grafts, which was initiated by the Baltimore group in the United States. 35 , 45 – 47 With the development of haplo-HSCT, strategies to address the associated side effects have become a research trend. A substantial improvement in non-relapse mortality and supportive care (e.g., treatment and prevention of infections or GVHD) has contributed to improved OS of allogeneic transplantation over the past decades. 48 , 49 In addition, to overcome barriers such as donor availability, novel transplantation strategies have been refined. For example, post-transplant cyclophosphamide for GVHD prevention after haploidentical donor transplants has shown similar outcomes with a reduced risk of GVHD. 50 , 51 The recurrence of the malignancy remains the most prevalent cause of post-transplant failure or even death, emphasizing the importance of enhancing the immune system in the treatment of hematologic malignancies and how far we have yet to go to achieve a cure. Although much is still being discovered, we have learned a great deal about how the host immune system affects the treatment of hematologic malignancies from the growing and evolving field of allogeneic transplantation, which is helping to advance the field of novel immunotherapies. 20

mAbs

The mAbs are highly homogeneous IgG antibodies produced from a single B cell clone and directed against only specific antigenic epitopes. The first-generation mAbs are derived from mice and typically prepared using the hybridoma technique, which is based on cell fusion technology that fuses sensitized murine B cells with the capacity to secrete specific antibodies and myeloma cells with the capacity to multiply indefinitely into B cell hybrids. 52 Through culturing individual hybridoma cells with such properties into cell populations, it is possible to generate antibodies against corresponding antigenic epitopes. However, murine mAbs can be recognized by the immune system and result in human anti-mouse antibody reactions, particularly human anti-mouse antibody (HAMA), 53 – 55 resulting in limited efficacy of mAbs and potentially serious AEs. Since then, mAbs have gradually evolved toward the trend of humanization. The second generation is human/mouse chimeric mAbs (with the suffix -ximab, e.g., rituximab), 21 using chimeric antibody or humanized modified monoclonal antibody technology. 56 , 57 Both approaches greatly reduce the human anti-mouse immune response, but a certain degree of immunogenicity still exists because they contain mouse-derived sequence fragments. The subsequent mAbs are fully humanized (with the suffix -zumab and -mumab), with the amino acid sequences that make up the antibodies all derived from humans. These mAbs are mainly manufactured by phage display screening, 58 , 59 yeast surface display, 60 , 61 human hybridoma technology and single B-cell antibody preparation technology, 62 or even metabolic strategy like glycoengineering. 63 Meanwhile, these mAbs have a 100 percent human component and reduced immunogenicity, although they may still have immunogenicity due to anti-idiotype antibodies.

The mAbs are the major component of cancer immunotherapy. 64 mAbs have various mechanisms of action and each type of antibody has multiple mechanisms of action in parallel, mobilizing multiple aspects and components of immunity to ultimately kill tumor cells. The mAbs, when combined with their targets, can kill cancer cells in two ways (Fig. 2a ): (i) direct induction of apoptosis through programmed cell death (PCD); 65 (ii) immune-mediated mechanisms, mainly including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and antibody-dependent macrophage-mediated phagocytosis due to the binding of Fc and FcγR (Fc gamma receptor). 65 – 70 Fig. 2 Mechanisms of action of four kinds of immunotherapy drugs. a The monoclonal antibodies (mAbs), when combined with their targets, can kill cancer cells by direct induction of apoptosis through programmed cell death, antibody-dependent cell cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent macrophage-mediated phagocytosis. b The BiTE ((bispecific T cell engager) molecule usually targets one CD3 molecule and one tumor antigen simultaneously. Thus, in addition to the anti-cancer role of the tumor antigen-targeted antibody, it can promote the activation and recruitment of CD3 + T cells. c After bound to the tumor surface antigen, the antigen undergoes endocytosis and the antibody-drug conjugates (ADCs) will be internalized into the tumor cell and subsequently transported to the lysosome to release the cytotoxic payload, which can induce apoptosis and kill surrounding cancer cells through bystander effects. d The blockade of PD-1 or its ligands PD-L1 and PD-L2 can help to restore the anti-tumor immunity of the body and simultaneously enhance the lysis effect of cytotoxic T cells to achieve the effect of tumor eradication. CTLA-4 inhibitors can block the binding between CTLA-4 molecule and B7 during T cell activation, increase the level of the recognition of T cells to tumor-associated antigens (TAAs) and enhance the anti-tumor responses of the body’s immune effector cells

Rituximab is a first-generation anti-CD20 mAb. Ofatumumab is one kind of second-generation, fully-humanized anti-CD20 mAb that binds to a different site from rituximab and was approved by the FDA for the treatment of CLL in 2009, as well as in combination with chlorambucil for the treatment of CLL in 2014. 71 , 72 Obinutuzumab is another second-generation anti-CD20 mAb and was approved by the FDA in combination with chlorambucil for the treatment of CLL in 2013 and in combination with bendamustine for the treatment of R/R FL in 2016. 73 , 74 Daratumumab is an anti-CD38 mAb that was FDA-approved for the treatment for patients with MM. 24 Elotuzumab is an anti-CS1 mAb that was approved by FDA in combination with lenalidomide and dexamethasone for the treatment of R/R MM in November 2015. 20 Furthermore, the FDA-approved mAbs, such as daratumumab, 75 – 78 elotuzumab, 79 – 81 and isatuximab, 82 – 84 have already revolutionized the standard of care for treatment of MM, or even in the front-line therapeutic setting. Up to now, as presented in Table 1 , many kinds of mAbs have been developed for the treatment of hematologic malignancies with their targets involving CD20, CD19, CD22, CD38, CS1 (SLAMF7), CD52, CD40, CD80, CD74, and CD33. 25 , 74 – 114 Table 1 Representative antibody-based drugs used for treating hematologic malignancies Type Drug Target Indication If FDA approved? Refs. mAbs Rituximab CD20 B-NHL Yes 85 – 88 Ofatumumab CD20 CLL Yes 90 Obinutuzumab CD20 DLBCL, MCL, FL, CLL Yes 74 , 92 – 95 Ibritumomab tiuxetan CD20 B-NHL Yes 89 Veltuzumab CD20 B-NHL, CLL No 91 Ocrelizumab CD20 FL No 96 Ocaratuzumab CD20 B-NHL, CLL No 97 – 99 Ublituximab CD20 CLL No 354 Epratuzumab CD22 B-NHL No 114 Tafasitamab CD19 DLBCL, FL Yes 23 , 352 Inelituzumab CD19 B-NHL No 112 Galiximab CD80 FL No 113 Alemtuzumab CD52 PTCL, CLL Yes 100 , 101 MDX-060 CD30 HL, ALCL, T-NHL No 102 , 103 Daratumumab CD38 MM Yes 75 – 78 Isatuximab CD38 MM Yes 82 – 84 Dacetuzumab CD40 MM, NHL, DLBCL No 104 – 106 Elotuzumab CS1 (SLAMF7) MM Yes 79 – 81 Milatuzumab CD74 MM, MCL, FL, CLL Yes 107 – 110 Lintuzumab CD33 AML No 25 BI 836858 CD33 AML No 111 bsAbs Blinatumomab CD19/CD3 B-ALL, B-NHL, DLBCL Yes 124 – 126 AFM11 CD19/CD3 B-ALL No 127 Mosunetuzumab CD20/CD3 FL Yes 131 Glofitamab CD20/CD3 B-NHL, DLBCL No 132 , 133 Epcoritamab CD20/CD3 B-NHL, DLBCL/LBCL, FL No 134 , 135 Odronextamab CD20/CD3 B-NHL, DLBCL No 136 Plamotamab CD20/CD3 B-NHL, DLBCL No 137 , 138 Teclistamab BCMA/CD3 MM Yes 150 – 154 Linvoseltamab BCMA/CD3 MM No 155 , 156 Elranatamab BCMA/CD3 MM No 157 , 158 Alnuctamab BCMA/CD3 MM No 159 AMG420 BCMA/CD3 MM No 162 TNB-383B BCMA/CD3 MM No 163 AMG701 BCMA/CD3 MM No 164 PF-06863135 BCMA/CD3 MM No 165 Bi38-3 CD38/CD3 MM No 160 AMG424 CD38/CD3 MM No 161 ISB-1342 CD38/CD3 MM No 166 GBR-1342 CD38/CD3 MM No 167 Talquetamab GPRC5D/CD3 MM No 168 Cevostamab FcRH5/CD3 MM No 169 Flotetuzumab CD123/CD3 AML/MDS No 142 , 146 XmAb14045 CD123/CD3 AML No 147 AMG330 CD33/CD3 AML No 143 AMV564 CD33/CD3 AML/MDS No 144 JNJ-63709178 CD33/CD3 AML No 145 MCLA117 CLEC12A/CD3 AML No 148 ESK1-BiTE WT1/CD3 AML No 149 AFM26 BCMA/CD16A MM No 175 TandAb CD30/CD16A HL No 176 CS1-NKG2D biAb CS1/NKG2D MM No 178 tsAbs TsAb CD19/CD22/CD3 B-ALL No 177 161533 TriKE CD16/IL-15/CD33 AML No 179 CiTE CiTE PD-L1/CD33/CD3 AML No 613 SMITE SMITE CD19/CD3 & CD28/PD-L1 CD19-positive lymphoma or leukemia No 614 ADC Inotuzumab ozogamicin CD22 B-NHL, B-ALL Yes 187 , 188 Moxetumomab pasudotox CD22 HCL, B-ALL Yes 189 , 190 Pinatuzumab vedotin CD22 DLBCL, FL No 191 BL22 CD22 B-ALL, HL No 192 , 193 Polatuzumab vedotin CD79b B-NHL, DLBCL, FL Yes 191 , 209 , 210 Loncastuximab tesirine CD19 B-NHL, DLBCL Yes 203 , 204 Coltuximab ravtansine CD19 B-ALL, B-NHL No 205 , 206 Denintuzumab mafodotin CD19 B-ALL No 207 Combotox CD19 and CD22 B-ALL No 208 Naratuximab emtansine CD37 B-NHL No 213 AGS67E CD37 B-NHL, T-NHL, CLL, AML No 214 , 215 Brentuximab vedotin CD30 cHL, PTCL, ALCL, CTCL Yes 181 , 194 – 197 Camidanlumab tesirine CD25 cHL No 221 Belantamab mafodotin BCMA MM Yes 211 HDP-101 BCMA MM No 212 Indatuximab ravtansine CD138 MM No 216 Lorvotuzumab mertansine CD56 MM No 217 Milatuzumab doxorubicin CD74 MM No 218 LM-305 GPRC5D MM No 219 Gemtuzumab ozogamicin CD33 AML Yes 198 Vadastuximab talirine CD33 AML No 199 , 200 IMGN779 CD33 AML No 201 , 202 Pivekimab sunirine CD123 AML No 220 mAbs monoclonal antibodies, bsAbs bispecific antibodies, tsAb trispecific antibodies, CiTE bifunctional checkpoint inhibitory T cell–engager, SMITE Simultaneous multiple interaction bispecific T-cell engager, ADC antibody-drug conjugate, FDA Food and Drug Administration, B-NHL B-cell non-Hodgkin lymphoma, DLBCL diffused large B-cell lymphoma, FL follicular lymphoma, MCL mantle cell lymphoma, CLL chronic lymphocytic leukemia, cHL classical Hodgkin lymphoma, ALCL anaplastic large cell lymphoma, PTCL peripheral T-cell lymphoma, MM multiple myeloma, AML acute myelocytic leukemia, B-ALL B-cell acute lymphoblastic leukemia, MDS myelodysplastic syndromes, HCL hairy cell leukemia, CTCL cutaneous T-cell lymphoma, BCMA B cell maturation antigen, GPRC5D G protein-coupled receptor, FcRH5 Fc receptor homolog 5, CLEC12A C-type lectin domain family 12 member A, NKG2D natural killer cell group 2 member D

bsAbs

In complex disease pathogenesis, multiple mediators facilitate the stimulation of different signaling pathways or promote overlapping signaling cascades, which limits the therapeutic efficacy of the targeting of a single molecule. 115 Therefore, the bsAbs, which combine the binding sites of two mAbs in the same molecule, were developed and transformed into immunotherapy. 116 The emerging bsAbs, exemplified by BiTEs, which promote the activation and recruitment of CD3 + T cells, have facilitated the fast development of cancer immunotherapy in hematologic malignancies. 117 – 120 Similar as mAbs, the targeted antigens of bsAbs must be selected from tumor-associated antigens (TAAs) with high specificity and high correlation with the malignant phenotype of the tumor. 120 , 121 The bsAbs are mainly divided into three categories according to their targets: (i) antibodies that target two different tumor antigens; (ii) antibodies that target one tumor antigen and one immune-related molecule, such as CD3 for BiTE; and (iii) antibodies that target two immune-related molecules. 117 Because the BiTE molecule usually targets one CD3 molecule and one tumor antigen simultaneously, it belongs to the second category of bsAbs (Fig. 2b ). 117 BiTEs are the main patterns by which bsAbs work in hematologic malignancies, such as blinatumomab (anti-CD19/CD3 bsAb) approved by the FDA for R/R ALL, 26 , 122 – 126 AFM11 for B-ALL, 127 anti-CD19/CD3 or anti-CD20/CD3 bsAbs for B-NHL, 128 – 138 anti-CD33/CD3, CD123/CD3, WT1/CD3, or CLEC12A (C-type lectin domain family 12 member A)/CD3 bsAbs for AML or MDS, 139 – 149 and anti-BCMA (B cell maturation antigen)/CD3 or CD38/CD3 bsAbs for MM. 150 – 167 In addition, the anti-GPRC5D (G protein-coupled receptor, family C, group 5, member D)/CD3 and anti-FcRH5 (Fc receptor homolog 5)/CD3 bsAbs were also used for the treatment of MM. 168 , 169 Table 1 presents the bsAbs currently developed for hematologic malignancies. Although BiTEs have been proven to be efficient in many R/R hematologic malignancies, several patients still show no responsiveness to BiTE therapy. It is not only due to defects in the structure itself but also the immune escape, involving the aspects of loss of target antigen expression, disrupted trafficking of the target antigens and extramedullary lesions. 170 – 174 Based on this fact, bsAbs and trispecific antibodies (tsAbs) engaging NK cells have also been explored in pre-clinical and/or clinical studies. 175 – 179 Ross et al. reported the NK-cell mediated lysis of BCMA-positive MM cell lines induced by AFM26 (anti-BCMA/CD16A bsAb). 175 Moreover, the anti-CD19/CD22/CD3 tsAb that site-specifically fuses anti-CD19 scFv (single chain variable fragment) and anti-CD22 nanobody to CD3 antigen-binding fragment, was designed for treating patients with B-ALL. 177 It demonstrated enhanced anti-tumor efficacy and the capacity to overcome immune evasion when compared with the corresponding bsAbs alone or multiple antibodies in combination. 177 The therapeutic effects provide a new direction for the development of bispecific and even multi-specific antibodies.

ADCs

The mAbs have the advantage of a longer plasma half-life, yet they are not inherently cytotoxic. In contrast, small molecule cytotoxic agents commonly utilized in chemotherapy have high cytotoxicity and relatively low costs of production, but they are poorly targeted to cancer cells and have a plasma half-life of only a few hours. 180 – 182 The concept of utilizing the specific binding properties of mAbs as a mechanism to selectively deliver cytotoxic agents to tumor cells is an appealing approach to overcome the challenges of increasing the therapeutic potentials of cytotoxic agents. All three components of an ADC, the antibody, cytotoxic payload, and the linker chemistry that joins them together, are important for the design of an effective anticancer agent. Mechanistically, ADC differs from the previously mentioned mAb and bsAb in that after it binds to the tumor surface antigen, the antigen undergoes endocytosis and ADC will be internalized into the tumor cell and subsequently transported to the lysosome to release the cytotoxic payload (Fig. 2c ). The released toxic payload can induce apoptosis and kill surrounding cancer cells through bystander effects (Fig. 2c ). 183 Perhaps the most essential aspect of developing an effective molecule is the selection of the targeted antigen to which the ADC will bind. 184 – 186 Advances in related technology, improvements in the selection of cytotoxic agents and the use of smaller conjugates have all dramatically enhanced the potential clinical benefits of ADCs. Several ADCs have been designed and used for clinical use in hematologic malignancies and their targets include CD22, 187 – 193 CD30, 181 , 194 – 197 CD33, 198 – 202 CD19, 203 – 208 CD79, 191 , 209 , 210 BCMA, 211 , 212 CD37, 213 – 215 CD138, 216 CD56, 217 CD74, 218 GPRC5D, 219 CD123, 220 and CD25, 221 (Table 1 ). The initial excitement for ADCs has risen and then fallen with the approval and subsequent withdrawal of gemtuzumab ozogamicin in the years 2000 and 2010, respectively. 20 With effectiveness in the treatment of R/R HL and SALCL, brentuximab vedotin, an anti-CD30 antibody linked to a microtubule inhibitor monomethyl auristatin E (MMAE), received FDA approval for cancer treatment in 2011 and for post-autologous HSCT consolidation in 2015. 196 , 222 Inotuzumab ozogamicin is comprised of a humanized anti-CD22 mAb conjugated to calicheamicin, a cytotoxic antibiotic agent and was as monotherapy for the treatment of CD22-positive B-ALL in 2017. 180 , 223 , 224 Vadastuximab talirine (SGN-CD33A, 33A), a novel ADC consisting of pyrrolobenzodiazepine dimers linked to a mAb targeting CD33, has demonstrated activity and a tolerable safety profile as a single agent in patients with AML. 199 Belantamab mafodotin 225 targeting BCMA is currently the only ADC approved by the FDA for MM. Furthermore, other TAAs expressed highly on MM cells are also designed as targets of ADCs. Clinical trials of lorvotuzumab mertansine (anti-CD56 ADC), 217 indatuximab ravtansine (anti-CD138 ADC), 216 milatuzumab doxorubicin (anti-CD74 ADC), 218 and the first anti-GPRC5D ADC, LM-305, 219 are ongoing in present.

ICIs

Although more ICIs have been developed already, 226 , 227 anti-CTLA-4 (ipilimumab), PD-1 (pembrolizumab, nivolumab, pidilizumab) and PD-L1 antibodies (atezolizumab, avelumab and durvalumab) have been the focus of current clinical consideration of checkpoint inhibitors. 32 PD-1 is a prominent immunosuppressive trans-membrane molecule that is expressed on the surface of T cells. 228 In the tumor microenvironment (TME), T cells express high levels of PD-1 molecules, which can bind to PD-L1 on tumor cells or other immune cells and PD-L2 on macrophages and dendritic cells (DCs). This will inhibit the intracellular signaling transduction of T cells, reduce effector T cell activity, induce T cell apoptosis, negatively regulate the anti-tumor immune response and ultimately cause tumor cells to undergo immune escape. 229 – 233 In addition to surface PD-L1 molecule, tumors can also secrete soluble PD-L1, which more readily binds to PD-1 on T cells. 234 , 235 Furthermore, immune cells in TME sometimes are accomplices as well. Despite the direct suppression of T cells, Treg-expressed CTLA-4 can deplete CD80/CD86 by trogocytosis to release free PD-L1 on antigen-presenting cells. 236 Presence of PD-L1-expressing DCs and macrophages in TME may play a dominant role in mediating T-cell immunosuppression. 234 The use of mAbs or inhibitors targeting PD-1 or its ligands PD-L1 and PD-L2 can selectively block PD-1 and ligand binding between tumor cells and T cells, thereby helping to restore the anti-tumor immunity of the body and simultaneously enhance the lysis effect of cytotoxic T cells to achieve the effect of tumor eradication (Fig. 2d ). 237 Once the “Cancer-Immunity Cycle” is established, it can produce long-lasting anti-tumor effects. PD-1 inhibitors also enhance the efficacy through the activation of other immune cells within the TME. 238 A robust anti-tumor T-cell response is induced in tumor-draining lymph nodes by blocking PD-L1-mediated inhibition of host antigen-presenting cells (APCs) at off-tumor sites. 239 A further opinion has been recently expressed that the activity of ICI is not limited to TME. PD-1 blockade drives the expansion of a subset of PD-1 low CD8+ progenitor cells with self-renewal properties, resulting in the mobilization of stem-like precursor CD8 + T cells that reside outside the tumor. 240 CTLA-4 molecule is normally expressed on the surface of CD4+ and CD8 + T cells and can bind with high affinity to B7 ligands on APCs, producing signals that inhibit T cell activation, reduce cytokine production and decrease the anti-tumor immune response. 241 , 242 CTLA-4 inhibitors block the co-stimulatory signal between CTLA-4 molecule and Fc on the surface of regulatory T cells, which can induce regulatory T cell death; in addition, this can also block the binding between CTLA-4 molecule and B7 during T cell activation, increase the level of T cell recognition to TAAs and enhance the anti-tumor responses of the immune cells (Fig. 2d ). 243 – 245 T cell dysfunction, the metabolic profile of CD8 + T cells and immunosuppressive factors lead to resistance of ICIs. 246 – 249 The use of PD-1 blockade can also induce anti-PD-1 resistance by induction of dysfunctional PD-1+CD38 high CD8+ cells. 250 Therefore, combination therapy of ICIs is emerging in the treatment of hematologic malignancies. 251 – 253

ACTs

ACT is a kind of immunotherapy in which autologous or allogeneic immune effector cells, activated and expanded in vitro, are infused into the patient. Such therapies are divided into non-specific and specific cellular therapies. Non-specific cellular therapy includes the direct infusion of cytokine-induced killer (CIK) cells, tumor-infiltrating lymphocytes (TIL), γ/δ T cells and NK cells, some of which have been used for hematologic malignancies. 254 – 258 The mechanism by which non-specific cellular therapy alleviates tumor symptoms is to boost the immunity of the entire body, leading to limited efficacy. Therefore, specific cellular therapies, particularly CAR-T cells, have become more popular in clinical studies. 259 , 260 An incredible area of immunotherapy for hematologic malignancies is the development and refinement of CAR-T cell therapy. Such therapies involve not only targeting tumor antigens but also augmenting these targeted immune effectors. CAR-T cells are designed to express CAR that aims to target specific tumor surface antigens with antigen specificity and HLA independence and is therefore not dependent on MHC (major histocompatibility complex) expression. CAR-NK cells, not only recognize tumor antigens specifically via the CAR but also eliminate tumors by the NK cell receptor itself. NK cell activity depends on the balance of stimulatory and inhibitory signals and is antigen non-specific. Targeted lysis of CAR-NK cells is based on CAR-dependent and NK receptor-dependent mechanisms and this lysis effect is also indicated for antigen-negative cancer cells. 34 , 261 , 262 The main sources of CAR-NK cells are usually peripheral blood, cord blood, induced pluripotent stem cells (iPSCs) and NK92 cell lines. Since CAR-T therapy has the largest number of clinical trials and the widest range of applications in the field of cell therapy in hematologic malignancies, especially for multi-line therapy-refractory patients, we will focus on CAR-T therapy in the following sections.

The design of the CAR is the pivotal issue and has undergone several updates throughout the evolution of CAR-T therapy (Fig. 3a ). Eshhar et al. were the first to construct the CAR-T cells for the expression of antigen receptors. 263 The intracellular structural domain of first-generation CAR-T cells contains only the signal transduction structural domain CD3-ζ, so that CAR-T cells have poor proliferative abilities and a short survival time in vivo, due to the absence of co-stimulatory signaling and cytokine signaling, such as interleukin-2 (IL-2). 264 , 265 The co-stimulatory structural domain CD28 or 4-1BB (also known as CD137) were integrated with the CD3-ζ molecule in the design of the second-generation CAR-T cells, which allowed CAR-T cells to continuously proliferate and induce enhanced anti-tumor activity. 266 , 267 The second-generation CAR-T cells, which are the most widely used in clinical practice, were able to exert anti-tumor effects even in the absence of exogenous costimulatory molecules. 268 Two different costimulatory domains (CD28/4-1BB or ICOS/4-1BB) are present in third-generation CAR-T cells. 269 – 271 The fourth-generation CAR-T cells incorporate cytokines or co-stimulatory ligands to further enhance T-cell responses, or suicide genes to enable CAR-T cells to self-destruct when needed. 272 , 273 The fifth-generation CAR-T cell is also derived from the second-generation and includes a shortened cytoplasmic IL-2 receptor β chain domain (IL-2Rβ) and a STAT3 binding moiety. 274 This design enables the fifth-generation CAR-T cells to enhance the T cell receptor (TCR) and cytokine-driven JAK-STAT signaling pathways to promote the proliferation and activation of the bioengineered T cells. 274 In addition to improvements through co-stimulatory domains and cytokines, more important is the design of the antigen-binding region scFv of CARs. The earliest scFv targeting CD19 was also of murine origin (FMC63) and it would generate murine-derived mAbs, namely anti-CAR immune responses. Moreover, this response has also been shown to affect CAR-T efficacy and even lead to late relapse. 275 , 276 Therefore, researchers are continuously working on humanizing scFv fragments and directly design fully human CAR fragments to reduce the occurrence of this response and its impact on efficacy. 277 – 279 Besides, more novel types of CAR-T cells are being developed to improve the flexibility of CAR target recognition. To address the problem of wait for a long time, the “off-the-shelf” CAR-T cells, in which all T cells are derived from healthy donors, have been developed. 280 , 281 The universal CAR-T cells replace scFv extracellular structural domain used in previous generations of CAR T cells with an adapter-specific recognition structural domain which binds to an adaptor molecule specific to a tumor target. This design enables CAR-T cells to recognize multiple antigens by separating the antigen-targeting structural domain from the T-cell signaling unit. Fig. 3 The evolution of CAR design and the process of CAR-T therapy in clinic. a The design of the CAR has undergone several updates throughout the evolution of CAR-T therapy. To date, there have been five generations of CAR structures. b CAR-T cell therapy is a multi-step process that involves selecting eligible patients, collecting cells, manufacturing CAR-T cells, lymphodepletion and infusion of CAR-T cells and subsequent longitudinal follow-up

CAR-T cell therapy is a multi-step process that involves selecting eligible patients, collecting cells, manufacturing CAR-T cells, lymphodepletion, infusion of CAR-T cells, and subsequent longitudinal follow-up (Fig. 3b ). The eligibility of patients depends on their disease status, previous treatment regimens, risk factors, co-morbidities, performance status and social factors. 282 The patient’s peripheral blood mononuclear cells (PBMCs) are collected by leukapheresis and CD3 + T cells are further purified and isolated. T cell subpopulations are genetically modified to express the CAR of interest, then expanded in vitro. The expanded CAR T cells are frozen and stored for future use and ultimately reinfused into the patients after lymphodepletion-directed chemotherapy. CAR T-cell therapy generally requires hospitalization and the patient’s physical reactions, especially the possibility of AEs, should be closely monitored for several weeks after infusion.

CAR-T cell immunotherapy has gradually become the main therapeutic option for malignant hematological diseases, with impressive results to date. From Kymriah and Yescarta, which were the first to be approved by the FDA for the treatment of leukemia and lymphoma in August and October 2017, respectively, to the latest advances such as CB-010 therapy, they all play a pivotal role in treating malignancies, especially in cases of R/R patients. CAR-T cell immunotherapy has already achieved notable successes in the treatment of B-cell malignancies such as ALL, CLL, and DLBCL. Meanwhile, the most commonly utilized CAR targets for B-cell malignancies are CD19, CD20, and CD22. 283 Of these, CD19 is the most commonly used target and is highly expressed in the majority of B-cell malignancies. CD7 is an important target in T-cell ALL and T-cell lymphoma. 284 – 286 CD30 is usually expressed on tumor cells of HL, 287 and CD33 is a favorable target for AML. 288 Two CAR T-cell products, idecabtagene vicleucel and ciltacabtagene autoleucel, are the currently FDA-approved BCMA-targeting therapies. In addition to BCMA, many other investigational CAR T-cell therapies for MM are being studied, including cell products targeting SLAMF7, CD19, CD38, TACI (transmembrane activator and CAML interactor), GPRC5D (G protein-coupled receptor, class C, group 5, member D), and CD138. 282 , 289 – 291 However, the application of CAR-T therapy has been limited by relapse, resistance and toxicity. 292 – 298 Researchers have used diverse approaches to improve CAR-T therapy. In terms of target selection, new targets have been diligently searched for, 299 , 300 and even dual-target and even multi-antigen-targeted CAR-T have been introduced 291 , 301 – 306 to prevent subpopulations of tumors from being ignored. 307 For T-ALL, patients’ own T cells are difficult to make CAR-T, thus healthy donor T cells are used to prepare CAR-T. 281 Recently CAR-NK and CAR-macrophage cells have also become new popular products and novel CARs are designed to overcome treatment failure. 308 – 310 Despite these advancements in CAR-T cell therapy, there are still several unanswered questions. For example, the optimal CAR T cell design and engrafting technique, the ideal intracellular costimulatory domain or the generation of CARs, the appropriate CD4:CD8 T cell ratio in infusion products and even factors such as the dominance of effector versus central memory cells and the influence of Tregs are unknown. The best timing for the engraftment of CAR-T cells is also not yet clear and may vary depending on the type of malignancies. In addition, the impact of TME may be an additional critical factor in CAR T-cell therapy. Although these questions remain unanswered, CAR T-cell therapy will be an essential strategy for the treatment of hematologic malignancies. As more research is conducted on this breakthrough therapeutic approach, it will be improved in its efficacy and applicability.

Tumor vaccines

Tumor vaccines, one of the hot topics in research in recent years, are immunotherapeutic modalities in which tumor antigens are infused into patients in various forms to generate tumor-specific lymphocytes in the patient and kill the tumor. 311 It consists of molecular vaccines and cellular vaccines, among which molecular vaccines include tumor-associated proteins or peptides and gene vaccines expressing tumor antigens. Cellular vaccines, on the other hand, are tumor cells, which are genetically modified to express MHC molecules and then injected into patients. Tumor vaccines can enhance the immunogenicity of the tumor, activate the patient’s immune system, induce the body’s cellular and humoral immune response and also override the immunosuppressive state caused by the tumor. It is designed to not only induce tumor regression, but also to eliminate minimal residual disease (MRD), establish long-lasting anti-tumor memory and avoid non-specific or adverse reactions. Such vaccines have been developed for B-cell leukemia and lymphoma, ranging from commonly-mutated genes to DC vaccines. 312 , 313 Vaccines targeting immunoglobulin light chain and EBV antigens are also available. 314 , 315 As clinical trials have been conducted, 316 – 318 although not yet widely used, the prospects are promising.

How immunotherapies work: to promote “Cancer-Immunity Cycle”

The generation of anti-cancer immunity is a cyclical process that can be self-perpetuating, with the accumulated immunostimulatory factors that should, in principle, boost the T cell immune response. This cycle can also be interrupted by suppressive stimuli, which result in immunomodulatory feedback mechanisms that impede the generation of anti-cancer immunity. 6 Generally, the “Cancer-Immunity Cycle” can be divided into multiple steps. First, the neoantigens that are produced during tumorigenesis are released and then captured by the DCs for processing. This must be accompanied by immune-specific signals so as not to induce peripheral immune tolerance to the tumor antigens. Then, DCs deliver antigens that are captured on MHC molecules to T cells, leading to the priming and activation of effector T cells. Subsequently, through the interaction between the TCR and the cognate antigen bound to MHC-I, these activated effector T cells traffic towards and infiltrate into the tumor, where they specifically recognize and bind to the cancer cells and kill them. Noteworthy, the killing of these targeted cancer cells also leads to the release of more TAAs. This in turn extends the breadth and depth of the immune response in subsequent cycles of rotation. 6 Dysregulation of the “Cancer-Immunity Cycle” is the consequence of tumorigenesis and treatment failure. Meanwhile, the TME may also suppress these effector cells engaged in the “Cancer-Immunity Cycle” and resultant cancer immune evasion. 6 , 7 Therefore, cancer immunotherapy requires initiating and promoting the self-sustainability of the “Cancer-Immunity Cycle” so that it can normally amplify and spread, but not to the point of generating an unrestrained autoimmune inflammatory response. In the meantime, cancer immunotherapy also needs to be carefully tailored to counteract these negative feedback mechanisms. 8 – 10 Numerous factors that play a part in any step of the “Cancer-Immunity Cycle” offer a wide range of potential therapeutic targets (Fig. 4 ): (i) promoting antigen release, presentation and recognition; (ii) priming and activating the immune response; (iii) overcoming immune evasion; (iv) targeting immune suppression in the TME. Fig. 4 How immunotherapies work? To promote “Cancer-Immunity Cycle”. The “Cancer-Immunity Cycle” can be divided into multiple steps. 6 Dysregulation of the “Cancer-Immunity Cycle” is the consequence of tumorigenesis and treatment failure. Meanwhile, the TME may also suppress these effector cells engaged in the “Cancer-Immunity Cycle” and resultant cancer immune evasion. Numerous factors that play a part in any step of this cycle offer a wide range of potential therapeutic targets: (i) promoting antigen release, presentation and recognition; (ii) priming and activating the immune response; (iii) overcoming immune evasion; (iv) targeting immune suppression in the TME

Promote antigen release, presentation and recognition

Although not established as immunotherapies, chemotherapy, radiotherapy and targeted therapies (e.g., mAbs, bsAbs, and ADCs) can kill large numbers of cancer cells, then promote antigen release and T cell activation. The majority of tumor vaccines are therapeutic vaccines, which are based on the principle that tumor antigens are introduced into the patient’s body to improve immunogenicity, activate the immune system and elicit cellular and humoral immune responses to control or eliminate the tumor. 311 Theoretically, it is feasible to promote the activation of the immune system through the specific proteins of cancer cells so as to eliminate cancer cells. Nevertheless, tumor antigens are heterogeneous thus the primary problem in tumor vaccine development is to find the universal or specific antigens expressed on the surface of tumor cells. 319 , 320 CD40 agonist antibodies are used to promote the maturation and antigen-presenting ability of DCs by mimicking CD40L cross-linking CD40, inducing the expansion of tumor antigen-specific cytotoxic T cells and thus eradicating tumors. 105 , 321 , 322 CAR T-cell therapy is the process of transferring genetic material with specific antigen recognition structural domain and T cell activation signal into T cells through genetic modification. In this way, the modified T cells can be activated in an MHC-independent manner by directly binding with specific tumor antigens and directly killing the tumor cells by releasing perforin, granzyme B, etc. and also by secreting cytokines to recruit human endogenous immune cells to help to kill tumor cells.

Priming and activation of immune response

CTLA-4, an inhibitory receptor that is expressed primarily on T cells, has a suppressive function on T cell activation and is upregulated upon T cell activation. Antibodies targeting the immunomodulatory receptor CTLA-4 have two putative mechanisms of action: direct inhibition of CLTA-4 binding to its cognate ligand and depletion of immunosuppressive regulatory T (Treg) cells via Fc-mediated immune-mediated mechanisms, mainly including ADCC and CDC. 245 More importantly, the BiTEs are able to redirect T cells to specific tumor antigens and to directly activate the T cells. 323 Because T cells lack Fcγ receptors, natural antibodies cannot directly recruit these T cells. The BiTE molecule typically targets a tumor antigen and a CD3 molecule at the same time. The CD3 molecule associates non-covalently with the T cell receptor (TCR) and participates in antigen-specific signal transduction that can induce T cell activation. In addition, directly expanding and making available increased numbers of functionally competent immune cells represents an intuitively desirable therapeutic concept. 19 HSCT refers to the transplantation of hematopoietic stem cells from a donor into a recipient to rebuild or restore the recipient’s immune system. Cellular immunotherapy stimulates the body’s anti-tumor immune response by isolating autologous or allogeneic immune effector cells, activating them in vitro and then injecting them into the body. As with CAR-T cell therapy, the scFv recognizes specific TAAs, including the proteins, glycoproteins and other components. CD3-ζ is typically a signaling region containing three ITAMs (immunoreceptor tyrosine-based activation motifs). Upon scFv recognition and binding to TAA, phosphorylation of the ITAM triggers ZAP70 signal transduction and subsequent signaling to initiate and prime the T cell immune responses. 324 This is a principle similar to antigen-antibody complementarity, which can bypass the MHC-dependent antigen presentation and enable the TAA to directly stimulate the activation of CAR-T cells.

Overcoming immune evasion

An important mechanism by which tumor immune evasion occurs is by suppressing the function of effector immune cells. Immune checkpoints are a class of molecules that have a negative effect on immune cell function and are most expressed in immune cells. They can regulate the degree of activation of the immune system, resulting in them playing an important role in the prevention of autoimmune effects. However, these molecules are susceptible to being hijacked by tumor cells, which means the tumor cells can bind to the corresponding ligand/receptor on the immune cell, activating the inhibitory pathway and preventing immune cells from killing the tumor, thus enabling the immune escape of the tumor. 3 ICIs aim to block the corresponding immune checkpoints to prevent the activation of the relevant immunosuppressive pathways and have been widely used in various types of solid and hematologic malignancies. 325 , 326 Moreover, T cell exhaustion occurs due to a multi-factorial etiology resulting from sustained exposure to tumor antigens, the loss of stimulation/secretion of effector cytokines, the involvement of immunosuppressive cell types and immunophenotypic alterations including increased expression of inhibitory receptors and checkpoints such as LAG3 (lymphocyte-activation gene 3), TIGIT (T cell immune receptor with Ig and ITIM domains), TIM3 (T cell immunoglobulin mucin 3). Therefore, T cell exhaustion may be reversed and the anti-tumor immune response enhanced by inhibitors targeting these inhibitory receptors and checkpoints.

Targeting immune suppression in TME

The TME is the internal environment in which tumor cells survive and develop and immune cells in the TME have different mechanisms of pro- or anti-tumor immune action in tumor growth and progression. Tregs suppress T cell activity either directly or by secreting suppressor cytokines such as IL-10 and TGF-β; myeloid-derived suppressor cells (MDSCs) suppress T cell activity and modulate the intrinsic immune response to suppress the immune response. Therefore, targeting the TME is another important mechanism of cancer immunotherapy. For example, overexpression of indoleamine 2,3-dioxygenase (IDO) in tumors inhibits T cell proliferation and promotes regulatory T cell differentiation and IDO inhibitors can effectively improve the immunosuppressive microenvironment of tumors and enhance the anti-tumor immune response.

Representative clinical trials and outcomes

HSCT

Numerous clinical trials have validated the elimination of hematologic malignancies through transplantation. 327 – 329 Transplantation-related clinical trials mainly involve two aspects: (i) exploration of peripheral blood stem cell transplantation (PBSCT) and RIST; (ii) comparison of allogeneic HSCT with HLA genotype identical sibling donors (ISD) and haploidentical donors (HID). Around the beginning of the 21st century, several clinical trials were conducted to investigate the efficacy and safety of PBSCT. 330 , 331 These results confirmed the advantage of PBSCT in terms of hematopoietic system reconstitution. Meanwhile, it makes HSCT less harmful to the donor. To expand the application, RIST has been raised for those who can’t tolerate allo-HSCT. And relevant clinical trials were designed to discover the appropriate chemotherapy regimen and compared RIST with high-dose conventional conditioning. A 7-year clinical trial showed that 8 out of 12 patients who received RIST were still alive after 1 year, while only 3 out of 13 patients who received high-dose chemotherapy were still alive. 332 Fludarabine-melphalan as a preparative regimen for RIST is associated with a significant reduction in transplant-related mortality according to an update from the MD Anderson Center. 333 The study in Europe has also shown a reduction in the non-relapse mortality rate in RIST. 334 To date, more clinical trials are ongoing to evaluate RIST in elderly patients with AML and MDS. 335 – 337 Haplo-HSCT is now being used regularly for patients. However, it was not until 2015 that the technology became more mature and clinical trials comparing it to the ISD-HSCT were conducted. 338 , 339 The results of haplo-HSCT performed in patients who were in remission did not differ significantly from those of ISD-HSCT. In later studies, both transplantation methods were applied to patients not in remission, where haplo-HSCT showed better efficacy. 340 Although there may be a higher rate of GVHD, it has the potential to be used in high-risk child patients. 341 In addition, haplo-HSCT can be followed by adoptive T-cell therapy and the results of such trials have shown that T-cell infusion can be beneficial in reconstituting the immune system and preventing relapse. 342 , 343

mAbs

The most representative mAb used in the treatment of lymphoma is none other than Rituximab. There is a pivotal phase II trial of rituximab monotherapy that was conducted in 166 patients with R/R low-grade NHL, in which the ORR was 48 and 6% of the patients achieved the complete response. 344 The stage was set for the approval of rituximab with these and subsequent results. 345 However, an increasing number of clinical trials have opted to use rituximab in combination with other chemotherapy regimens to improve efficacy. In 2001, one phase II trial of the first-line R-CHOP regimen was initiated in 33 patients with aggressive NHL. The results were surprising with an ORR of 94% and a CRR (complete response rate) of 61%, demonstrating for the first time the feasibility and safety of the R-CHOP regimen in these patients. 86 Clinical trials of R-CHOP in MCL were then conducted. As implied by the results of a prospective randomized trial conducted by the German Low-Grade Lymphoma Study Group (GLSG), R-CHOP was significantly superior to CHOP as first-line therapy in terms of ORR (94%), CRR (34%) and time to treatment failure (21 months), although no differences were observed in progression-free survival (PFS). 346 Currently, R-CHOP has been designated as the first-line treatment agent for NHL by the National Comprehensive Cancer Network (NCCN), while there are numerous clinical trials to validate the efficacy of R-CHOP as a treatment to overcome relapse or refractory of NHL. 347 It is approved in Europe and the United States for use in combination with chemotherapy to treat patients with previously untreated or R/R CLL. 348 For example, a phase II trial evaluated the efficacy of the addition of rituximab to first-line chemotherapy with fludarabine and cyclophosphamide. And the chemo-immunotherapy group achieved a better clinical outcome, with 65% of patients free of disease progression at 3 years after the randomization. 349 Venetoclax-rituximab was also proved to be able to be applied in R/R CLL with significantly higher rates of PFS(84.9%) at 2 years. 88

The development of new mAbs is ongoing and clinical trials are being conducted. Ofatumumab, a fully human mAb, has been used as a single-agent CD20 immunotherapy in R/R CLL and FL in international clinical trials and has been shown to be an active, well-tolerated treatment with significant clinical improvements. 71 , 90 , 350 There are some clinical trials, such as GAUDI, GAUGUIN and GADOLIN, to investigate the efficacy of obinutuzumab (also called GA101) monotherapy and immunochemical combination with it in treating patients with DLBCL, MCL, FL and CLL. 73 , 92 – 95 It has also been used to treat CD20-positive indolent NHL refractory to rituximab. In this study, the median PFS was 25.8 months and OS was also prolonged, demonstrating the clinical benefit of obinutuzumab. 74 , 351 As well, tafasitamab (anti-CD19 mAb) is also approved for the treatment of R/R DLBCL and FL as a novel agent. 23 , 209 , 210 , 352 , 353 Some mAbs which has already been approved in autoimmune disease, such as alemtuzumab (anti-CD52 mAb) and ublituximab (anti-CD20 mAb), also expanded their indications to hematologic malignancies. In the GENUINE trial, ublituximab plus ibrutinib achieved encouraging efficacy in high-risk CLL and the ORR was 83%. 354 Alemtuzumab combined with CHOP similarly showed better outcomes with an ORR of 72% and CRR of 60% in the phase 3 trial. 100 In recent years, mAbs have gradually been introduced into the treatment of other hematologic malignancies. Daratumumab, an anti-CD38 mAb, is initially used as monotherapy in R/R MM. In a phase I-II dose-expansion study, daratumumab was administered to patients who had received a median of four prior therapies, including 76% of patients who had received autologous HSCT. The ORR was 36% in the cohort with a dose of 16 mg/kg and 10% in the cohort with a dose of 8 mg/kg. PFS was 5.6 months and 65% of patients who responded had no disease progression at 12 months. 76 The results of the SIRIUS trial were similar and both were favorable in terms of safety and exciting efficacy. 77 Daratumumab was also combined with classical regimens of MM to investigate the efficacy. The phase 3 trial suggested that the ORR was higher in the daratumumab combination group (82.9%) than that in the control group with bortezomib and dexamethasone alone (63.2%). 24 A similar outcome also occurred in the trial that compared the regimen of lenalidomide and dexamethasone, with an ORR of 92.9%. 75 Afterwards, daratumumab plus bortezomib, melphalan and prednisone was also considered as a prior-line therapy for untreated MM patients. And the outcome indicated that the addition of daratumumab resulted in a lower risk of disease progression or death. 78 Another anti-CD38 mAb named isatuximab has improved its effectiveness when combined with classical therapy regimens. Randomized phase 3 trials have been completed for all of thesecombinations. 82 – 84 Meanwhile, elotuzumab targeted CS1 on MM cells and also indicated encouraging results in serial clinical trials called ELOQUENT that was conducted in R/R and newly diagnosed MM patients. 80 , 81 In a word, mAbs occupy an important position in hematologic cancers and chemoimmunotherapy associated with mAbs has become a popular trend at the present.

bsAbs

In hematologic malignancies, bsAb therapy usually refers to the BiTEs. Blinatumomab is the first bsAb designed for this field. Some early clinical trials were conducted for NHL in the year 2008. Out of 38 patients who received blinatumomab, a response was only observed in 11 patients. And the longest duration of CR is 13 months in one MCL patient. 355 Furthermore, it has been studied in more cases of B-ALL. A phase II trial has demonstrated that blinatumomab is effective in MRD-positive B-ALL patients who are resistant to previous chemotherapy. The drug showed a high response rate, with an ORR of 76% and a relapse-free survival (RFS) rate of 78%. 356 Other studies showed similar results, 26 , 357 , 358 and blinatumomab is also effective in children and young adults with the first relapse of B-ALL. 359 , 360 Therefore, it has already become an approved therapy for R/R B-ALL. Recently, there’re emerging trials to discover the efficacy of the combination therapies of blinatumomab and other regimens for newly diagnosed Philadelphia chromosome (Ph) positive or negative B-ALL. 124 , 361 – 363 Blinatumomab was also used to treat patients with R/R B-NHL and DLBCL and showed great anti-tumor efficacy. 125 , 126 , 364 , 365 Meanwhile, some novel bsAbs entered the market in 2022, representing the rapid development of this field. Mosunetuzumab, a CD20/CD3 bispecific antibody, was approved for R/R FL based on the results of the multicenter phase II study in which 90 patients with FL received mosunetuzumab and the ultimate CRR was 60%. 131 Glofitamab is also targeted to CD20 but has been shown to induce durable CR in patients with R/R DLBCL. 132 , 133 In the phase I/II study, 52 patients who had previously received CAR-T therapy were enrolled and 35% of them achieved a CR and 78% of CR were sustained at 12 months. 133 Epcoritamab, odronextamab and plamotamab are all anti-CD20/CD3 antibodies and relevant clinical trials have demonstrated that they are competitive in terms of efficacy and safety. 134 , 136 A anti-BCMA/CD3 bsAb, teclistamab, was the first BiTE developed for MM. 150 – 154 In the trial MajesTEC-1, teclistamab demonstrated promising efficacy, with durable responses that deepened over time and was well tolerated in R/R MM patients. 153 Another phase 1–2 study also showed that teclistamab resulted a high rate of deep and durable response in patients with triple-class-exposed R/R MM. 151 The ORR was 63%, the median duration of response was 18.4 months and the median duration of PFS was 11.3 months. 151 Patients enrolled in the trial MajesTEC-2 had received ≥1 prior line of therapy. 152 While in the trial s MajesTEC-4 and MajesTEC-7, newly-diagnosed patients were enrolled and teclistamab was combined with classical regimens for treating MM. 150 , 154 In addition to teclistamab, other anti-BCMA/CD3 bsAbs have emerged currently, including linvoseltamab, elranatamab and alnuctamab and serial trials are being conducted. 155 – 159 , 366 – 368 In a Phase 2 study, 232 patients received talquetamab (anti- GPRC5D/CD3 bsAb) monotherapy and 70% of those experienced a response and the median duration of response was 10.2 months. 168 A multicenter, open-label, phase 1/2 study of flotetuzumab (MGD006, anti-CD123/CD3 bsAb) was conducted in 88 adults with R/R AML and showed acceptable safety and encouraging evidence of activity in PIF (primary induction failure)/ER (early relapse) patients. 142 JNJ-63709178, another kind of anti-CD123/CD3 bsAb, was found to have limited exposures and clinical activity with an unfavorable safety profile. 145

ADCs

Over the past several decades, ADCs have been evaluated in many preclinical models and early-phase clinical trials of hematologic malignancies. Gemtuzumab ozogamicin, an anti-CD33 ADC, was once used in AML patients with their first relapse and no history of an antecedent hematologic disorder and a median age of 61 years. This was based on the result of the clinical trial which revealed that 30% of patients who were treated with gemtuzumab ozogamicin achieved a remission, characterized by 5% or fewer blasts in the bone marrow. 369 However, a phase III SWOG S0106 randomized comparative trial did not confirm the clinical benefit of gemtuzumab ozogamic in combination therapy, such as CR rate, disease-free survival (DFS) and OS. Moreover, increased toxicity was observed and probably caused by relatively high instability of the linker in the bloodstream combined with a high recommended dose. 370 Thus, gemtuzumab ozogamicin was withdrawn in 2010 due to its serious toxicities and poor outcomes of survival. 371 – 373 It has been re-approved until 2017, following adjustments to the dosage and conditions as well as extensive clinical trials. 374 – 377 At present, it is believed that the benefit of gemtuzumab ozogamicin can be predicted by some related conditions and this is the reason why gemtuzumab ozogamicin is used in AML with high CD33 expression levels and corresponding mutated genetic profiles (e.g. NPM-1 mutated, KMT2A rearranged). 198 , 378 , 379 Furthermore, gemtuzumab ozogamicin is effective when used in newly diagnosed core binding factor (CBF)-deficient AML in the clinical trial conducted by MD Anderson. 380 In addition, a humanized anti-CD22 ADC called inotuzumab ozogamicin was initially given to patients with R/R B-NHL in a phase 1 clinical trial. Unfortunately, the final ORR was only 39% for the 79 patients enrolled. 187 Later on, inotuzumab ozogamicin has been tried to be used in R/R B-ALL patients. In the phase 2 trial, the ORR was 57% for the 49 patients in the study. 381 To further demonstrate the promise of inotuzumab ozogamicin, it was compared to standard intensive chemotherapy for ALL in a phase 3 trial. In the inotuzumab ozogamicin group, the CR rate was significantly higher (80.7%), the median duration of remission was longer (4.6 months) and the median PFS was also longer (5.0 months). 180 Based on these results, the FDA approved the use of inotuzumab ozogamicin in adult R/R B-ALL. Meanwhile, clinical trials continued to evaluate the efficacy of the combination therapy in Ph(-) ALL and in pediatric patients. 188 , 382 , 383 Another anti-CD22 ADC, called moxetumomab pasudotox, has been developed for the treatment of R/R hairy cell leukemia (HCL). 189 In the long-term follow-up from the pivotal trial, complete responders lasting ≥60 months was 61% and median PFS without the loss of hematologic remission was 71.7 months. Moxetumomab pasudotox fills the gap in R/R HCL where there is no adequate therapy. 384 In 2022, brentuximab vedotin (anti-CD30 ADC) was used in patients with III/IV-stage cHL. Compared with the classical ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) regimen, the combination of brentuximab vedotin plus BVD (bleomycin, vinblastine and dacarbazine) showed better consequences with a 6-year OS of 93.9%. 181 Polatuzumab vedotin has been designed to target CD79b and used for the treatment of R/R B-NHL including DLBCL and FL. 191 , 209 , 210 Polatuzumab vedotin combined with bendamustine and rituximab resulted in a significantly higher CR rate and reduced the risk of death by 58% compared with bendamustine and rituximab in patients with transplantation-ineligible R/R DLBCL. 210 Loncastuximab tesirine (ADCT-402) is a humanized anti-CD19 IgG1 mAb conjugated through a protease-cleavable Val-Ala linker to a pyrrolobenzodiazepines dimer, a DNA crosslinking agent. 203 , 204 A phase 1 study of loncastuximab tesirine in R/R B-cell NHL showed that ORR in evaluable patients was 45.6%, including 26.7% CRs. ORRs in patients with DLBCL, MCL, and FL were 42.3%, 46.7%, and 78.6%, respectively. 185 Further, a multicentre, open-label, single-arm, phase 2 trial (LOTIS-2) was conducted in patients with R/R DLBCL after two or more multiagent systemic treatments with an ORR of 48.3% and a CRR of 24.1%. 203 Belantamab mafodotin chose BCMA as the target and fills the gap of ADC in MM and the serial trials continue to discover its clinical efficacy and durability as monotherapy or combined with other regimens. 211 , 385 , 386 The DREAMM-2, a two-arm, randomized, open-label, phase 2 study, demonstrated that 31% of 97 patients in the 2·5 mg/kg cohort and 34 of 99 patients in the 3–4 mg/kg cohort achieved an overall response. 211 In DREAMM-6 trial, belantamab mafodotin showed a better outcome with an ORR of 75% and a median PFS of 8.6 months. 386 It seems that ADCs have already played an important role and became a new trend in immunotherapy for hematologic malignancies nowadays. These ADC drugs have achieved satisfactory results in clinical trials and have been approved for use in the diseases for which they are intended. 191 , 203 , 204 , 210 , 353 Furthermore, there’re still some novel ADCs waiting for approval and the corresponding clinical trials are ongoing. 199 , 200 , 221

ICIs

Several clinical trials of ICIs have been conducted in hematologic malignancies, including MM, ALL, AML, NHL and HL. 387 – 390 However, only the results of PD-1 blockade in HL are particularly remarkable. Some observations may suggest why HL is uniquely sensitive to PD-1/PD-L1 blockade. 391 First, HL biopsies typically show the Reed-Sternberg (R-S) cells that are surrounded by an extensive immune infiltration, but it is ineffective. Moreover, increased surface expression of PD-L1 was also observed in HL biopsies. Second, HL is characterized by the genetic alterations in 9p24.1 that result in copy gain and overexpression of PD-L1 and PD-L2, with an increase in copy gain or amplification of 9p24.1 in more than 97% of newly diagnosed HL biopsy specimens. 392 , 393 Third, infection with Epstein-Barr virus (EBV) is common in HL patients and also causes PD-L1 to be overexpressed, which is one of the key mechanisms by which the virus could persist in the host. 394 In contrast, NHL does not display a high frequency of 9p24.1 alterations, thus the efficacy of ICI decreased for NHL patients. 395

Table 2 gives a summary of representative clinical trials of ICIs that are already approved by the FDA or some novel ICIs (e.g., dual-target ICI) that are still in the stage of the clinical study. 387 , 396 – 407 Ipilimumab, a CTLA-4 inhibitor, has been evaluated in clinical trials of the treatment for NHL and HL patients, 396 – 398 but only showed certain therapeutic effects in HL with an ORR of 76% and CRR of 57%. 398 Since HL has the property of being more sensitive to ICIs targeting PD-1, most of the clinical trials of PD-1 blockades, including nivolumab, pembrolizumab and pidilizumab, were conducted on R/R HL. 194 , 387 , 396 , 398 , 400 , 408 In recent years, nivolumab and pembrolizumab have been used in patients with NHL, CLL 404 , 409 , 410 and even in some lymphomas for which there is no effective therapy, such as PCNSL (primary central nervous system lymphoma) and PMBCL (primary mediastinal large B-cell lymphoma). 402 , 403 , 411 Moreover, there’s a clinical trial of pidilizumab conducted in advanced hematologic malignancies including MM, promoting the wide application of ICIs. 412 In addition to PD-1 blockade, CD47 blockade has emerged as the treatment for R/R NHL, MM and especially for AML/MDS, where PD-1 blockade shows poor efficacy. 413 – 417 To improve the overall response, one phase 1b trial explored the safety and efficacy of combined PD-1 and CTLA-4 blockade in patients with R/R lymphoid malignancies, including HL, NHL, and MM. 399 But it is regrettable that there was no meaningful improvement in the efficacy of the combinations over single-agent nivolumab in the diseases studied. While this combination was active in HL (ORR 74%, CRR 23%), the toxicity of nivolumab /ipilimumab was higher than expected from nivolumab alone. Table 2 Representative clinical trials and outcomes of ICIs for treating hematologic malignancies Drug & Target Trial Phase Monotherapy/combination therapy Type of disease Prior lines of treatment No. of patients Response Survival FDA approval Refs. Ipilimumab, CTLA-4 NCT00060372 I Monotherapy Pan-cancers, including R/R cHL Received allo-HSCT 29 Only 3 patients demonstrated objective disease responses after ipilimumab alone, 1 patient achieved PR and 2 patients achieved CR Median OS of all 29 patients was 24.7 months Yes 396 NCT00089076 I Monotherapy R/R B-NHL 1–4 chemotherapy regimens 18 Only 2 patients had clinical response: 1 patient achieved PR and 1 patient achieved CR 1 patient with FL had PR lasting 19 months and 1 patient with DLBCL had an ongoing CR ( > 31 months) Yes 397 NCT01896999 I/II Combination therapy R/R cHL ≥1 61 ORR 76% CRR 57% Median PFS 1.2 years Yes 398 Ipilimumab and Nivolumab, CTLA-4 and PD-1 NCT01592370 I Combination therapy R/R cHL, NHL, and MM ≥1 or ≥2 65 cHL: ORR 74%, CRR 23% NHL: ORR 19%, CRR 6% MM: ORR 0% cHL: median PFS was not reached at 17 months all corhorts: median PFS was 1–2 months Yes 399 Nivolumab, PD-1 NCT01592370 I Monotherapy R/R cHL ≥1 without ASCT in 100 days 23 ORR 87% CRR 17% PFS: 86% at 24 weeks; OS: 91% at 1 year Yes 387 NCT03016871 II Comparison of monotherapy and combination therapy R/R cHL / 43 ORR 93% CRR 91% PFS 72% at 2 years Yes 400 ADVL1412 I/II Monotherapy Pan-cancers, including NHL and HL ≥1 HL 10, NHL 10 HL: ORR 30% NHL: ORR 10% HL: the median of cycles the patients completed was 4.5; NHL: one patient had response and remained on therapy for 11 cycles. Yes 401 / / Monotherapy R/R PCNSL and PTL with CNS relapse ≥1 5 ORR 100% CRR 80% PFS: 60% at 17 months Yes 402 CheckMate 436 I/II Combination therapy R/R PMBCL ≥2 or received ASCT 30 ORR 73% CRR 37% Median PFS and OS were not reached Yes 403 NCT02038933 II Monotherapy R/R DLBCL Experienced failure of ASCT 121 Allo-HSCT-failed: ORR 10% at 9 months, ASCT-ineligible: ORR 3% at 6 months Allo-HSCT-failed: median PFS 1.9 months, median OS 12.2 months; allo-HSCT-ineligible: median PFS 1.4 months, OS 5.8 months Yes 404 NCT02329847 I/II Combination therapy R/R FL/DLBCL/CLL and SLL/RT ≥1 144 CLL/SLL: ORR 61% FL: ORR 33% DLBCL: ORR 36% RT: ORR 65% CLL/SLL: median duration of response 19.2 months FL: median PFS 9.1 months DLBCL: median PFS 2.6 months RT: median PFS 5.0 months Yes 409 Pembrolizumab, PD-1 KEYNOTE-013 I Monotherapy R/R cHL Received BV without ASCT 21 ORR 65% CRR 16% PFS 46% at 52 weeks Yes 408 KEYNOTE-013 I Monotherapy R/R PMBCL Median 3 18 ORR 41% Median OS was not reached Yes 411 NCT02453594 II Monotherapy R/R cHL Received BV and/or HSCT 210 ORR 69% CRR 22.4% PFS 72.4%, OS 99.5% at 6 months Yes 405 KEYNOTE-204 III Monotherapy R/R cHL ≥1 without ASCT 151 ORR 65.6%, CRR 24.5% Median PFS was 13.2 months Yes 194 NCT02332980 II Monotherapy R/R CLL, RT ≥1 16 RT: ORR 44% CLL: ORR 0% RT cohort: median OS 10.7 months Yes 410 Pidilizumab (CT-011), PD-1 NCT00532259 II Monotherapy R/R DLBCL Received ASCT 66 ORR 51% PFS 72%, OS 85% at 16 months Yes 390 NCT00904722 II Combination therapy R/R FL ≥1 32 ORR 62%, CRR 52% Median PFS was 18.8 months Yes 406 CT-011 Trial I Monotherapy Advanced NHL, HL, CLL, MM / 7 B-NHL: ORR 14%, CRR 14% The survival time ranged from 1.7 to >77 weeks. Yes 412 Margrolimab, CD47 NCT02953509 I Combination therapy DLBCL, FL ≥2 22 ORR 50%, CR 36% 91% of response were ongoing at median follow-up. No 407 Lemzoparlimab, CD47 NCT03934814 I Combination therapy R/R NHL ≥2 8 ORR 57%, overall DCR 100% All responders remained in clinical response at the time of data cutoff. Yes 414 NCT04202003 I Monotherapy R/R AML and MDS ≥2 5 1 patient achieved morphologic leukemia-free state / – n– 415 Evorpacept, SIRPα/CD47 ASPEN-02 I/II Combination therapy R/R MDS ≥1 HMA-based regimen 13 ORR 60% of 5 ND patients, 40% of 5 R/R patients / Yes 417 TG-1081, CD19/CD47 NCT03804996 I Comparison of monotherapy and combination therapy R/R B-cell lymphoma ≥1 14 Monotherapy: ORR 21%; Combination with ublituximab: ORR 44%, CRR 6% 10 patients had durable response at the time of data cutoff. No 413 FDA Food and Drug Administration, R/R refactory/relapse, ND newly diagnosed, cHL classical Hodgkin lymphoma, ASCT autologous stem cell transplantation, ORR overall response rate, CR complete response, PFS progression-free survival, OS overall survival, DCR disease control rate, NHL non-Hodgkin lymphoma, PCNSL primary central nervous system lymphoma, CNS central nervous system, PTL primary testicular lymphoma, PMBCL primary mediastinal large B-cell lymphoma, DLBCL diffused large B-cell lymphoma, CLL chronic lymphocytic leukemia, BV brentuximab vedotin, RT Richter transformation, FL follicular lymphoma, MM multiple myeloma, AML acute myelocytic leukemia, MDS myelodysplastic syndromes, HMA hypomethylating agents, “/”, not available

ACTs

Our primary focus has been on the large clinical trials of CAR-T cell therapy in various hematologic malignancies. Table 3 gives a summary of representative clinical trials and outcomes of CAR-T cell monotherapy for blood cancers. Tisagenlecleucel, axicabtagene ciloleucel and lisocabtagene maraleuecel are the most representative anti-CD19 CAR-T cell products and they have been studied in a large number of clinical trials. For tisagenlecleucel, ELIANA has indicated its efficacy in pediatric patients with B-ALL. 418 Other clinical trials with tisagenlecleucel are predominantly focused on B-NHL. Among them, JULIET investigated the CAR-T therapeutic efficacy in R/R DLBCL, 419 BELINDA raised tisagenlecleucel as second-line treatment, 420 and ELARA enrolled patients with R/R FL. 421 The clinical trials for axicabtagene ciloleucel are called ZUMA 422 – 427 and cover the treatment of R/R LBCL, B-ALL, and MZL. The most recent one, ZUMA-12, demonstrated the high response rate of axicabtagene ciloleucel as first-line therapy for untreated high-risk LBCL. 427 Lisocabtagene maraleuecel has fewer trials in comparison with the two products above, but the 2022 TRANSCEND CLL 004 study showed surprising results suggesting an ORR of 82% in patients with R/R CLL and small lymphocytic lymphoma (SLL). 428 However, the antigen expression of tumor cells still limits the efficacy of CAR-T therapy. Since CD19 may not cover all types of lymphoma subclones, 428 – 430 CAR-T cells targeting other highly-specific antigens and dual targets, 302 , 431 – 437 such as CD22, CD19/CD20, and CD30, have been developed as well. The anti-CD30 CAR-T cells have also been developed in HL, 435 – 437 and more clinical trials are being conducted to verify their efficacy. Table 3 Representative clinical trials and outcomes of CAR-T monotherapy for treating hematologic malignancies Type of CAR-T therapy CAR-T Product & Target Structure of binding domain & costimulatory domain Trial Phase Type of disease No. of prior lines of treatment No. of patients Response Survival FDA approval Refs. Monospecific, autologous Tisagenlecleucel, CD19 FMC63 scFv, 4-1BB ELIANA I/II R/R B-ALL 1–8 (median 3) 75 ORR 81%, CR/CRi 81% EFS 50%, OS 76% (12months) Yes 418 JULIET II R/R DLBCL 1–6 (median 3) 93 ORR 52%, CRR 40% RFS 65%, OS 49% (12 months) Yes 419 BELINDA III Aggressive B-NHL 1 322 ORR 46.3% PFS 25.9% (6 weeks) Yes 420 ELARA II R/R FL 2–13 (median 4) 97 ORR 86.2%, CRR 69.1% PFS 67% (12 months) Yes 421 Axicabtagene ciloleucel (KTE- X19), CD19 FMC63 scFv, CD28 ZUMA-1 I/II R/R LBCL 1–4 (median 3) 101 ORR 82%, CRR 58% PFS 44% (12months), OS 52% (18 months) Yes 422 Brexucabtagene, CD19 FMC63 scFv, CD28 ZUMA-2 II R/R MCL 1–5 (median 3) 71 ORR 93%, CRR 67% PFS 61%, OS 83% (12months) Yes 423 Axicabtagene ciloleucel (KTE- X19), CD19 FMC63 scFv, CD28 ZUMA-3 I/II R/R B-ALL ≥2 (median 2) 55 CR/CRi: 71% Median RFS 11.6 months, median OS 18.2 months – 424 ZUMA-5 I/II R/R FL or MZL 2–3 (median 3) 153 ORR 96%, CRR 77% PFS 74%, OS 93% (12 months) – 425 ZUMA-7 III R/R LBCL 1 179 ORR 83%, CRR 65% EFS 41% (24 months) – 426 ZUMA-12 I/II High-risk LBCL Untreated 40 ORR 89%, CRR 78% PFS 75%, OS 91% (12 months) Yes 427 PD1-19bbz, CD19 Anti-CD19 scFv, 4-1BB NCT04213469 I R/R B-NHL Not treated with CAR-T 8 ORR 100%, CRR 87.5% PFS 100% (12 months) No 465 Lisocabtagene maraleuecel, CD19 FMC63 scFv, 4-1BB TRANSCEND NHL001 I R/R LBCL 1–4 (median 3) 269 ORR 73%, CRR 53% Median follow-up for OS 18.8 months Yes 267 TRANSFORM III R/R LBCL 1 92 ORR 79%, CRR 61% PFS 52.3%, OS 79.1% (12 months) Yes 429 PILOT II R/R LBCL 1 (without HSCT) 61 ORR 49%, CRR 33% Median PFS 9.03 months Yes 430 TRANSCEND CLL 004 I R/R CLL/SLL ≥2 (median 4) 23 ORR 82%, CRR 45% Median PFS 18 months Yes 428 CD20 CAR-T / ChiCTR2000036350 I R/R B-NHL 1 15 ORR 100%, CRR 80% PFS and OS 100% (12.4 months) No 431 CD22 CAR-T Anti-CD22 scFv, 4-1BB NCT02315612 I R/R B-ALL ≥1 (except 1 untreated) 21 CRR 57% Among the 12 patients who attained CR, 3 remain in ongoing CR at 21, 9 and 6 months. 8 patients relapsed 1.5–12 months post CAR infusion. No 432 Monospecific, universal (allogenic) ALLO-501A, CD19 Anti-CD19 scFv, with disrupted TCRα and edited CD52 gene ALPHA2 I/II R/R LBCL ≥2 15 ORR and CR 50% / No 456 CTX110, CD19 Anti-CD19 scFv, with disrupted TCR and elimination of β 2 -microglobulin gene CARBON I R/R LBCL ≥2 32 ORR 67%, CRR 41% Nearly 50% patients received CR maintained it out to at least 6 months No 459 PBCAR0191, CD19 Anti-CD19 scFv, with TCR/CD3 knockout NCT03666000 I/II R/R B-ALL ≥2 15 CR/CRi 60% One patient achieved progression-free more than 250 days. Others had progression or died less than 150 days. No 461 R/R B-NHL ≥2 13 ORR 77%, CRR 54% Duration of response assessment is ongoing. No 460 UCART22, CD22 anti-CD22 scFv,4-1BB BALLI-01 I R/R B-ALL ≥1 9 CRi 11% / No 457 Bispecific, autologous CD19/22-CAR T Anti-CD19 FMC63 scFv and anti-CD22 m971 scFv, 4-1BB NCT03233854 I R/R B-ALL/ LBCL ≥2 38 B-ALL: ORR 100%, CRR 88%; LBCL: ORR 62%, CRR 29% B-ALL: median OS 11.8 months, median PFS 5.8 months LBCL: median OS 22.5 months, median PFS 3.2 months No 433 LV20.19, CD19/20 Anti-CD19 FMC63 scFv and anti-CD20 leu-16 scFv, 4-1BB NCT03019055 I R/R B-NHL, CLL 2–12 (median 4) 22 ORR 82%, CRR 64% Median OS 20.3 months No 434 TanCAR7 T cells, CD19/CD20 Anti-CD19 FMC63 scFv and anti-CD20 leu-16 scFv, 4-1BB NCT03097770 I/II R/R B-NHL ≥1 (most are 3–5) 28 ORR 79%, CRR 71% PFS 64% (12 months) No 302 Bispecific, universal (allogenic) CTA101, CD19/CD22 Anti-CD19 FMC63 and anti-CD22 m971 scFv with CRISPR/Cas9-disrupted TCRα region and CD52 gene, 4-1BB NCT04227015 I R/R B-ALL ≥1 6 CR/CRi 83.3% 50% patients remained MRD negative at a median follow-up of 4.3 months No 301 Monospecific, autologous CD30.CAR-Ts, CD30 Anti-CD30 scFv derived from HSR3 antibody, 4-1BB NCT02690545 NCT02917083 II R/R HL 2–23 (median 7) 41 ORR 62%, CRR 51% PFS 36%, OS 94% (1 year) No 435 CD30.CAR-Ts, CD30 NCT01316146 I R/R HL/ALCL ≥3 9 ORR 33.3% HL; 1 patient remained CR for 2.5 years, 1 patient remained CR for 2 years ALCL: 1 patient remained CR for 9 months No 436 CART-30, CD30 NCT02259556 I R/R HL ≥10 18 ORR 39% Median PFS 6 months No 437 Monospecific, autologous Idecabtagene vicleucel (ide-cel, bb2121), BCMA Murine anti-BCMA scFv, 4-1BB NCT02658929 I R/R MM 3–23 (median 7) 33 ORR 85%, CRR 45% Median PFS 11.8 months Yes 438 KarMMa II R/R MM 3–16 (median 6) 128 ORR 73%, CRR 33% Median PFS 8.8 months Yes 439 KarMMa III R/R MM 2–4 254 ORR 71%, CRR 39% Median PFS 13.3 months Yes 440 bb21217, BCMA CRB-402 I R/R MM 3–17 (median 6) 69 ORR 60%, CRR 28% Median PFS was not reached No 441 Ciltacabtagene autoleucel, BCMA Llama- derived anti-BCMA VHH, 4-1BB CARTITUDE-1 I/II R/R MM 4–8 (median 6) 97 ORR 97%, sCR 67% PFS 77%, OS 89% (12 months) Yes 442 CT103A, BCMA Fully human anti-BCMA scFv, 4-1BB ChiCTR1800018137 I R/R MM 3–6 (median 4) 18 ORR 100%, sCR/CR 72.2% PFS 58.3% (12 months) No 278 P-BCMA-101, BCMA Murine anti-BCMA scFv, 4-1BB PRIME I/II R/R MM 2–18 (median 8) 53 ORR 57% / No 443 Orva-cel, BCMA Humanized anti-BCMA scFv, 4-1BB EVOLVE I/II R/R MM 3–18 (median 6) 62 ORR 92%, CRR 36% / No 444 CT053, BCMA Humanized anti-BCMA scFv, 4-1BB Lummicar-2 I/II R/R MM 2–11 (median 4) 14 ORR 100%, sCR/CR 40% / No 445 Monospecific, universal (allogenic) ALLO-715, BCMA Humanized anti-BCMA scFv with CD52 & TCR knockout, 4-1BB UNIVERSAL I R/R MM 3–11 (median 5) 43 ORR 55.8% Median DOR 8.3 months No 446 Monospecific, autologous MCARH109, GPRC5D Humanized anti-GPRC5D scFv, 4-1BB NCT04555551 I R/R MM 4–14 (median 6) 17 ORR 71%, CRR 35% PFS 50% (10.1 months) No 299 CC-95266, GPRC5D Anti-GPRC5D scFv, 4-1BB NCT04674813 I R/R MM ≥3 17 ORR 89%, CR 47% PFS 88% (at the time of analysis) No 448 OriCAR-017, GPRC5D Anti-GPRC5D scFv with Ori, 4-1BB POLARIS I R/R MM ≥3 10 ORR 100%, sCR 60% PFS 80% (12months) No 290 Combination of two monospecific CAR-T CD19 and BCMA CAR-T Humanized anti-CD19 scFv, murine anti-BCMA scFv, 4-1BB ChiCTR-OIC-17011272 II R/R MM 5–8 (median 6) 21 ORR 95%, sCR 43%, CR 14% PFS 85% (602 days) No 450 Bispecific, autologous BM38, BCMA/CD38 Humanized anti-BCMA/CD38 scFv, 4-1BB ChiCTR1800018143 I R/R MM 2–9 (median 4) 23 ORR 87%, sCR/CR 54.5% Median PFS 17.2 months No 291 BCMA/CS1 Murine anti-BCMA/CS1 scFv, 4-1BB NCT04662099 I R/R MM ≥2 16 ORR 100%, sCR 31% OS 83.9%, PFS 55.2% (12 months) No 449 Monospecific, HSCT donor-derived (allogenic) CD7 CAR-T Anti-CD7 scFv, 4-1BB ChiCTR2000034762 I R/R T-ALL 2–4 (median 3) 20 ORR 95%, CRR 90% / No 284 Monospecific, autologous nanobody-derived fratricide-resistant CD7-CAR T Humanized anti-CD7 nano- body-derived CAR, ICOS and 4-1BB NCT04004637 I R/R T-ALL/LBL ≥4 8 CRR 87.5% / No 285 Monospecific, autologous/donor-derived NS7CAR, CD7 / NCT04572308 I R/R T-ALL/LBL ≥1 20 CRR 95% / No 454 Monospecific, universal (allogenic) RD13-01, CD7 Anti-CD7 scFv with TCR/CD3 knockout and NK cell inhibitor, 4-1BB NCT04538599 I R/R T-ALL/LBL 2–7 (median 4) 12 ORR 81.8%, CRR 63.6% / No 281 Monospecific, autologous CAR-T-38, CD38 Anti-CD38 scFv same as daratumumab, CD28 and 4-1BB NCT04351022 I R/R AML >1 (received HSCT) 6 CR/CRi 66.7% Median OS 7.9 months, LFS 6.4 months No 289 NKG2D CAR-T Humanized NKG2D gene, without co-stimulation domain NCT02203825 I R/R AML/MDS/MM 0–4 12 ORR not seen Median OS 4.7 months No 451 CLL-1 CAR-T Anti-CLL-1 scFv, 4-1BB ChiCTR2000041054 I R/R AML 2–10 (median 5) 10 CR/CRi 70% / No 452 Monospecific, universal (allogenic) UCART123v1.2, CD123 Anti-CD123 scFv, with disrupted TRAC and CD52 genes Ameli-01 I R/R AML ≥2 or received prior allogenic HSCT 8 ORR 25% / No 453 CAR-T chimeric antigen receptor T cell, FDA Food and Drug Administration, scFv single chain variable fragment, R/R relapsed or refractory, B-ALL B-cell acute lymphoblastic leukemia, ORR overall response rate, CR complete response, CRi complete remission with incomplete hematological recovery, EFS event-free survival, OS overall survival, DLBCL diffused large B-cell lymphoma, RFS relapse-free survival, NHL non-Hodgkin lymphoma, PFS progression-free survival, FL follicular lymphoma, CRR complete response rate, LBCL large B-cell lymphoma, MCL mantle cell lymphoma, MRFS median relapse-free survival, MZL marginal zone lymphoma, HSCT hematopoietic stem cell transplantation, CLL chronic lymphocytic leukemia, SLL small lymphocytic lymphoma, HL Hodgkin lymphoma, ALCL anaplastic large cell lymphoma, MM multiple myeloma, sCR stringent complete response, DOR duration of response, T-ALL T-cell acute lymphoblastic leukemia, T-ALL/LBL T-cell acute lymphoblastic leukemia/lymphoma, AML acute myelocytic leukemia, LFS leukemia-free survival, MDS myelodysplastic syndromes, TRAC T-cell receptor alpha constant, “/”, not available

In addition to lymphoma and leukemia, CAR-T cells have also made great progress in treatment of MM. 278 , 438 – 446 Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) have already been approved by the FDA based on responses and safety demonstrated in the KarMMa and CARTITUDE-1 trials. 439 , 440 , 442 Meanwhile, more companies have launched CAR-T cell products for MM, such as orva-cel, P-BCMA-101. 443 , 444 , 446 – 449 CAR-T cell products against the new target, GPRC5D, have also been developed without delay. Usually, patients enrolled in CAR-T clinical trials have a good baseline condition. This is to prevent them from not being able to tolerate side effects such as CRS. However, the first clinical trial of the GPRC5D target was conducted in patients with poor baseline conditions who had received multiple lines of therapy. 299 The clinical results also showed a high level of safety and efficacy, taking the development of CAR-T to a new level. In other types of hematological malignancies, CAR-T therapy is still in the exploratory phase of development. A single-center, single-arm, phase 2 trial assessed the activity and safety of a combination of humanized anti-CD19 and anti-BCMA CAR T cells in patients with R/R MM and confirmed that this combined infusion is feasible with ORR of 95% and CRR of 43%. 450 As for AML, CAR-T therapy seems to be less effective due to the lack of appropriate tumor targets and is still being explored in preclinical and clinical studies. 289 , 451 – 453 The difficulty of manufacturing cell products using autologous T cells is the major problem facing CAR-T therapy in T-ALL. As a result, several institutions have developed donor-derived CAR-T cells and have conducted clinical trials to confirm the efficacy and safety of these CAR-T cells. 281 , 284 , 454 The donor-derived CAR-T cells suggested encouraging effects, especially in those patients who received allo-HSCT. 455

The universal CAR-T cells, also known as “off-the-shelf”, can overcome the problem of long period of manufacturing and enable those patients whose T cells are under poor condition to receive CAR-T therapy. Due the heterologous nature of allogeneic CAR-T cells, many products are designed to knock out of the TCR or edit the CD52 gene to overcome GVHD and HVGD (host versus graft disease). It is slao essential to examine the safety and in vivo persistence of universal CAR-T cells through clinical trials. 446 , 456 – 460 Anti-CD19 universal CAR-T cells, like PBCAR0191 and bispecific universal CAR-T CTA101, also showed high rates of CR (60% and 83.3%). 301 , 461 81.8% of patients showed OR after RD13-01 infusion (CRR 63.6%) without GVHD and severe CRS. 458 A phase 1 UNIVERSAL trial reported a first-in-class, allogeneic, anti-BCMA CAR-T cell therapy (ALLO-715) engineered to abrogate GVHD and minimize CAR-T rejection. ALLO-647 (anti-CD52 antibody) was used for lymphodepletion with fludarabine and/or cyclophosphamide before ALLO-715 infusion. There was obvious expansion in 83.3% of patients yet 63.3% of patients showed undetectable levels of CAR-T cells by the day 28. 446 Overall, universal CAR-T cells have made some progress, but the clinical safety, efficacy and the duration of response of these products still requires further observation.

Although CAR-T cell therapy has achieved outstanding results when used as a monotherapy, there are still certain patients who do not benefit from it and further research is urgently needed to improve and prolong the efficacy of CAR-T therapy. Therefore, researchers are focusing on the combination of other immunotherapies with CAR-T cell therapy. The immune checkpoint molecule PD-1 on the surface of CAR-T cells has been reported to be overexpressed due to T-cell overactivation and thus blocking the PD-1/PD-L1 pathway might effectively restore the function of CAR-T cells. 462 Clinical trials have been performed with the combination of PD-1 blockers and CAR-T therapy and the results have been encouraging. A phase II clinical trial of anti-CD30 CAR-T treatment in combination with PD-1 inhibitor in R/R CD30-positive lymphoma has been conducted. Among the 12 patients who were evaluated for response, the ORR was 91.7% and the CRR was 50%. And 7 patients maintained their response until the end of the follow-up. 463 Additionally, the combination of CD19 CAR-T cells and PD-1 blockade was proven to reduce intracranial tumor burden in a patient with centrally-invasive lymphoma. 464 However, some researchers have chosen to construct endogenous PD-1 dominant-negative receptors (DNRs) within CAR-T cells to allow them to bind both TAA and PD-1 on tumor cells, ensuring that CAR-T function is not inhibited. 465 , 466 In combination with CAR-T cell therapy, HSCT is also a popular alternative. Bridging therapy with donor CAR-T cells after allogeneic transplantation can have shown a prolonged effect on the efficacy of the transplant. 467 , 468 According to the results from a retrospective study, haplo-HSCT with pre-transplant negative MRD after CAR-T cell therapy can significantly improve LFS (leukemia-free survival) and OS in patients with R/R B-ALL. 469 This finding was confirmed in subsequent clinical trials. In the subgroups of patients who achieved MRD-negative CR after CAR-T cell therapy, event-free survival (EFS), and RFS were significantly prolonged by allo-HSCT. 470 As a result, CAR-T therapy followed by transplantation can improve survival in a similar manner and is a viable option for achieving a durable remission of the disease.

Currently, CAR-NK is also a hot topic of research, with the major advantage that NK cells are able to be produced from healthy donor-derived PBMC, core blood, or iPSCs (induced pluripotent stem cells) without any appreciable toxicity. 11 patients were treated in a phase 1/2 study with anti-CD19 CAR-NK derived from core blood. Among them, 8 patients experienced a response and 7 of them experienced a CR. The infused CAR-NK cells proliferated and persisted in vivo at low levels for at least 12 months. 471 Although it was not effective in B-ALL patients unfortunately, NKX019 showed a favorable efficacy in R/R B-NHL patients and the ORR was 83% and CRR was 50% in the higher-dose group. 472 Besides, NKX101 targeted NKG2D (natural killer cell group 2 member D) and achieved an ORR of 47% in all R/R AML patients enrolled. 473 For R/R MM, FT576 was proved to be safe and tolerates without CRS, GVHD, or neurotoxicity and was determined a recommended dose in a phase 1 trial. 474 In addition, more researches on CAR-NK cells are still in the pre-clinical stage or early clinical trials. 308 , 475 Further research is also needed to perfect the design and manufacturing to improve the efficacy and durability of CAR-NK cells. 476 , 477

AEs and toxicity management

The era of immunotherapy has brought revolutionary breakthroughs for hematologic malignancies. These therapies are designed to stimulate the immune system to recognize and attack cancer cells, thereby extending survival and improving outcomes. However, immunotherapy poses new clinical problems and challenges for hematologists due to its toxicity, which is different from traditional chemotherapy, depending on the specific mechanism of action. 478 The occurrence of AEs cannot be ignored and can affect almost all organs and systems. These AEs further impede the clinical application of immunotherapy and, in severe cases, even threaten the patient’s life. 478 Therefore, the need for and importance of toxicity management has become increasingly apparent. Treatment of AEs usually depends on the organ involved and the severity of symptoms. These toxicities often require specific management, including steroids and immunomodulatory therapy, for which consensus guidelines have been proposed and published. Here, we summarize the typical AEs associated with various immunotherapies, including HSCT, antibody-based therapies, ICIs, and CAR-T cell therapies, and then discuss their clinical management.

AEs of HSCT

Although HSCT can give some patients a chance at a cure, it is not an easy decision to be made. Transplantation has been a cure for thousands of patients with lethal forms of cancer. However, there can still be life-threatening risks and complications. Most of the side effects that can occur shortly after the transplant are the result of the bone marrow being destroyed by drugs or radiation just before the transplant. Others may be due to side effects of the conditioning treatments themselves. A short-term side effect that can occur with chemotherapy and radiation is mucositis. To prevent this, doctors often give anti-nausea medication at the same time as chemotherapy. Patients can easily get serious infections for at least the first six weeks after the transplant until the new stem cells start to produce white blood cells. 479 – 481 To prevent possible infections, antibiotics are used until the blood counts reach a certain level. It can take about 6 months to 1 year after the transplant for the immune system to take effect. Injuries and bleeding are other potential risk because the conditioning regimen can damage the body’s ability to generate platelets. Pneumonitis is a type of inflammation of the lung tissue that’s most commonly seen in the first 100 days after the transplant. However, some kinds of lung problems can occur much later after a transplant. Pneumonia caused by an infection is more common, but pneumonitis can also be caused by radiation, GVHD, or chemotherapy, rather than by the infection itself. Pneumonitis can be particularly severe if the patient has received total body irradiation with chemotherapy as part of the pre-transplant regimen. Acute kidney injury (AKI) directly related to stem cell transplant encompasses a wide range of both structural and functional disorders, which may be of the vascular (hypertension, thrombotic microangiopathy), glomerular (albuminuria, nephrotic glomerulopathies), and/or tubulointerstitial type. 482 – 484 AKI is a common complication following stem cell transplantation, affecting ~10–73% of patients. 482 A serious side effect in which tiny veins and other blood vessels in the liver become blocked is a hepatic veno-occlusive disease (VOD). 485 It is very rare and is only seen in people who have had an allogeneic transplant. 485 , 486 The onset of VOD is usually about 3 weeks after transplantation. It is more common in older patients who have had liver disease before the transplant and in patients who have acute GVHD. The symptoms are yellow skin and eyes, dark urine, tenderness under the rib cage and a rapid increase in body mass. 485 It is life-threatening, so it is very important to recognize and diagnose VOD at an early stage. 487 , 488

GVHD

GVHD is a leading contributor to mortality and morbidity after allo-HSCT. 489 , 490 The donated immune cells may also attack some of the organs, most typically the skin, the gastrointestinal tract and the liver. As a result, there may be some changes in the functioning of the body’s organs and an elevated risk of infections. 491 GVHD reactions are very common and can range in severity from barely noticeable to life-threatening. 39 , 492 , 493 Acute GVHD can occur between 10 and 90 days after the transplant and lasts for a short period of time. Chronic GVHD has a later onset and longer duration. The patient may experience one or both types of GVHD, or neither type of GVHD. Acute GVHD develops in approximately one-third to one-half of allogeneic transplant recipients. It is less frequent in the younger patients and the ones with a more closely matched HLA. A rash, burning and redness of the skin on the palms and the soles of the feet are usually the first symptoms. The rash may spread to the rest of the body. Other symptoms may include nausea, vomiting, stomach cramps, decreased appetite, jaundice, abdominal pain, and weight loss. Medications that can suppress the immune system may be given to prevent acute GVHD, such as steroids (glucocorticoids), methotrexate, cyclosporine, tacrolimus, or some types of mAbs. 492 , 494 These are administered before acute GVHD begins to occur. The risk of acute GVHD can also be reduced by the removal of immune cells from the donor stem cells prior to transplantation. However, this also increases the risk of viral infection, leukemic recurrence and graft failure. Researchers are exploring new ways to remove allo-activated T cells from donor transplants, which would reduce the severity of GVHD while still allowing donor T cells to destroy any remaining cancer cells. Mild cases of GVHD can usually be treated with topical steroid medications. More severe cases of GVHD may need to be treated with oral steroid medications or intravenous steroid medications. Chronic GVHD, which can lead to significant morbidity and mortality, usually occurs within one year of allo-HSCT. 495 When engrafted immune cells attack host cells, it causes inflammation and fibrosis in various types of tissues and multiple organ systems, such as the esophagus, gastrointestinal tract, neuromuscular system, genitourinary tract, liver, lungs, mouth, eyes, muscles, and joints. 495 , 496 Symptoms of chronic GVHD may include dry eyes, raised or discolored rash, thickened skin, swollen abdomen, yellowing of the skin and eyes, dry mouth, breathlessness, difficulty swallowing, fatigue, muscle weakness, and joint stiffness. Chronic GVHD can also be treated with immunosuppressive drugs, but these drugs increase the risk of infection. Most patients who have chronic GVHD will be able to stop taking the immunosuppressive medication if their symptoms are getting better.

Secondary cancers

It is possible for the original type of cancer to come back and for a second type of cancer to develop after the transplant. 497 – 499 The cancers that can develop are solid tumors in various organs, leukemia and MDS. They tend to occur a few years or even longer after engraftment. 500 , 501 Post-transplant lymphoproliferative disorder (PTLD) is an out-of-control growth of lymphocytes that can occur following alloHSCT. 502 , 503 Normally, T cells assist the body in getting rid of virally infected cells. The pretransplant treatment compromises the immune system, enabling EBV infections to get out of control. PTLD after allo-HSCT is relatively rare and generally occurs within one to six months. The symptoms of PTLD consist of swollen lymph nodes, fever and chills. 503 Although there is no standard treatment, the usual management is to reduce the use of immunosuppressive drugs and encourage the patient’s immune system to fight back. Other options involve infusing lymphocytes to boost the immune response and the administration of antiviral drugs. 503 – 506

AEs of antibody-based therapies

Antibody-based drugs have been generally considered to be less toxic than cytotoxic chemotherapeutics used for cancer therapy, while some of these elements may be recognized as foreign substances and thereby cause hyperactivation of immune and innate reactions. A wide spectrum of AEs to antibodies is observed, necessitating efforts to identify, manage and minimize side effects. Some toxicities result from the binding of a therapeutic antibody to its target antigen on normal cells, which refers to the “on-target, off-tumor” toxicity. Therefore, the manifestations of such toxicities are dependent on the target of antibody drugs. For example, rituximab can cause profound first-dose toxicity related to the rapid lysis of normal and malignant B cells that bear the target antigen, CD20. 507 Acute reactions can be caused by a variety of mechanisms, including acute IgE-mediated hypersensitivity and anaphylactoid reactions against the antibodies, serum sickness, tumor lysis syndrome (TIS) and CRS. 508 , 509 Clinical manifestations include local skin reactions at the injection site, fever and influenza-like syndrome and potentially fatal acute anaphylaxis and systemic inflammatory response syndrome (SIRS). Hypersensitivity reactions may be severe enough to require aggressive management and discontinuation of therapy. Meanwhile, these antibodies have immunomodulatory effects thus they can also induce various autoimmune diseases. AEs are also common in patients receiving bsAbs, with the majority of them being grade 3 or higher-grade AEs. A phase II study which included R/R B-ALL patients revealed that the common AEs during blinatumomab therapy included pyrexia (81%), fatigue (50%), headache (47%), tremor (36%), and leukopenia (19%), and most of the AEs occurred during the first cycle of administration. 357 In another trial, patients in the blinatumomab group suffered more AEs but the rate of serious AEs in the blinatumomab group was lower than that in the chemotherapy group. 510 The T-cell activation induced by BiTE poses the risk of unique complications such as CRS, neurotoxicity and TIS. 511 Moreover, severe CRS and neurological toxicity are the main reasons for the interruption of BiTE therapy, which can be controlled by close clinical monitoring and timely preventive or therapeutic intervention.

More importantly, the immunogenicity of antibodies is not only related to the percentage of homology, as specific amino acid changes at some positions can also affect immunogenicity. Drug-induced immunogenicity has been recognized as a major challenge in the development of antibodies, resulting in adverse effects and loss of efficacy. Drug administration to patients may induce humoral immune responses, causing the formation of anti-drug antibodies (ADAs). ADAs can complex with circulating therapeutic antibodies, making it difficult to achieve efficacious levels of circulating therapeutic antibodies. ADAs may not only inactivate the drug and cause a loss of targeting and/or increased clearance of ADA-drug complexes but also induce increased toxicity caused by the immune response that accompanies ADA formation, loss of drug targeting, or formation of highly immunogenic complexes. 508 , 512 Therefore, ADA assays should be rationally designed to allow an understanding of the characteristics and consequences of the detected ADAs.

Both the cytotoxic molecules and the antibody portion of ADCs can affect normal cells, resulting in “off-tumor” toxicities. 513 These “off-tumor” toxicities can be divided into “on-target” and “off-target” toxicities. The “on-target” toxicity is caused by ADCs killing normal tissues that express the target antigen, while “off-target” toxicity refers to the killing of ADCs in tissues that do not express the target antigen. Based on clinical observations, “on-target toxicity” caused by small molecule toxins is the major source of adverse effects of ADCs. Both antibody-mediated ADCC and CDC effects can occur in normal cells expressing the target antigen and lead to adverse reactions such as secondary kidney injury. In addition, like mAbs and bsAbs, ADCs can block the signaling of target antigens in normal cells, resulting in adverse reactions such as lung injury and liver toxicity. The “off-target toxicity” can be caused by the shedding of cytotoxic molecules into the circulation, bystander effect on normal cells and endocytosis and uptake of ADC by normal cells, causing normal cells to suffer damage from cytotoxic molecules. 514 The main victims are lymphocytes, granulocytes, and platelets in the bloodstream, followed by kidneys, lungs, nerves, skin and other tissues, causing clinically observed side effects similar to those of chemotherapeutic drugs. 513 Common AEs include fever, nausea, infection, vomiting, and stomatitis. Severe side effects were low blood counts, liver damage including hepatic VOD, infusion-related reactions and hemorrhage. Treatment discontinuation should be considered for patients who develop obvious signs or symptoms of anaphylaxis, including severe respiratory symptoms or clinically significant hypotension. Premedication with a corticosteroid, antihistamine and acetaminophen is recommended about one hour prior to the administration of ADC agent. 515

Immune-related adverse effects during ICI therapy

AEs linked to the use of ICIs are referred to as immune-related AEs (irAEs). These primarily include immune-related skin toxicity, endocrinopathies, hepatotoxicity, gastrointestinal toxicity, pulmonary toxicity, hematologic toxicity, central nervous system toxicity, cardiovascular toxicity, rheumatologic toxicity, immunotoxicity, renal toxicity, ocular toxicity, etc.). The incidence of irAEs with single-agent ICIs varies depending on the single agent, the tumor type and the disease setting. 478 Grading of irAEs is in accordance with the Common Terminology Criteria for AEs (CTCAE). Recommendations for the monitoring, diagnosis and treatment of irAEs are available in consensus guidelines from the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO), the NCCN and the Society for Immunotherapy of Cancer (SITC). 516 – 520 In principle, there are four sequential steps in the management of irAE: (i) diagnosing and grading irAEs, (ii) ruling out differential diagnoses and workup before immunosuppression, (iii) selecting the appropriate immunosuppression strategy for grade ≥2 cases, and (iv) actively evaluating at 72 h to make treatment adjustments. 521 While the management depends on the affected organ system, in general, ICI therapy should be followed with close monitoring for grade 1 toxicities, except for some neurologic, hematologic and cardiovascular toxicities. 521 ICI therapy may be discontinued for the majority of grade 2 toxicities. Consideration should be given to resuming ICI therapy if symptoms revert ≤grade 1. Suspension of ICIs and initiation of high-dose corticosteroids is generally warranted for grade 3 toxicities. Corticosteroids should be tapered over the course of a minimum of 4 to 6 weeks. For grade 4 toxicities, permanent discontinuation of ICIs is generally recommended. This does not apply to endocrinopathies that have been controlled with hormone replacement therapy. 521 , 522

Immune-related skin toxicity

Dermatologic toxicity seems to be one of the most commonly occurring AEs during treatment with ICIs. 523 – 527 Maculopapular eruption and pruritus are the most common symptoms. Serious dermatologic toxicities, such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug rash with eosinophilia and systemic symptoms (DRESS) and acute febrile neutrophilic dermatosis (Sweet syndrome) and systemic symptoms, are rare. 524 Although serious cutaneous AEs are rare, cutaneous side events can have a significant impact on the quality of life, reduce patient compliance and lead to dose adjustments or even discontinuation of treatment. 525 , 528 The question of whether ICIs can be resumed after grade 3 skin toxicity has been reduced to grade 1 or less with hormonal therapy should be discussed with the dermatologist. ICIs should be discontinued permanently and patients referred to a dermatologist if severe (grade 4) herpetic dermatoses occur. 516 – 520

Immune-related endocrinopathies

Immune-related endocrinopathies involving the thyroid gland (hypothyroidism or thyrotoxicosis), pituitary hypophysitis, adrenal glands (adrenal insufficiency), and pancreas (diabetes mellitus) are a frequent cause of acute and prolonged morbidity and may even be fatal. 529 – 533 Mild symptoms can be managed with continuation of ICI therapy with appropriate hormone replacement therapy; moderate symptoms require immediate discontinuation of ICI therapy and moderate symptoms require oral prednisolone 0.5–1 mg/kg; severe symptoms require intravenous prednisolone 1 mg/kg (methyl) tapered to 5 mg depending on symptom control, but hormone therapy cannot be discontinued. Routine monitoring of blood glucose levels is recommended in patients treated with ICIs and caution is required for the development of life-threatening ketoacidosis. 533 Unlike other irAEs, endocrinopathies are almost always permanent and require lifelong hormone replacement. 520 Due to the relatively vague nature of the symptoms associated with these endocrinopathies, prompt recognition and initiation of treatment can have a dramatic impact on a patient’s health and quality of life.

Immune-related hepatotoxicity

ICI-associated hepatitis is mainly characterized by elevated levels of transaminases with mildly elevated levels of bilirubin. 534 – 536 The diagnosis of immune-related hepatitis may be aided by laboratory tests, which include viral serologies, liver ultrasound, cross-sectional imaging, and liver biopsy. 534 Serum transaminase and bilirubin levels are recommended for all patients receiving ICI therapy before each treatment cycle to assess liver function. Hepatitis is usually asymptomatic, with some patients presenting with low-grade fever and malaise, which may be associated with transaminase levels. 535 Most patients with immune-related hepatitis respond to corticosteroids, but a substantial fraction require treatment with a secondary immunosuppressive agent. 534 It is also important to be alert to cases in which rebound transaminase levels or even fulminant hepatitis have been observed clinically, even after transaminase levels have been reduced to normal. The patient’s clinical presentation and serologic test results must continue to be monitored after recovery of liver function.

Immune-related gastrointestinal toxicity

Immune-related gastrointestinal toxicity is also a common adverse effect of ICI therapy, mainly manifested as diarrhea, colitis and small bowel inflammation. 537 – 540 The risk of gastrointestinal side effects is much higher with anti-CTLA-4 mAbs than with anti-PD-1/PD-L1 mAbs and can occur at any time during treatment, even months after treatment has ended. The median time for gastrointestinal side effects was 3 months. Following the diagnosis of immune-related gastrointestinal adverse events, the clinical selection of treatment options was based on the severity and duration of diarrhea. In addition to discontinuation of ICI, patients with grade 1 diarrhea may be treated with antidiarrheal drugs alone (loperamide, etc.) based on active rehydration and correction of water-electrolyte imbalance; for grade 2 diarrhea and above, glucocorticoids are the first recommended treatment; for grade 3–4 diarrhea or if glucocorticoid therapy is ineffective, immunosuppressive agents (e.g, infliximab, vedolizumab) are also an option.

Immune-related pulmonary toxicity

Immune-related pulmonary toxicity is a heterogeneous group of disorders that includes various clinical manifestations such as interstitial lung disease (ILD) or pneumonitis and rarer presentations such as bronchiolitis or pulmonary sarcoidosis. 519 , 541 – 543 Immune-related pulmonary toxicity usually appears in the first few months and is accompanied by non-specific clinical manifestations but with suggestive radiologic signs. 544 Exploratory endoscopy, including bronchoalveolar lavage and transbronchial lung biopsies, can further refine the diagnosis by ruling out a lung infection and demonstrating lymphocytic alveolitis. Any new respiratory symptoms, such as upper respiratory tract infection, cough, wheezing and dyspnea, should prompt a chest CT (computerized tomography) scan. Follow-up and monitoring are recommended for those who have imaging changes only and no clinical symptoms (grade 1); prednisolone therapy is suggested for those with mild to moderate symptoms (grade 2) and those with severe or life-threatening symptoms. For grade 2 pneumonia, clinical symptoms should be evaluated every 2–3 days; for grade 3–4 pneumonia, clinical symptoms and imaging should be evaluated after 2 days of treatment and if there is no evidence of improvement, immunosuppressive agents such as infliximab, cyclophosphamide, or mycophenolate mofetil can be considered. 517 – 519

Other rare immune-related toxicities

Rare immune-related toxicities during ICI treatment mainly include neurotoxicity, cardiotoxicity, rheumatologic immunotoxicity, hematologic toxicity, neuromuscular toxicity, and nephrotoxicity. 545 – 553 However, they are still reported in 1–12% of cases and are more common in patients receiving combination therapy. As an increasing number of patients with cancer are being treated with checkpoint inhibitors, the balance between clinical benefits and treatment-related toxicities for each patient is becoming more challenging. 554 Rarity is not the same as insignificance and the extent of damage to patients after its occurrence can even lead to death in a short period of time. In general, patients who experience a severe grade 3 or 4 irAE during ICI therapy are at risk of experiencing serious toxicities when rechallenged with checkpoint inhibitors. 555

CAR-T therapy-related toxicities

Cytokine Release Syndrome (CRS) and neurotoxicity are the most common and unique toxicities associated with CAR T-cell therapies, 556 – 567 and they are completely different from the irAEs that are associated with the treatment of ICIs. CAR-based therapies have the advantage of higher targeting specificity over conventional chemotherapy and radiotherapy. However, like antibody-based therapies, targeted antigens od CAR-T cells are also expressed in normal cells, such as CD19 in the normal B-cell lineage. The “on-target, off-tumor” toxicity is widespread, although a large part of others has not been identified or overlapped with other symptoms. Some toxicities, such as hypogammaglobulinemia, are a direct consequence of the “on-target, off-tumor” effects of the CAR-T cells and others may be an indirect result of the immunosuppressed state of the host. 565 For early recognition of potential toxicities and timely intervention, clinical monitoring before, during and after CAR-T cell therapy is critically required. Perhaps more importantly, with the appropriate management strategies, some of these toxicities associated with CAR-T therapies can be reversed with appropriate monitoring and management (Table 4 ). 559 , 568 – 570 Table 4 Monitoring and management of toxicities associated with CAR-T therapy CAR-T therapy-related AEs Biomarkers to monitor Toxicity management CRS CRP, IFN-γ, IL-1, IL-2, IL2Rα, IL-4, IL-6, IL-8, IL-10, TNF-α, granzyme B, MIP-1α, MCP-1, and GM-CSF in PB Grade 1: broad-spectrum antibiotics along with supportive care; Grade ≥2: Intravenous tocilizumab ≤4 doses; Grade ≥3 and in cases of grade 2 toxicity with sustained hypotension after anti-IL-6 therapy: add corticosteroids; Refractory to both tocilizumab and corticosteroids: use other agents include the Janus-associated kinase inhibitor, cyclophosphamide, extracorporeal cytokine adsorption with continuous renal replacement therapy, IVIG and anti-thymocyte globulin. Neurotoxicity IL-1, IL-6, IFN-γ, TNF-α/β, CRP, coagulation markers, ferritin in PB; MCP1, IL-6, IL-8 in CSF; ICE score Grade ≥1 ICANS: monitoring, supportive care and corticosteroids alone; Tocilizumab was not recommended unless patients have concurrent CRS. HLH/MAS Blood routine test; IFN-γ, IL-6, GM-CSF, CRP, ferritin in PB Suppress the overactive immune cells; Corticosteroids, anakinra or intrathecal cytarabine can be considered in cases when the HLH/MAS is caused by resistance to tocilizumab. CARAC Primary coagulation markers including platelet count in PB, APTT, PT, FIB, FDP, and D-dimer; test for CRS Management of CRS; replacement therapy to decrease the risk of bleeding and control active bleeding, including the transfusion of platelet, fresh frozen plasma and prothrombin complex concentrates and fibrinogen and cryoprecipitate; anticoagulant therapy and/or antifibrinolytic therapy should be used as appropriate for patients with high-grade CRS. Cytopenia Blood routine test, CRP, ferritin in PB; cytology of blood marrow Growth factors, thrombopoietin receptor agonists, stem cell enhancement, transfusion support; Elimination of infectious risk Hypogammaglobulinemia Gammaglobulinemia in PB Intravenous or subcutaneous immunoglobulin G Infection IL-6, CRP in PB; lymphocyte count; CT of lungs; viral and bacterial etiologic test Provide antibacterial or antifungal prophylaxis; For certain patients with concurrent severe or recurrent infections and hypogammaglobulinemia: IVIG is recommended as replacement treatment. ADAs Detection of ADAs in serum (HAMA is the ADA occurred in CAR-T therapy with murine-derived scFv) Secondary reinfusion by altering the target and strengthening lymphodepletion. CAR-T chimeric antigen receptor T cell, AEs adverse effects, CRS cytokine release syndrome, CRP C-reactive protein, IFN interferon, IL interleukin, TNF tumor necrosis factor, MIP macrophage inflammatory protein, MCP monocyte chemoattractant protein, GM-CSF granulocyte/macrophage colony-stimulating factor, PB peripheral blood, IVIG intravenous immunoglobulin G, CSF cerebrospinal fluid, ICE immune effector cell associated encephalopathy, ICANS immune effector cell-associated neurotoxicity syndrome, HLH/MAS Hemophagocytic lymphohistiocytosis/macrophage activation syndrome, CARAC CAR-T therapy-associated coagulopathy, APTT activated partial thromboplastin time, PT prothrombin time, FIB fibrinogen, FDP fibrin degradation products, CT Computed Tomography, ADA anti-drug antibody, HAMA human-anti-mouse antibody, scFv single chain variable fragment

CRS

CRS is the most common life-threatening adverse event associated with CAR T-cell therapy. Variable incidence of CRS has been reported with different CAR T-cell therapies due to differences in grading scales used to assess CRS severity, CAR T-cell design and generation and clinical trial design. 565 , 571 The typical time to the onset of CRS ranges from 2 to 3 days, with a persistent duration of 7 to 8 days, although CRS can occur within a few hours or as late as 10 to 15 days after CAR-T cell infusion. The onset of CRS is usually characterized by fever and constitutional symptoms such as malaise and anorexia. In severe cases, CRS also manifests with features of a systemic inflammatory response. These include hypotension, hypoxia, cytopenia, coagulopathy and even organ dysfunction. The organ dysfunction may be the secondary effect of hypotension or hypoxia, but it may also be a direct result of the release of cytokines. Organ dysfunction can be prevented or even reversed in the majority of patients if the symptoms and signs of CRS are recognized and addressed in a prompt and timely manner. 564 CAR-T cell-mediated cancer elimination was also the trigger for the systemic inflammatory response, which is the hallmark of CRS. 556 , 558 , 572 Thus, from a clinical standpoint, the most important management to overcome CRS is to block the feedback loop of cytokines. 573 Cytokines and markers of inflammation that have been implicated in more severe CRS are C-reactive protein (CRP), ferritin, interferon (IFN)-γ, IL-1, IL-2, soluble IL2-Rα, IL-4, IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-α, granzyme B, granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage inflammatory protein-1α (MIP-1α), and monocyte chemoattractant protein-1 (MCP-1). 564 , 574 – 577 A number of risk factors for severe CRS have been implicated, although these vary between different studies and likely between different indications. In general, these include an increased CAR-T cell expansion and a higher tumor burden. 578 , 579 Moreover, bone marrow (BM) suppression is also considered a determinant of the occurrence and evolution of CRS. 579 Because the management of CRS depends on the severity of the disease, several institutions had independently developed different CRS grading systems prior to the publication of consensus guidelines. These guidelines have contributed to the standardization of CRS management. Both direct targeting and non-specific immunosuppressive strategies to counteract overactive immune cells and elevated cytokine are used to control CRS in patients receiving CAR T-cell therapy. IL-6 has been implicated as an activating signal for CAR-T cells and is considered a pivotal mediator of CRS. The empirical testing of various blocking antibodies soon identified IL-6 as a critical driver of CRS. Tocilizumab, a monoclonal antibody that blocks signaling through the IL-6 receptor (IL-6R), became a cornerstone of CRS management. 564 , 580 – 583 In general, patients with grade 1 CRS should be given broad-spectrum antibiotics along with supportive care. This may vary depending on the end-organ toxicities that are observed. Intravenous tocilizumab should be administered for a maximum of 4 doses to patients with grade ≥2 CRS. In cases of grade ≥3 CRS and in cases of grade 2 toxicity with sustained hypotension after anti-IL-6 therapy, the addition of corticosteroids should be considered. 518 To prevent the progression of CRS, emergent intervention is warranted. However, other potential causes of the inflammatory response, including infection and malignant progression, should be ruled out. If there is no improvement in CRS after treatment with tocilizumab and steroids, an examination for infection should be performed and managed as necessary. In addition to siltuximab and anakinra, other agents may be considered for patients who are refractory to both tocilizumab and corticosteroids. These agents include the Janus-associated kinase inhibitor, cyclophosphamide, extracorporeal cytokine adsorption with continuous renal replacement therapy, intravenous IgG (IVIG) and anti-thymocyte globulin. Data in support of the use of any of these agents are mostly from anecdotal reports or small case series.

Neurotoxicity

Neurotoxicity is another adverse event that has been a concern in clinical trials of various immune effector cell therapies. 577 , 584 , 585 Neurologic toxicity may occur concurrently with CRS. However, in some cases, neurologic toxicity may not occur simultaneously but may occur before or days after CRS. Like CRS rates, neurotoxicity incidence rates across clinical trials vary considerably. Neurologic toxicities are diverse and may include temporary working memory loss, delirium, seizures and rarely, acute cerebral edema. 564 Neurotoxicity associated with CAR T-cell therapies has been referred to as immune effector cell-associated neurotoxicity syndrome (ICANS). It is characterized by a pathologic process involving the central nervous system following any immunotherapy that results in the activation or engagement of endogenous or infused T cells and other immune effector cells. The time to the onset of neurotoxicity is typically 4–10 days after the administration of CAR-T cells, with a duration of 14–17 days. For BCMA-directed CAR T-cell therapies, the duration may be somewhat shorter. CRS is considered to be a potent risk factor for ICANS and the severity of CRS is highly correlated with that of ICANS. The development of neurotoxicity is associated with a higher pre-treatment disease burden, a higher peak CAR T-cell expansion, a higher baseline inflammatory status, an earlier and higher elevation of pro-inflammatory cytokines in the blood and cerebrospinal fluid and the presence of pre-existing neurological comorbidities. 563 Pro-inflammatory cytokines were accumulated in the cerebrospinal fluid during severe neurotoxicity, with a disproportionately high level of IL-6, IL-8, and MCP1, suggesting a production that is specific to the central nervous system. 563 IL-1, derived from monocytes, has recently been highlighted as a key driver of neurotoxicity. 556 Gust et al. also described the endothelial dysfunction and increased permeability of the blood-brain barrier (BBB) during neurotoxicity following adoptive immunotherapy with CD19 CAR-T cells, which may help to identify risk predictors for neurotoxicity. 585 Increased BBB permeability may enable inflammatory cytokines and immune cells to migrate into the central nervous system and potentially contribute to inflammation of the nervous system. 585 , 586 As in the case of CRS, the risk factors and the incidence of CRS are reported with variability between studies. CD19-directed CAR is more likely than BCMA-directed CAR to be accompanied by high-grade ICANS. The grade of ICANS determines the management of neurotoxicity. Consensus guidelines with recommended grading of ICANS have been issued by the American Society for Transplantation and Cellular Therapy (ASTCT). It’s recommended that clinicians use this scale to grade any CAR-T cell-related neurotoxicity. 587 , 588 Along with careful monitoring and supportive care, corticosteroids are the cornerstone of ICANS management. Since tocilizumab may exacerbate ICANS, 575 for patients with grade 1 CRS (fever only) and higher grade ICANS, corticosteroids alone may be preferred. The NCCN consensus panel does not recommend treating patients receiving CAR T-cell therapy for neurotoxicity with tocilizumab unless they have concurrent CRS. 518

Hemophagocytic lymphohistiocytosis/macrophage activation syndrome

Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) is regarded as a serious immunologic syndrome that is triggered by out-of-control immune activation, which includes the hyperactivation of macrophages and lymphocytes, increased production of pro-inflammatory cytokines, infiltration of lymphocytes and histiocytes into tissues and organs and multi-organ failure. 569 , 584 , 589 , 590 In contrast to primary HLH/MAS, CAR T-cell therapy-induced HLH/MAS is thought to be a type of secondary HLH/MAS because it is initiated by an immune trigger. 558 In a recent study, it was estimated that HLH/MAS occurs in 3.5% of the patients who receive CAR T-cell therapy. 591 Nevertheless, the actual incidence of HLH/MAS has been disputed, in part because of the close overlap in symptoms between CRS and HLH/MAS. The definitive diagnosis of HLH/MAS after CAR T-cell therapy can be challenging as the clinical features and laboratory abnormalities overlap substantially with the CRS. 558 , 591 The majority of patients with moderate-to-severe CRS exhibit the typical laboratory abnormalities of HLH/MAS, such as elevated levels of CRP, cytopenia, hyperferritinemia, hypofibrinogenemia, coagulopathy, and increased levels of several serum cytokines, in particular IL-6, INF-γ and GM-CSF. 478 , 569 , 584 , 589 The clinical manifestations related to CAR T cell-induced HLH/MAS typically comprise fever, multi-organ dysfunction and central nervous system disorders and occasionally hepatosplenomegaly or hemophagocytosis in the bone marrow or other organs. 589 , 591 Suppressing the overactive immune cells that are contributing to symptoms is the ultimate goal of clinical management of HLH/MAS. In some cases, resistance to tocilizumab may also lead to late-onset HLH/MAS-like lesions. Corticosteroids, anakinra, or intrathecal cytarabine should be considered in such cases. 584 , 589 , 590 However, there is still a lack of data to support the use of such drugs in this setting.

Hypogammaglobulinemia

Hypogammaglobulinemia is another potential risk related to CAR T-cell therapy. Hypogammaglobulinemia has been reported in up to 53% of patients who have been treated with CAR-T cells in clinical studies. 592 , 593 Hypogammaglobulinemia is a disorder that is characterized by decreased levels of antibodies in the blood and an increase in the risk of infection. Hypogammaglobulinemia is the consequence of an extremely small number of B cells or plasma cells, termed B cell aplasia or plasma cell aplasia, respectively. 593 Even in patients in CR after CAR T-cell therapy, long-term hypogammaglobulinemia may still occur. The recommendations are made based on experts’ opinions, institution-specific experience and infection prevention approaches and strategies from other contexts due to the lack of randomized, controlled clinical trials for the treatment of hypogammaglobulinemia. 593 Hypogammaglobulinemia can be controlled with either intravenous or subcutaneous immunoglobulin G, a product of fractionated blood derived from the pooled plasma of many individuals. 592 – 595 Immunoglobulin offers broad protection from opportunistic infections because it contains antibodies against a variety of infectious agents. 592

Cytopenia

Patients receiving CAR T-cell therapy are also at high risk for developing hematologic toxicities, particularly sustained cytopenia such as neutropenia, thrombocytopenia, anemia and/or leukopenia. 596 – 598 Cytopenia may appear following CAR-T infusion and always presents at an early stage (<30 days), frequently for a prolonged period (30–90 days) and sometimes persists or appears at a late stage (>90 days). 597 The onset and duration of cytopenia are often correlated with the severity of CRS and ICANS, the burden of the tumor, the number of prior therapies, baseline blood counts, peak levels of CRP and ferritin, as well as the CAR construct. 596 , 597 , 599 , 600 Bone marrow biopsy is critical for the evaluation of both primary disease and secondary bone marrow neoplasm in patients with persistent or late-onset cytopenia. The management options for cytopenia are somewhat limited and need to be individualized based on the likely underlying etiology. These options may include growth factors, thrombopoietin receptor agonists, stem cell enhancement, transfusion support and the elimination of infectious risk. 597 , 601 , 602

Coagulopathy

The typical time to onset of CAR-T therapy-associated coagulopathy (CARAC) is often 6 to 10 days after CAR-T cell infusion and closely follows the elevation of IL-6 and other cytokines and gradually relieves as the CRS is controlled. 503 CARAC, including disseminated intravascular coagulation (DIC), prolonged prothrombin time/activated partial thromboplastin time, and hypofibrinogenemia, often occurs in patients with severe CRS. 603 Over half of the patients experienced thrombocytopenia or at least one abnormal coagulation parameter after CAR-T therapy. Clinically bleeding events occurred in about 19.6% of patients with coagulopathy and 14 to 50% of patients with coagulopathy developed DIC; 6.7 to 42.9% of patients with DIC died. 503 Monitoring of patients with CARAC is imperative to avoid the potential for bleeding events and even life-threatening hemorrhage. Since the severity of CARAC is highly associated with that of CRS, the management of CRS is of great importance. As bleeding is the main feature of CARAC, replacement therapy can decrease the risk of bleeding and control active bleeding, including the transfusion of platelet, fresh frozen plasma and prothrombin complex concentrates and fibrinogen, and cryoprecipitate. More importantly, anticoagulant therapy and/or antifibrinolytic therapy should be used as appropriate for patients with high-grade CRS. 503

Infection

Infectious complications following CAR T-cell therapy are very common. They have been reported in up to ~70% of recipients. 604 – 606 The majority of infections develop shortly following infusion and can be attributed to several causes, such as the depletion of normal B cells or plasma cells resulting from the direct action of the CAR-T cells, the depletion of lymphocytes and granulocytes caused by conditioning chemotherapy, anti-cytokine, or corticosteroid therapies given for CRS or neurologic toxicity and immunocompromise induced by the patient’s underlying malignancy. 604 , 607 Infections, including bacterial, viral and fungal infections, have been reported following CAR T-cell therapy and can be life-threatening. 604 An increased likelihood of acute infections may also be linked to the seriousness of CRS. The control of infections is generally with agents that are selective for the source of the infection. Risk stratification should be performed based on patient characteristics such as prior suppressive therapy, history of infection, etc. when determining whether to provide antibacterial or antifungal prophylaxis. 604 For certain patients with concurrent severe or recurrent infections and hypogammaglobulinemia, the NCCN guidelines suggest IVIG as a replacement treatment. 518

ADA

Since CAR is an exogenous sequence, it has certain immunogenicity which leads to ADA production by humoral immunity after infusion. Early-generation CAR-T cells were constructed from murine-derived scFv and the species difference resulted in the generation of a HAMA. 276 Even though humanized CAR circumvented immunogenicity to a certain extent, some patients were still reported to have ADA in clinical trials of CD19 and BCMA, which eventually affected the efficacy or led to earlier relapse. 278 , 608 Therefore, monitoring of ADA has become an important part of current CAR-T clinical trials. Although with large individual variability, the factors related to the production of ADA are currently thought to be the use of CAR-T with murine scFv and multiple infusions of the same CAR-T product. 275 , 609 There is no targeted method to solve the problem of ADA, but it should be monitored by ELISA (enzyme-linked immunosorbent assay) and flow cytometry, to understand the reason for drug resistance or recurrence in patients in time, 610 , 611 and to reduce the impact of ADA on secondary reinfusion by replacing the target and strengthening lymphodepletion. 609 , 612

Challenges and future prospects

Each immunotherapy strategy has achieved varying degrees of encouraging results in hematologic malignancies. Different immunotherapeutic approaches have their advantages but also shortcomings that need to be addressed (Table 5 ). Further clinical exploration will be needed to further improve the prognosis of patients with hematologic malignancies. The allo-HSCT remains the primary treatment for hematologic malignancies with a potentially curative outcome. The haplo-HSCT modality can best address the limited source of allo-HSCT donors, but it’s still necessary to further explore how to minimize the severity of GVHD and transplant-related death while improving anti-tumor effects, especially for patients with R/R hematologic cancers. The future direction of transplantation will be toward personalization, in which a combination therapy strategy is very essential. R/R patients can be pre-treated with CAR-T therapy or other targeted therapies to achieve remission before bridging to HSCT. Patients, who still have residual disease after incomplete remission with various treatments such as chemotherapy, targeted therapy and immunotherapy, can be treated with donor CAR-T combined with allo-HSCT. For patients with positive MRD after transplantation, CAR-T therapy can also be recommended. The second direction is to optimize donor selection, especially for familial donors and to avoid selecting donors who carry the same genetic defect as the patient. Molecular testing can be used to detect HLA loss and guide the search for donors for patients who need a second transplantation. In addition, anti-tumor therapy needs to be considered along with GVHD prevention and thus individualized management should be conducted after transplantation to balance the anti-GVHD and anti-tumor benefits. The mAbs, bsAbs, and ADC-based agents have also improved the treatment of cancer patients to some extent, but the clinical toxicities remain unavoidable. Meanwhile, some patients have demonstrated little or no responsiveness to such treatments. Ideal tumor antigens need to be screened for these antibody-based therapies to improve the anti-tumor effects and reduce the incidence of “off-tumor, on-target” effects. The technical threshold for the development of bsAbs is more difficult compared to single-target mAbs. Selecting the best target combination is only the first step, followed by a rational structural design based on the receptor structure as well as the biological mechanism of the disease. In addition, inappropriate clinical design and dosing regimens will result in higher toxicity in patients, which can be improved by optimizing treatment strategy, dose and timing to reduce side effects to some extent. The payload and linker in ADC drugs can also directly affect effectiveness and safety. In addition, how to solve the complexity of pharmacokinetics, enhance drug stability, improve drug efficacy and reduce drug resistance are also urgent to be explored. The bsADC (bispecific antibody-drug conjugate) combines the advantages of bsAbs and ADCs and is a major challenge for the future. Compared to mAbs, bsADCs can target tumor cells more specifically through two antibodies, overcoming drug resistance while increasing the safety. Meanwhile, novel therapeutic agents, such as bifunctional checkpoint-inhibitory T cell engager (CiTE), 613 simultaneous multiple interaction T cell engager (SMITE), 614 trispecific killer engager (TriKE) and BiTE-expressing CAR-T cells, are being designed to integrate various immune functions into one molecule or a single cellular vector and thereby enhance efficacy without compromising safety. 172 ICIs have shown superior efficacy mainly in HL and primary mediastinal large B-cell lymphoma, but has limited efficacy in other hematologic cancers. Serious irAEs may also occur with ICI therapy, which will impede its application in the clinic. The exploration of more-effective and rational combinatorial approaches is an area of great interest in improving the efficacy of ICI therapy. The emergence of ACTs, especially CAR T-cell therapy, offers a new therapeutic avenue and hope for R/R patients with hematologic malignancies. However, these therapeutic approaches are usually accompanied by serious complications such as CRS, ICANS, and “off-target” effects, while achieving remarkable results. Challenges remain in the optimization of CAR design and cell products, improvement of remission rates, prolongation of remission duration, reduction of toxicity and expansion of this therapeutic modality to other cancer types. To further improve patient outcomes, innovative strategies are needed to enhance the therapeutic efficacy and in vivo persistence of CAR-T cells and to mitigate tumor cell resistance. Elucidation of mechanisms of resistance and immune escape has long been a big challenge. Epigenetic mechanisms play an important role in both tumor development and anti-tumor immune regulation and epi-drugs represented by DNA methylation inhibitors and histone deacetylation inhibitors can coordinate, potentiate and reduce immune escape effects in several aspects by regulating tumor killing and enhancing the anti-tumor immunity. 615 – 617 Therefore, a deeper and broader exploration of epi-immunotherapy will further advance the understanding of this emerging concept and bring more creative breakthroughs in immunotherapy. Allogeneic CAR-T cells also have the potential to overcome many of the manufacturing limitations of traditional autologous CAR T-cell therapies. Universal CAR-T cells will undoubtedly be the future direction of CAR-T therapy. While there are still concerns about host-versus-graft and graft-versus-host reactions caused by CAR-T cells in the allogeneic environment, the risks and side effects are being reduced through gene knockout technology and the safety of universal CAR-T cells will be further enhanced. Universal CAR-T therapies are expected to bring less expensive and more immediately available “off-the-shelf” therapies to patients with malignant hematologic cancers. However, there are many challenges with universal CAR-T cells and clinical studies are still in the early stages. Tumor vaccines take advantage of tumor-associated antigens or tumor-specific antigens to stimulate the immune system but are currently in their infant stage and there is still much space for refinement to discover their full potential. Table 5 The advantages and limitations of various immunotherapies in hematologic malignancies Type of immunotherapy Advantages Limitations Future directions allo-HSCT The only option to achieve a cure for hematologic malignancies. Incidence of transplant related mortality and graft-versus-host disease. Personalization and combination therapy; optimization of donor selection, maintenance therapy to balance the anti-GVHD and anti-tumor benefits. mAb Specifically targeting tumor antigen and inducing cancer cell death; their combination with chemotherapy has been first-line therapy for several cancers. Incidence of “off tumor, on target” effect and therapy-related toxicities. Requirement for suitable target antigen; optimization of treatment strategy; overcome drug resistance to single-agent therapies. bsAb Combining the binding sites of two monoclonal antibodies in the same one molecule to promote cancer cell killing. Incidence of “off tumor, on target” effect and therapy-related toxicities; a lack of co-stimulation might induce T-cell anergy and compromise the clinical efficacy; Requirement for suitable target antigen; need to selecting the best target combination; require rational structural design; optimization of treatment strategy; overcome drug resistance to single-agent therapies. ADC Utilizing the specific binding properties of mAb to selectively deliver cytotoxic agents to cancer cells to increase the therapeutic potentials of cytotoxic agents. Incidence of “off tumor, on target” effect and therapy-related toxicities. Requirement for suitable target antigen; require rational structural design; solve the complexity of pharmacokinetics, enhance drug stability, improve drug efficacy and reduce drug resistance; optimization of treatment strategy; design of bsADCs; overcome drug resistance to single-agent therapies. ICI Blockade of immunosuppressive checkpoint signaling pathway. Incidence of irAEs; only the therapeutic results in HL was remarkable. Overcome drug resistance to single-agent therapies; combination therapy with epi-drugs, CAR-T therapy and/or HSCT. CIK, γδ T and NK cells Non-specific cellular therapies; no demand for genetical modification. Requirement for a large number of cells; limited efficacy in hematologic malignancies. Improvement of clinical efficacy and reduction of toxicity; combination therapy with epi-drugs, ICIs and/or HSCT. CAR-T cell therapy Specific cellular therapies; no restriction of MHC; achieve rapid development and great success in treating hematologic malignancies, especially R/R patients; serve as the “bridge” to transplant; several cell products have achieved FDA’s approval and entered into the commercialized field. Therapy-related toxicities, such as CRS and neurotoxicity; long period of manufacturing; high cost. Requirement for suitable target antigen; optimization of CAR design and cell products; improvement of remission rates; prolongation of remission duration; reduction of toxicity and expansion of this therapeutic modality to other cancer types; universal CAR-T products; overcome drug resistance to monotherapy; combination therapy with epi-drugs, ICIs and/or HSCT. CAR-NK cell therapy Specific cellular therapies; no restriction of MHC; provide an “off-the-shelf” cell product and could be readily available for immediate clinical use; serve as the “bridge” to transplant. Still in early stage of clinical studies; limited efficacy in hematologic malignancies. Requirement for suitable target antigen; optimization of CAR design and cell products; improvement of clinical efficacy and reduction of toxicity; expansion of this therapeutic modality to other cancer types; overcome drug resistance to monotherapy; combination therapy with epi-drugs, ICIs and/or HSCT. Tumor vaccine Taking advantage of tumor-associated antigens or tumor-specific antigens to stimulate the immune system. Still in very early stage of clinical study; limited efficacy in hematologic malignancies. Requirement for suitable target antigen and vaccine vectors; improvement of clinical efficacy and reduction of toxicity. allo-HSCT allogeneic hematopoietic stem cell transplantation, mAb monoclonal antibody, bsAb bispecific antibody, ADC antibody-drug conjugate, bsADC bispecific antibody-drug conjugate, ICI immune checkpoint inhibitor, HL Hodgkin lymphoma, irAEs immune-related adverse effects, MHC major histocompatibility complex, R/R refractory and relapsed, FDA Food and Drug Administration, CIK cytokine-induced killer cells, γδ T gamma/delta T, NK natural killer, CAR-T chimeric antigen receptor T, CRS cytokine release syndrome

The current status quo in cancer treatment is that immunotherapy is generally used as a second-, third-, or even last-line treatment option when patients have no better options. Based on promising results in terms of efficacy and safety, immunotherapy is expected to become the first line of treatment in the future, while conventional treatment will be relegated to the second line. 618 Treatment regimens for patients with hematologic cancers typically include 3–4 or even 5 cytotoxic drugs and the addition of immunotherapy drugs can reduce the use of these chemotherapy agents. Several clinical trials have confirmed that the combination of immunotherapy with reduced chemotherapy regimens has improved rather than suppressed therapeutic effects. Therefore, one of the major trends in cancer treatment is that immunotherapy will become increasingly prominent. 618 Combination immunotherapy is an exciting area of research that may further enhance our ability to utilize the immune system against hematologic malignancies. Currently, HSCT remains a fundamental treatment option and combining HSCT with novel immunotherapies is a promising direction for our future. Many clinical questions remain to be answered. Which immunotherapy works best in the context of HSCT? Which immunotherapy is better suited as a bridge to HSCT or as a preferred option after HSCT relapse? Which immunotherapy approach is more appropriate for patients who are ineligible for HSCT? With the continuous development and advancement of molecular biology and immunology technologies, immunotherapy is expected to further change the existing treatment paradigm of hematological cancers. The detailed information generated by multidimensional omics technologies, single-cell sequencing and others will not only provide insights into the complex determinants of efficacy and toxicity of immunotherapies but also help identify predictive biomarkers and develop new treatment strategies. As future research helps to address these challenges, these advanced technologies may eventually become the standard and necessary tool in the field of immunotherapy, revealing the relationship between key drivers of cancer phenotypes and enabling clinicians to better predict and monitor patient responses, thereby facilitating more comprehensive and realistic personalized treatments for cancer patients. 619 – 632

Conclusion

Malignant hematologic cancers are major diseases that pose a serious threat to human health. The past and present are very exciting eras for immunotherapy of hematologic malignancies, but the future looks quite incredible and we are rapidly moving in that direction. Although the various immunotherapies aim to treat cancer patients through different mechanisms of action, the core is to restart and maintain the “Cancer-Immunity Cycle” and restore normal anti-tumor immunity. Multiple categories of immunotherapies have been developed for the treatment of blood cancers and are being further evaluated in clinical trials. More importantly, some of these immunotherapies have been approved by the FDA for the treatment of blood cancers or have even entered the commercialization stage. At present, immunotherapy for blood cancers still faces a series of challenges. The most important of these is safety, where different therapies are accompanied by varying degrees of treatment-related side effects, thus emphasizing the importance of early detection and intervention of toxicities. As mentioned above, clinical experts have been developing guidelines for the management of toxicities based on clinical trials and real-world clinical experience. The establishment of these guidelines has provided a solid foundation for improving the safety and widespread use of immunotherapy. In addition, they are gaining experience in managing the unique complications associated with novel immunotherapies and establishing practice guidelines that will be critical to expanding their use worldwide. Another notable issue is treatment failure due to resistance and relapse. This illustrates the striking difference in the ability of each patient to respond to immunotherapy, highlighting the potentially urgent need for and importance of personalized cancer treatment.

These authors contributed equally: Lu Tang, Zhongpei Huang

Acknowledgements

This work was supported by grants from the National Key R&D Program of China (2022YFC2502700), the National Natural Science Foundation of China (81873434; 82100190) and the China Postdoctoral Innovative Talent Support Foundation (BX2021106). All the figures were created by the website tool BioRender ( https://www.biorender.com/ ).

Author contributions

L.T. and H.M.: conception and offering critical comments. L.T., Z.H., and H.M.: data collection. L.T., Z.H., and H.M.: writing and original draft preparation. L.T. and Z.H.: table and figure preparation and editing. L.T., Y.H., and H.M.: review and editing. All authors contributed to the article have read and approved the submitted version.

Competing interests

The authors declare no competing interests.

References

1. Koebel CM Adaptive immunity maintains occult cancer in an equilibrium state Nature 2007 450 903 907 18026089 10.1038/nature06309

2. von Locquenghien, M., Rozalén, C. & Celià-Terrassa, T. Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response. J. Clin. Invest . 131 , e143296 (2021). 10.1172/JCI143296 PMC7773346 33393507

3. Vinay DS Immune evasion in cancer: mechanistic basis and therapeutic strategies Semin. Cancer Biol. 2015 35 S185 s198 25818339 10.1016/j.semcancer.2015.03.004

4. Zitvogel L Tesniere A Kroemer G Cancer despite immunosurveillance: immunoselection and immunosubversion Nat. Rev. Immunol. 2006 6 715 727 16977338 10.1038/nri1936

5. Dunn GP Old LJ Schreiber RD The immunobiology of cancer immunosurveillance and immunoediting Immunity 2004 21 137 148 15308095 10.1016/j.immuni.2004.07.017

6. Chen DS Mellman I Oncology meets immunology: the cancer-immunity cycle Immunity 2013 39 1 10 23890059 10.1016/j.immuni.2013.07.012

7. Motz GT Coukos G Deciphering and reversing tumor immune suppression Immunity 2013 39 61 73 23890064 10.1016/j.immuni.2013.07.005 PMC3782392

8. McNutt M Cancer immunotherapy Science 2013 342 1417 24357273 10.1126/science.1249481

9. Couzin-Frankel J Breakthrough of the year 2013. Cancer immunotherapy Science 2013 342 1432 1433 24357284 10.1126/science.342.6165.1432

10. Couzin J Cancer immunotherapy. select T cells, given space, shrink tumors Science 2002 297 1973 12242411 10.1126/science.297.5589.1973a

11. Pui CH Evans WE Acute lymphoblastic leukemia N. Engl. J. Med. 1998 339 605 615 9718381 10.1056/NEJM199808273390907

12. Döhner H Weisdorf DJ Bloomfield CD Acute myeloid leukemia N. Engl. J. Med. 2015 373 1136 1152 26376137 10.1056/NEJMra1406184

13. Kayser S Levis MJ The clinical impact of the molecular landscape of acute myeloid leukemia Haematologica 2023 108 308 320 36722402 10.3324/haematol.2022.280801 PMC9890016

14. Armitage JO Gascoyne RD Lunning MA Cavalli F Non-Hodgkin lymphoma Lancet 2017 390 298 310 28153383 10.1016/S0140-6736(16)32407-2

15. Wang HW Balakrishna JP Pittaluga S Jaffe ES Diagnosis of hodgkin lymphoma in the modern era Br. J. Haematol. 2019 184 45 59 30407610 10.1111/bjh.15614 PMC6310079

16. Ansell SM Hodgkin lymphoma: diagnosis and treatment Mayo Clin. Proc. 2015 90 1574 1583 26541251 10.1016/j.mayocp.2015.07.005

17. van de Donk N Pawlyn C Yong KL Multiple myeloma Lancet 2021 397 410 427 33516340 10.1016/S0140-6736(21)00135-5

18. Kennedy JA Ebert BL Clinical implications of genetic mutations in myelodysplastic syndrome J. Clin. Oncol. 2017 35 968 974 28297619 10.1200/JCO.2016.71.0806 PMC5455680

19. Bachireddy P Burkhardt UE Rajasagi M Wu CJ Haematological malignancies: at the forefront of immunotherapeutic innovation Nat. Rev. Cancer 2015 15 201 215 25786696 10.1038/nrc3907 PMC4511812

20. Im A Pavletic SZ Immunotherapy in hematologic malignancies: past, present, and future J. Hematol. Oncol. 2017 10 94 28434396 10.1186/s13045-017-0453-8 PMC5402171

21. Salles G Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience Adv. Ther. 2017 34 2232 2273 28983798 10.1007/s12325-017-0612-x PMC5656728

22. Tilly H Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann. Oncol. 2015 26 v116 v125 26314773 10.1093/annonc/mdv304

23. Salles G Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study Lancet Oncol. 2020 21 978 988 32511983 10.1016/S1470-2045(20)30225-4

24. Palumbo A Daratumumab, bortezomib, and dexamethasone for multiple myeloma N. Engl. J. Med. 2016 375 754 766 27557302 10.1056/NEJMoa1606038

25. Feldman EJ Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia J. Clin. Oncol. 2005 23 4110 4116 15961759 10.1200/JCO.2005.09.133

26. Topp MS Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study Lancet Oncol. 2015 16 57 66 25524800 10.1016/S1470-2045(14)71170-2

27. Connors JM Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma N. Engl. J. Med. 2018 378 331 344 29224502 10.1056/NEJMoa1708984 PMC5819601

28. Horwitz S Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial Lancet 2019 393 229 240 30522922 10.1016/S0140-6736(18)32984-2 PMC6436818

29. Oka Y Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis Int. J. Hematol. 2003 78 56 61 12894852 10.1007/BF02983241

30. Oka Y Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression Proc. Natl Acad. Sci. USA 2004 101 13885 13890 15365188 10.1073/pnas.0405884101 PMC518848

31. Xu-Monette ZY Zhou J Young KH PD-1 expression and clinical PD-1 blockade in B-cell lymphomas Blood 2018 131 68 83 29118007 10.1182/blood-2017-07-740993 PMC5755041

32. Bagchi S Yuan R Engleman EG Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance Annu Rev. Pathol. 2021 16 223 249 33197221 10.1146/annurev-pathol-042020-042741

33. Sebestyen Z Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies Nat. Rev. Drug Discov. 2020 19 169 184 31492944 10.1038/s41573-019-0038-z

34. Wang W Jiang J Wu C CAR-NK for tumor immunotherapy: clinical transformation and future prospects Cancer Lett. 2020 472 175 180 31790761 10.1016/j.canlet.2019.11.033

35. Xu Z Huang X Cellular immunotherapy for hematological malignancy: recent progress and future perspectives Cancer Biol. Med. 2021 18 966 980 34351724 10.20892/j.issn.2095-3941.2020.0801 PMC8610149

36. Melenhorst JJ Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells Nature 2022 602 503 509 35110735 10.1038/s41586-021-04390-6 PMC9166916

37. Holstein SA Lunning MA CAR T-cell therapy in hematologic malignancies: a voyage in progress Clin. Pharmacol. Ther. 2020 107 112 122 31622496 10.1002/cpt.1674

38. Holtick, U. et al. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. Cochrane Database Syst. Rev . Cd010189 (2014). 10.1002/14651858.CD010189.pub2 PMC10612998 24748537

39. Penack O Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation Lancet Haematol. 2020 7 e157 e167 32004485 10.1016/S2352-3026(19)30256-X

40. Du J Comparison of allogeneic stem cell transplant and autologous stem cell transplant in refractory or relapsed peripheral T-cell lymphoma: a systematic review and meta-analysis JAMA Netw. Open. 2021 4 e219807 34042995 10.1001/jamanetworkopen.2021.9807 PMC8160596

41. Cornelissen JJ Blaise D Hematopoietic stem cell transplantation for patients with AML in first complete remission Blood 2016 127 62 70 26660427 10.1182/blood-2015-07-604546

42. Gagelmann N Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis Blood Adv. 2022 6 1222 1231 35051996 10.1182/bloodadvances.2021006827 PMC8864646

43. Kato K Khaled Y Mineishi S Reduced-intensity stem cell transplantation for hematological malignancies: current status and the future Curr. Stem Cell Res. Ther. 2007 2 149 162 18220900 10.2174/157488807780599248

44. Cohen S Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study Lancet Haematol. 2020 7 e134 e145 31704264 10.1016/S2352-3026(19)30202-9

45. Huang XJ Combined transplantation of G-CSF primed allogeneic bone marrow cells and peripheral blood stem cells in treatment of severe aplastic anemia Chin. Med. J. 2004 117 604 607 15109458

46. Luznik L HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide Biol. Blood Marrow Transpl. 2008 14 641 650 10.1016/j.bbmt.2008.03.005 PMC2633246 18489989

47. Kanakry CG Fuchs EJ Luznik L Modern approaches to HLA-haploidentical blood or marrow transplantation Nat. Rev. Clin. Oncol. 2016 13 132 26718103 10.1038/nrclinonc.2015.234

48. Chang YJ Controlled, randomized, open-label trial of risk-stratified corticosteroid prevention of acute graft-versus-host disease after haploidentical transplantation J. Clin. Oncol. 2016 34 1855 1863 27091717 10.1200/JCO.2015.63.8817

49. Gooley TA Reduced mortality after allogeneic hematopoietic-cell transplantation N. Engl. J. Med. 2010 363 2091 2101 21105791 10.1056/NEJMoa1004383 PMC3017343

50. Kanakry CG Fuchs EJ Luznik L Modern approaches to HLA-haploidentical blood or marrow transplantation Nat. Rev. Clin. Oncol. 2016 13 10 24 26305035 10.1038/nrclinonc.2015.128 PMC4695979

51. Ciurea SO Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia Blood 2015 126 1033 1040 26130705 10.1182/blood-2015-04-639831 PMC4543223

52. Tomita M Tsumoto K Hybridoma technologies for antibody production Immunotherapy 2011 3 371 380 21395379 10.2217/imt.11.4

53. Buist MR Kenemans P van Kamp GJ Haisma HJ Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: a comparison of five assays Cancer Immunol. Immunother. 1995 40 24 30 7828165 10.1007/BF01517232 PMC11037651

54. Klee GG Human anti-mouse antibodies Arch. Pathol. Lab. Med. 2000 124 921 923 10835540 10.5858/2000-124-0921-HAMA

55. Legouffe E Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6 Clin. Exp. Immunol. 1994 98 323 329 7955540 10.1111/j.1365-2249.1994.tb06145.x PMC1534395

56. Arakawa F Cloning and sequencing of the VH and V kappa genes of an anti-CD3 monoclonal antibody, and construction of a mouse/human chimeric antibody J. Biochem. 1996 120 657 662 8902633 10.1093/oxfordjournals.jbchem.a021462

57. Nishimura Y Recombinant human-mouse chimeric monoclonal antibody specific for common acute lymphocytic leukemia antigen Cancer Res. 1987 47 999 1005 2948638

58. Smith GP Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface Science 1985 228 1315 1317 4001944 10.1126/science.4001944

59. Saw PE Song EW Phage display screening of therapeutic peptide for cancer targeting and therapy Protein Cell 2019 10 787 807 31140150 10.1007/s13238-019-0639-7 PMC6834755

60. Chao G Isolating and engineering human antibodies using yeast surface display Nat. Protoc. 2006 1 755 768 17406305 10.1038/nprot.2006.94

61. Boder ET Wittrup KD Yeast surface display for screening combinatorial polypeptide libraries Nat. Biotechnol. 1997 15 553 557 9181578 10.1038/nbt0697-553

62. Glukhova XA Updates on the production of therapeutic antibodies using human hybridoma technique Curr. Pharm. Des. 2016 22 870 878 26696411 10.2174/1381612822666151223102845

63. Buettner MJ Improving immunotherapy through glycodesign Front. Immunol. 2018 9 2485 30450094 10.3389/fimmu.2018.02485 PMC6224361

64. Tsao LC Force J Hartman ZC Mechanisms of therapeutic antitumor monoclonal antibodies Cancer Res. 2021 81 4641 4651 34145037 10.1158/0008-5472.CAN-21-1109 PMC8448950

65. Mossner E Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity Blood 2010 115 4393 4402 20194898 10.1182/blood-2009-06-225979 PMC2881503

66. Tipton TR Anti-mouse FcγRIV antibody 9E9 also blocks FcγRIII in vivo Blood 2015 126 2643 2645 26492935 10.1182/blood-2015-09-671339

67. Herter S Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab In vitro and in xenograft models Mol. Cancer Ther. 2013 12 2031 2042 23873847 10.1158/1535-7163.MCT-12-1182

68. Overdijk MB Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma MAbs 2015 7 311 320 25760767 10.1080/19420862.2015.1007813 PMC4622648

69. Krejcik J Daratumumab depletes CD38(+) immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma Blood 2016 128 384 394 27222480 10.1182/blood-2015-12-687749 PMC4957162

70. Moreno L The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma Clin. Cancer Res. 2019 25 3176 3187 30692097 10.1158/1078-0432.CCR-18-1597

71. Wierda WG Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia J. Clin. Oncol. 2010 28 1749 1755 20194866 10.1200/JCO.2009.25.3187 PMC4979101

72. Hillmen P Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial Lancet 2015 385 1873 1883 25882396 10.1016/S0140-6736(15)60027-7

73. Goede V Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions N. Engl. J. Med. 2014 370 1101 1110 24401022 10.1056/NEJMoa1313984

74. Sehn LH Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial Lancet Oncol. 2016 17 1081 1093 27345636 10.1016/S1470-2045(16)30097-3

75. Dimopoulos MA Daratumumab, lenalidomide, and dexamethasone for multiple myeloma N. Engl. J. Med. 2016 375 1319 1331 27705267 10.1056/NEJMoa1607751

76. Lokhorst HM Targeting CD38 with daratumumab monotherapy in multiple myeloma N. Engl. J. Med. 2015 373 1207 1219 26308596 10.1056/NEJMoa1506348

77. Lonial S Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial Lancet 2016 387 1551 1560 26778538 10.1016/S0140-6736(15)01120-4

78. Mateos MV Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma N. Engl. J. Med. 2018 378 518 528 29231133 10.1056/NEJMoa1714678

79. Lonial S Elotuzumab therapy for relapsed or refractory multiple myeloma N. Engl. J. Med. 2015 373 621 631 26035255 10.1056/NEJMoa1505654

80. Dimopoulos MA Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial Lancet Haematol. 2022 9 e403 e414 35550060 10.1016/S2352-3026(22)00103-X

81. Dimopoulos MA Elotuzumab plus pomalidomide and dexamethasone for relapsed/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial J. Clin. Oncol. 2023 41 568 578 35960908 10.1200/JCO.21.02815 PMC9870233

82. Moreau P Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial Lancet 2021 397 2361 2371 34097854 10.1016/S0140-6736(21)00592-4

83. Attal M Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study Lancet 2019 394 2096 2107 31735560 10.1016/S0140-6736(19)32556-5

84. Goldschmidt H Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial Lancet Haematol. 2022 9 e810 e821 36328040 10.1016/S2352-3026(22)00263-0

85. Coiffier B Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study Blood 1998 92 1927 1932 9731049

86. Vose JM Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma J. Clin. Oncol. 2001 19 389 397 11208830 10.1200/JCO.2001.19.2.389

87. Salles G Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial Lancet 2011 377 42 51 21176949 10.1016/S0140-6736(10)62175-7

88. Seymour JF Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia N. Engl. J. Med. 2018 378 1107 1120 29562156 10.1056/NEJMoa1713976

89. Morschhauser F 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial J. Clin. Oncol. 2013 31 1977 1983 23547079 10.1200/JCO.2012.45.6400

90. Coiffier B Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study Blood 2008 111 1094 1100 18003886 10.1182/blood-2007-09-111781

91. Morschhauser F Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin’s lymphoma: phase I/II results J. Clin. Oncol. 2009 27 3346 3353 19451441 10.1200/JCO.2008.19.9117

92. Morschhauser FA Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study J. Clin. Oncol. 2013 31 2912 2919 23835718 10.1200/JCO.2012.46.9585

93. Radford J Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000) Blood 2013 122 1137 1143 23843495 10.1182/blood-2013-01-481341

94. Salles G Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients Blood 2012 119 5126 5132 22431570 10.1182/blood-2012-01-404368

95. Salles GA Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study J. Clin. Oncol. 2013 31 2920 2926 23835715 10.1200/JCO.2012.46.9718

96. Morschhauser F Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma Ann. Oncol. 2010 21 1870 1876 20157180 10.1093/annonc/mdq027

97. Forero-Torres A Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma Clin. Cancer Res. 2012 18 1395 1403 22223529 10.1158/1078-0432.CCR-11-0850

98. Ganjoo KN Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma Leuk. Lymphoma 2015 56 42 48 24717109 10.3109/10428194.2014.911859

99. Cheney CM Ocaratuzumab, an Fc- engineered antibody demonstrates enhanced antibody- dependent cell- mediated cytotoxicity in chronic lymphocytic leukemia Mabs 2014 6 748 754 10.4161/mabs.28282 PMC4011919 24594909

100. Wulf GG Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial Leukemia 2021 35 143 155 32382083 10.1038/s41375-020-0838-5

101. Cortelezzi A Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study Leukemia 2009 23 2027 2033 19641526 10.1038/leu.2009.148

102. Ansell S Phase I/II study of a fully human anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s disease (HD) and anaplastic large cell lymphoma (ALCL) Blood 2003 102 181 182 10.1200/JCO.2006.07.8972 17515574

103. Ansell SM Phase I/II, open-label, dose-escalating study of MDX-060 administered weekly for 4 weeks in subjects with refractory/relapsed CD30 positive lymphoma Blood 2004 104 721

104. Hussein M A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma Haematologica 2010 95 845 848 20133895 10.3324/haematol.2009.008003 PMC2864394

105. Advani R Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin’s lymphoma J. Clin. Oncol. 2009 27 4371 4377 19636010 10.1200/JCO.2008.21.3017

106. Fayad L Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial Leuk. Lymphoma 2015 56 2569 2578 25651427 10.3109/10428194.2015.1007504

107. Stein R Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines Clin. Cancer Res. 2009 15 2808 2817 19351768 10.1158/1078-0432.CCR-08-1953 PMC2681251

108. Alinari L Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma Blood 2011 117 4530 4541 21228331 10.1182/blood-2010-08-303354 PMC3099572

109. Smith MR Jin F Joshi I Milatuzumab and veltuzumab induce apoptosis through JNK signalling in an NF-κB dependent human transformed follicular lymphoma cell line Br. J. Haematol. 2014 165 151 153 24386925 10.1111/bjh.12711

110. Hertlein E Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells Blood 2010 116 2554 2558 20574049 10.1182/blood-2009-11-253203 PMC2953888

111. Vasu S A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia Haematologica 2022 107 770 773 34854276 10.3324/haematol.2020.274118 PMC8883544

112. Ohmachi K A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma Int. J. Hematol. 2019 109 657 664 30915717 10.1007/s12185-019-02635-9

113. Czuczman MS Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness Ann. Oncol. 2018 29 2271 29390097 10.1093/annonc/mdx812 PMC6290880

114. Leonard JP Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin’s lymphoma J. Clin. Oncol. 2005 23 5044 5051 15955901 10.1200/JCO.2005.13.821

115. Hicklin DJ Ellis LM Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis J. Clin. Oncol. 2005 23 1011 1027 15585754 10.1200/JCO.2005.06.081

116. Viardot A Bargou R Bispecific antibodies in haematological malignancies Cancer Treat. Rev. 2018 65 87 95 29635163 10.1016/j.ctrv.2018.04.002

117. Tian Z Liu M Zhang Y Wang X Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies J. Hematol. Oncol. 2021 14 75 33941237 10.1186/s13045-021-01084-4 PMC8091790

118. Wang Z Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity J. Hematol. Oncol. 2021 14 204 34886888 10.1186/s13045-021-01216-w PMC8656063

119. Suurs FV Lub-de Hooge MN de Vries EGE de Groot DJA A review of bispecific antibodies and antibody constructs in oncology and clinical challenges Pharmacol. Ther. 2019 201 103 119 31028837 10.1016/j.pharmthera.2019.04.006

120. Velasquez MP Bonifant CL Gottschalk S Redirecting T cells to hematological malignancies with bispecific antibodies Blood 2018 131 30 38 29118005 10.1182/blood-2017-06-741058 PMC5755042

121. Li H Er Saw P Song E Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics Cell. Mol. Immunol. 2020 17 451 461 32313210 10.1038/s41423-020-0417-8 PMC7193592

122. Nagorsen D Kufer P Baeuerle PA Bargou R Blinatumomab: a historical perspective Pharmacol. Ther. 2012 136 334 342 22940266 10.1016/j.pharmthera.2012.07.013

123. Kantarjian H Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia N. Engl. J. Med. 2017 376 836 847 28249141 10.1056/NEJMoa1609783 PMC5881572

124. Advani AS SWOG 1318: a phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia J. Clin. Oncol. 2022 40 1574 1582 35157496 10.1200/JCO.21.01766 PMC9084435

125. Goebeler ME Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study J. Clin. Oncol. 2016 34 1104 1111 26884582 10.1200/JCO.2014.59.1586

126. Viardot A Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma Blood 2016 127 1410 1416 26755709 10.1182/blood-2015-06-651380 PMC4797019

127. Reusch U A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells MAbs 2015 7 584 604 25875246 10.1080/19420862.2015.1029216 PMC4622993

128. Falchi L Vardhana SA Salles GA Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities Blood 2023 141 467 480 36322929 10.1182/blood.2021011994 PMC9936308

129. Sun LL Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies Sci. Transl. Med. 2015 7 287ra270 10.1126/scitranslmed.aaa4802 25972002

130. Bock AM Nowakowski GS Wang Y Bispecific antibodies for non-Hodgkin lymphoma treatment Curr. Treat. Options Oncol. 2022 23 155 170 35182296 10.1007/s11864-021-00925-1

131. Budde LE Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study Lancet Oncol. 2022 23 1055 1065 35803286 10.1016/S1470-2045(22)00335-7

132. Hutchings M Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial J. Clin. Oncol. 2021 39 1959 1970 33739857 10.1200/JCO.20.03175 PMC8210975

133. Dickinson MJ Glofitamab for relapsed or refractory diffuse large B-cell lymphoma N. Engl. J. Med. 2022 387 2220 2231 36507690 10.1056/NEJMoa2206913

134. Hutchings M Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study Lancet 2021 398 1157 1169 34508654 10.1016/S0140-6736(21)00889-8

135. Thieblemont C Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial J. Clin. Oncol. 2023 41 2238 2247 36548927 10.1200/JCO.22.01725 PMC10115554

136. Bannerji R Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial Lancet Haematol. 2022 9 e327 e339 35366963 10.1016/S2352-3026(22)00072-2 PMC10681157

137. Patel K A phase 1 study of plamotamab, an anti-CD20 x anti-CD3 bispecific antibody, in patients with relapsed/refractory non-Hodgkin’s lymphoma: recommended dose safety/efficacy update and escalation exposure-response analysis Blood 2022 140 9470 9472

138. Patel K Phase 2 randomized, open-label, multicenter study to evaluate the efficacy and safety of plamotamab combined with tafasitamab (Tafa) plus lenalidomide (Len) Vs Tafa plus Len in relapsed or refractory DLBCL Blood 2022 140 12066 12067

139. Yeung YA An optimized full-length FLT3/CD3 bispecific antibody demonstrates potent anti-leukemia activity and reversible hematological toxicity Mol. Ther. 2020 28 889 900 31981494 10.1016/j.ymthe.2019.12.014 PMC7054815

140. Reusch U Characterization of CD33/CD3 tetravalent bispecific tandem diabodies (TandAbs) for the treatment of acute myeloid leukemia Clin. Cancer Res. 2016 22 5829 5838 27189165 10.1158/1078-0432.CCR-16-0350

141. Campagne O Integrated pharmacokinetic/pharmacodynamic model of a bispecific CD3xCD123 DART molecule in nonhuman primates: evaluation of activity and impact of immunogenicity Clin. Cancer Res. 2018 24 2631 2641 29463552 10.1158/1078-0432.CCR-17-2265

142. Uy GL Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia Blood 2021 137 751 762 32929488 10.1182/blood.2020007732 PMC7885824

143. Aigner M T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct Leukemia 2013 27 1107 1115 23178753 10.1038/leu.2012.341

144. Cheng P Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma Mol. Ther. 2022 30 2315 2326 35150889 10.1016/j.ymthe.2022.02.005 PMC9171150

145. Boyiadzis M First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia Clin. Transl. Sci. 2023 16 429 435 36564917 10.1111/cts.13467 PMC10014690

146. Rettig, M. P. et al. Preliminary translational results from an ongoing phase 1 study of flotetuzumab, a CD123 x CD3 dart (R), in AML/MDS: rationale for combining flotetuzumab and anti-PD-1/PD-L1 immunotherapies. Blood . 130 , 637–637 (2017).

147. Ravandi F Complete responses in relapsed/refractory acute myeloid leukemia (AML) patients on a weekly dosing schedule of XmAb14045, a CD123 x CD3 T cell-engaging bispecific antibody: initial results of a phase 1 study Blood 2018 132 763

148. van Loo PF MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis Expert Opin. Biol. Ther. 2019 19 721 733 31286786 10.1080/14712598.2019.1623200

149. Dao T Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1 Nat. Biotechnol. 2015 33 1079 1086 26389576 10.1038/nbt.3349 PMC4600043

150. Krishnan AY MajesTEC-7: a phase 3, randomized study of teclistamab plus daratumumab plus lenalidomide (Tec-DR) versus daratumumab plus lenalidomide plus dexamethasone (DRd) in patients with newly diagnosed multiple myeloma who are either ineligible or not intended for autologous stem cell transplant Blood 2022 140 10148 10149

151. Moreau P Teclistamab in relapsed or refractory multiple myeloma N. Engl. J. Med. 2022 387 495 505 35661166 10.1056/NEJMoa2203478 PMC10587778

152. Searle E Teclistamab in combination with subcutaneous daratumumab and lenalidomide in patients with multiple myeloma: results from one cohort of MajesTEC-2, a phase1b, multicohort study Blood 2022 140 394 396

153. Usmani SZ Teclistamab, a B-cell maturation antigenxCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study Lancet 2021 398 665 674 34388396 10.1016/S0140-6736(21)01338-6

154. Zamagni E MajesTEC-4 (EMN30): a phase 3 trial of teclistamab plus lenalidomide versus lenalidomide alone as maintenance therapy following autologous stem cell transplantation in patients with newly diagnosed multiple myeloma Blood 2022 140 7289 7291

155. Zonder JA Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific antibody, in a phase 1/2 first-in-human study in patients with relapsed/refractory multiple myeloma Clin. Lymphoma Myeloma Leuk. 2022 22 S406 S407

156. Ferreri CJ Trial in progress: a phase II window of opportunity study of the BCMAxCD3 bispecific antibody REGN5458 in previously untreated patients with symptomatic multiple myeloma Blood 2022 140 10129 10130

157. Fonseca R MagnetisMM-9: an open-label, multicenter, non-randomized phase 1/2 study of elranatamab in patients with relapsed/refractory multiple myeloma J. Clin. Oncol. 2022 40 TPS8068 TPS8068

158. Landgren O Magnetismm-4: an open label, phase 1b/2 umbrella study of elranatamab in combination with other anti-cancer treatments for patients with multiple myeloma Blood 2022 140 10172 10173

159. Wong SW Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-cell maturation antigen (BCMA) x CD3 T-cell engager (TCE), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from a phase 1 first-in-human clinical study Blood 2022 140 400 402

160. Fayon M Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma Haematologica 2021 106 1193 1197 32675220 10.3324/haematol.2019.242453 PMC8018129

161. Zuch de Zafra CL Targeting multiple myeloma with AMG 424, a novel anti-CD38/CD3 bispecific T-cell-recruiting antibody optimized for cytotoxicity and cytokine release Clin. Cancer Res 2019 25 3921 3933 30918018 10.1158/1078-0432.CCR-18-2752

162. Topp MS Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma J. Clin. Oncol. 2020 38 775 783 31895611 10.1200/JCO.19.02657

163. Kumar S A phase 1 first-in-human study of Tnb-383B, a BCMA x CD3 bispecific T-cell redirecting antibody, in patients with relapsed/refractory multiple myeloma Blood 2021 138 900

164. Harrison SJ A phase 1 first in human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE (R) (bispecific T-cell engager) molecule, in relapsed/refractory (RR) multiple myeloma (MM) Blood 2020 136 181

165. Lesokhin AM Preliminary safety, efficacy, pharmacokinetics, and pharmacodynamics of subcutaneously (SC) administered PF-06863135, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM) Blood 2020 136 8 9

166. Mohan SR Initial results of dose escalation of ISB 1342, a novel CD3xCD38 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM) Blood 2022 140 7264 7266

167. Richter JR Phase 1, multicenter, open-label study of single-agent bispecific antibody t-cell engager GBR 1342 in relapsed/refractory multiple myeloma J. Clin. Oncol. 2018 36 TPS81

168. Chari A Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma N. Engl. J. Med. 2022 387 2232 2244 36507686 10.1056/NEJMoa2204591

169. Vij R CAMMA 1: a multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of cevostamab-containing regimens in patients with relapsed or refractory multiple myeloma J. Clin. Oncol. 2022 40 TPS8069

170. Zhao Y Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL Blood 2021 137 471 484 32881995 10.1182/blood.2020006287 PMC7845009

171. Jabbour E Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression Am. J. Hematol. 2018 93 371 374 29178361 10.1002/ajh.24987

172. Goebeler ME Bargou RC T cell-engaging therapies - BiTEs and beyond Nat. Rev. Clin. Oncol. 2020 17 418 434 32242094 10.1038/s41571-020-0347-5

173. Braig F Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking Blood 2017 129 100 104 27784674 10.1182/blood-2016-05-718395

174. Aldoss I Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia Am. J. Hematol. 2017 92 858 865 28494518 10.1002/ajh.24783

175. Ross T Preclinical characterization of AFM26, a novel B cell maturation antigen (BCMA)-directed tetravalent bispecific antibody for high affinity retargeting of NK cells against myeloma Blood 2018 132 1927

176. Reusch U A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells MAbs 2014 6 728 739 24670809 10.4161/mabs.28591 PMC4011917

177. Zhao L A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL Blood 2022 140 1790 1802 35981465 10.1182/blood.2022016243

178. Chan WK A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma Cancer Immunol. Res. 2018 6 776 787 29769244 10.1158/2326-6066.CIR-17-0649 PMC6030494

179. Felices M CD16-IL15-CD33 trispecific killer engager (TriKE) overcomes cancer-induced immune suppression and induces natural killer cell-mediated control of MDS and AML via enhanced killing kinetics Blood 2016 128 4291

180. Kantarjian HM Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia N. Engl. J. Med. 2016 375 740 753 27292104 10.1056/NEJMoa1509277 PMC5594743

181. Ansell SM Overall survival with brentuximab vedotin in stage III or IV Hodgkin’s lymphoma N. Engl. J. Med. 2022 387 310 320 35830649 10.1056/NEJMoa2206125

182. Chari RV Miller ML Widdison WC Antibody-drug conjugates: an emerging concept in cancer therapy Angew. Chem. Int. Ed. Engl. 2014 53 3796 3827 24677743 10.1002/anie.201307628

183. Jin Y Stepping forward in antibody-drug conjugate development Pharmacol. Ther. 2022 229 107917 34171334 10.1016/j.pharmthera.2021.107917 PMC8702582

184. Meyer S Rees AR The antibody molecule: from antitoxins to therapeutic antibodies Soc. Hist. Med. 2015 29 hkv119

185. Thomas A Teicher BA Hassan R Antibody-drug conjugates for cancer therapy Lancet Oncol. 2016 17 e254 e262 27299281 10.1016/S1470-2045(16)30030-4 PMC6601617

186. Bargh JD Isidro-Llobet A Parker JS Spring DR Cleavable linkers in antibody-drug conjugates Chem. Soc. Rev. 2019 48 4361 4374 31294429 10.1039/c8cs00676h

187. Advani A Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma: results of a phase I study J. Clin. Oncol. 2010 28 2085 2093 20308665 10.1200/JCO.2009.25.1900

188. Brivio E A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study) Blood 2021 137 1582 1590 33067614 10.1182/blood.2020007848 PMC7995290

189. Kreitman RJ Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia J. Clin. Oncol. 2012 30 1822 1828 22355053 10.1200/JCO.2011.38.1756 PMC3383181

190. Short NJ A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia Br. J. Haematol. 2018 182 442 444 28616864 10.1111/bjh.14806 PMC6511975

191. Morschhauser F Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS) Lancet Haematol. 2019 6 e254 e265 30935953 10.1016/S2352-3026(19)30026-2

192. Wayne AS Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial Clin. Cancer Res. 2010 16 1894 1903 20215554 10.1158/1078-0432.CCR-09-2980 PMC2840067

193. Kreitman RJ Phase II trial of CAT-3888 (BL22) in chemo-resistant hairy cell leukemia J. Clin. Oncol. 2007 25 7095

194. Kuruvilla J Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study Lancet Oncol. 2021 22 512 524 33721562 10.1016/S1470-2045(21)00005-X

195. Horwitz S The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma Ann. Oncol. 2022 33 288 298 34921960 10.1016/j.annonc.2021.12.002 PMC9447792

196. Pro B Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study J. Clin. Oncol. 2012 30 2190 2196 22614995 10.1200/JCO.2011.38.0402

197. Prince HM Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial Lancet 2017 390 555 566 28600132 10.1016/S0140-6736(17)31266-7

198. Pollard JA Gemtuzumab ozogamicin improves event-free survival and reduces relapse in pediatric KMT2A-rearranged AML: results from the phase III children’s oncology group trial AAML0531 J. Clin. Oncol. 2021 39 3149 3160 34048275 10.1200/JCO.20.03048 PMC8478392

199. Stein EM A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia Blood 2018 131 387 396 29196412 10.1182/blood-2017-06-789800 PMC5813721

200. Fathi AT A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML Blood 2018 132 1125 1133 30045838 10.1182/blood-2018-03-841171 PMC6265631

201. Kovtun Y IMGN779, a novel CD33-targeting antibody-drug conjugate with DNA-alkylating activity, exhibits potent antitumor activity in models of AML Mol. Cancer Ther. 2018 17 1271 1279 29588393 10.1158/1535-7163.MCT-17-1077

202. Cortes JE Maturing clinical profile of IMGN779, a next-generation CD33-targeting antibody-drug conjugate, in patients with relapsed or refractory acute myeloid leukemia Blood 2018 132 26

203. Caimi PF Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial Lancet Oncol. 2021 22 790 800 33989558 10.1016/S1470-2045(21)00139-X

204. Hamadani M Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma Blood 2021 137 2634 2645 33211842 10.1182/blood.2020007512 PMC8138546

205. Carol H The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia Clin. Cancer Res. 2013 19 1795 1805 23426279 10.1158/1078-0432.CCR-12-3613 PMC3618498

206. Ribrag V A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma Clin. Cancer Res. 2014 20 213 220 24132920 10.1158/1078-0432.CCR-13-0580

207. Jones L Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts Pediatr. Blood Cancer 2019 66 e27765 31012549 10.1002/pbc.27765 PMC6588422

208. Schindler J A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia Br. J. Haematol. 2011 154 471 476 21732928 10.1111/j.1365-2141.2011.08762.x PMC3877839

209. Diefenbach C Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study Lancet Haematol. 2021 8 e891 e901 34826412 10.1016/S2352-3026(21)00311-2

210. Sehn LH Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma J. Clin. Oncol. 2020 38 155 165 31693429 10.1200/JCO.19.00172 PMC7032881

211. Lonial S Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study Lancet Oncol. 2020 21 207 221 31859245 10.1016/S1470-2045(19)30788-0

212. Figueroa-Vazquez V HDP-101, an anti-BCMA antibody-drug conjugate, safely delivers amanitin to induce cell death in proliferating and resting multiple myeloma cells Mol. Cancer Ther. 2021 20 367 378 33298585 10.1158/1535-7163.MCT-20-0287

213. Stathis A Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study Invest. New Drugs 2018 36 869 876 29453628 10.1007/s10637-018-0570-4 PMC6153548

214. Pereira DS AGS67E, an anti-CD37 monomethyl auristatin E antibody-drug conjugate as a potential therapeutic for B/T-cell malignancies and AML: a new role for CD37 in AML Mol. Cancer Ther. 2015 14 1650 1660 25934707 10.1158/1535-7163.MCT-15-0067 PMC4557793

215. Pereira DS Ags67e, an anti-cd37 monomethyl auristatin e antibody (mmae) drug conjugate as a potential therapeutic for non-hodgkin’s lymphoma, chronic lymphocytic leukemia and acute myeloid leukemia Cancer Res. 2014 74 2650

216. Kelly KR Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study Lancet Haematol. 2021 8 e794 e807 34529955 10.1016/S2352-3026(21)00208-8

217. Ailawadhi S A phase I study to assess the safety and pharmacokinetics of single-agent lorvotuzumab mertansine (IMGN901) in patients with relapsed and/or refractory CD-56-positive multiple myeloma Clin. Lymphoma Myeloma Leuk. 2019 19 29 34 30340993 10.1016/j.clml.2018.08.018 PMC9059793

218. Govindan SV Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers Mol. Cancer Ther. 2013 12 968 978 23427296 10.1158/1535-7163.MCT-12-1170

219. Huang WT Preclinical activity of LM-305 targeting G-protein-coupled receptor class 5 member D (GPRC5D) antibody drug conjugate for the treatment of multiple myeloma Cancer Res. 2022 82 6020

220. Daver N Broad activity for the pivekimab sunirine (PVEK, IMGN632), azacitidine, and venetoclax triplet in high-risk patients with relapsed/refractory acute myeloid leukemia (AML) Blood 2022 140 145 149

221. Hamadani M Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study Lancet Haematol. 2021 8 e433 e445 34048682 10.1016/S2352-3026(21)00103-4 PMC9241579

222. Younes A Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma J. Clin. Oncol. 2012 30 2183 2189 22454421 10.1200/JCO.2011.38.0410 PMC3646316

223. Lamb YN Inotuzumab ozogamicin: firstg global approval Drugs 2017 77 1603 1610 28819740 10.1007/s40265-017-0802-5

224. Mori J Tsuda K Tanimoto T Inotuzumab ozogamicin for acute lymphoblastic leukemia N. Engl. J. Med. 2016 375 2100 27959721 10.1056/NEJMc1612040

225. Leong S Lam HPJ Kirkham Z Popat R Antibody drug conjugates for the treatment of multiple myeloma Am. J. Hematol. 2023 98 S22 s34 36199262 10.1002/ajh.26750

226. Bartok O Anti-tumour immunity induces aberrant peptide presentation in melanoma Nature 2021 590 332 337 33328638 10.1038/s41586-020-03054-1

227. Röhrig UF Inhibition mechanisms of indoleamine 2,3-dioxygenase 1 (IDO1) J. Med. Chem. 2019 62 8784 8795 31525930 10.1021/acs.jmedchem.9b00942

228. Ahmadzadeh M Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired Blood 2009 114 1537 1544 19423728 10.1182/blood-2008-12-195792 PMC2927090

229. Wei SC Duffy CR Allison JP Fundamental mechanisms of immune checkpoint blockade therapy Cancer Discov. 2018 8 1069 1086 30115704 10.1158/2159-8290.CD-18-0367

230. Qin G NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer Nat. Commun. 2020 11 1669 32245950 10.1038/s41467-020-15364-z PMC7125142

231. Fang W Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8(+) T cell exclusion J. Exp. Clin. Cancer Res. 2021 40 4 33390170 10.1186/s13046-020-01786-6 PMC7780622

232. Gordon SR PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity Nature 2017 545 495 499 28514441 10.1038/nature22396 PMC5931375

233. Juneja VR PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity J. Exp. Med. 2017 214 895 904 28302645 10.1084/jem.20160801 PMC5379970

234. Patsoukis N Wang Q Strauss L Boussiotis VA Revisiting the PD-1 pathway Sci. Adv. 2020 6 eabd2712 32948597 10.1126/sciadv.abd2712 PMC7500922

235. Mahoney KM Soluble PD-L1 as an early marker of progressive disease on nivolumab J. Immunother. Cancer 2022 10 e003527 35131863 10.1136/jitc-2021-003527 PMC8823247

236. Tekguc M Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells Proc. Natl Acad. Sci. USA 2021 118 e2023739118 34301886 10.1073/pnas.2023739118 PMC8325248

237. Wei SC Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade Cell 2017 170 1120 1133.e1117 28803728 10.1016/j.cell.2017.07.024 PMC5591072

238. Garris CS Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 Immunity 2018 49 1148 1161.e1147 30552023 10.1016/j.immuni.2018.09.024 PMC6301092

239. Mayoux M Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy Sci. Transl. Med. 2020 12 eaav7431 32161104 10.1126/scitranslmed.aav7431

240. Budimir N Thomas GD Dolina JS Salek-Ardakani S Reversing T-cell exhaustion in cancer: lessons learned from PD-1/PD-L1 immune checkpoint blockade Cancer Immunol. Res. 2022 10 146 153 34937730 10.1158/2326-6066.CIR-21-0515

241. Walker LS Sansom DM The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses Nat. Rev. Immunol. 2011 11 852 863 22116087 10.1038/nri3108

242. Wing K Yamaguchi T Sakaguchi S Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation Trends Immunol. 2011 32 428 433 21723783 10.1016/j.it.2011.06.002

243. Mahoney KM Rennert PD Freeman GJ Combination cancer immunotherapy and new immunomodulatory targets Nat. Rev. Drug Discov. 2015 14 561 584 26228759 10.1038/nrd4591

244. Mayes PA Hance KW Hoos A The promise and challenges of immune agonist antibody development in cancer Nat. Rev. Drug Discov. 2018 17 509 527 29904196 10.1038/nrd.2018.75

245. Romano E Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients Proc. Natl Acad. Sci. USA 2015 112 6140 6145 25918390 10.1073/pnas.1417320112 PMC4434760

246. Vesely MD Zhang T Chen L Resistance mechanisms to anti-PD cancer immunotherapy Annu. Rev. Immunol. 2022 40 45 74 35471840 10.1146/annurev-immunol-070621-030155

247. Chen L CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade Cancer Discov. 2018 8 1156 1175 30012853 10.1158/2159-8290.CD-17-1033 PMC6205194

248. Banta KL Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8(+) T cell responses Immunity 2022 55 512 526.e519 35263569 10.1016/j.immuni.2022.02.005 PMC9287124

249. Strauss L Targeted deletion of PD-1 in myeloid cells induces antitumor immunity Sci. Immunol. 2020 5 eaay1863 31901074 10.1126/sciimmunol.aay1863 PMC7183328

250. Verma V PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1(+)CD38(hi) cells and anti-PD-1 resistance Nat. Immunol. 2019 20 1231 1243 31358999 10.1038/s41590-019-0441-y PMC7472661

251. Hashimoto M PD-1 combination therapy with IL-2 modifies CD8(+) T cell exhaustion program Nature 2022 610 173 181 36171288 10.1038/s41586-022-05257-0 PMC9793890

252. Vari F Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL Blood 2018 131 1809 1819 29449276 10.1182/blood-2017-07-796342 PMC5922274

253. Yi M Combination strategies with PD-1/PD-L1 blockade: current advances and future directions Mol. Cancer 2022 21 28 35062949 10.1186/s12943-021-01489-2 PMC8780712

254. Zhang L Immunotherapy for advanced hepatocellular carcinoma, where are we? Biochim. Biophys. Acta Rev. Cancer 2020 1874 188441 33007432 10.1016/j.bbcan.2020.188441

255. Sommaggio R Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells Oncoimmunology 2020 9 1777046 32923140 10.1080/2162402X.2020.1777046 PMC7458615

256. Krishna S Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer Science 2020 370 1328 1334 33303615 10.1126/science.abb9847 PMC8883579

257. Lopez RD CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies Blood 2000 96 3827 3837 11090067

258. Laskowski TJ Biederstädt A Rezvani K Natural killer cells in antitumour adoptive cell immunotherapy Nat. Rev. Cancer 2022 22 557 575 35879429 10.1038/s41568-022-00491-0 PMC9309992

259. Ping Y Liu C Zhang Y T-cell receptor-engineered T cells for cancer treatment: current status and future directions Protein Cell 2018 9 254 266 28108950 10.1007/s13238-016-0367-1 PMC5829268

260. Zhang X CAR-T cell therapy in hematological malignancies: current opportunities and challenges Front. Immunol. 2022 13 927153 35757715 10.3389/fimmu.2022.927153 PMC9226391

261. Tanaka J Recent advances in chimeric antigen receptor natural killer cell therapy for overcoming intractable hematological malignancies Hematol. Oncol. 2021 39 11 19 32905618 10.1002/hon.2802

262. Yilmaz A Cui H Caligiuri MA Yu J Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy J. Hematol. Oncol. 2020 13 168 33287875 10.1186/s13045-020-00998-9 PMC7720606

263. Gross G Waks T Eshhar Z Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity Proc. Natl Acad. Sci. USA 1989 86 10024 10028 2513569 10.1073/pnas.86.24.10024 PMC298636

264. Heuser C T-cell activation by recombinant immunoreceptors: impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells Gene Ther. 2003 10 1408 1419 12900755 10.1038/sj.gt.3302023

265. Jensen MC Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans Biol. Blood Marrow Transplant. 2010 16 1245 1256 20304086 10.1016/j.bbmt.2010.03.014 PMC3383803

266. Locke FL Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma Mol. Ther. 2017 25 285 295 28129122 10.1016/j.ymthe.2016.10.020 PMC5363293

267. Abramson JS Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study Lancet 2020 396 839 852 32888407 10.1016/S0140-6736(20)31366-0

268. van der Stegen SJ Hamieh M Sadelain M The pharmacology of second-generation chimeric antigen receptors Nat. Rev. Drug Discov. 2015 14 499 509 26129802 10.1038/nrd4597 PMC6410718

269. Bôle-Richard E CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm Leukemia 2020 34 3228 3241 32111969 10.1038/s41375-020-0777-1

270. Wang J CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia J. Hematol. Oncol. 2018 11 7 29316944 10.1186/s13045-017-0553-5 PMC5761206

271. Roselli E 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells J. Immunother. Cancer 2021 9 e003354 34706886 10.1136/jitc-2021-003354 PMC8552146

272. Liu Z Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma Mol. Cancer 2023 22 3 36617554 10.1186/s12943-022-01711-9 PMC9827625

273. Zhou X Phase I trial of fourth-generation anti-CD19 chimeric antigen receptor T cells against relapsed or refractory B cell non-Hodgkin lymphomas Front. Immunol. 2020 11 564099 33329526 10.3389/fimmu.2020.564099 PMC7731732

274. Kagoya Y A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects Nat. Med. 2018 24 352 359 29400710 10.1038/nm.4478 PMC5839992

275. Turtle CJ CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients J. Clin. Invest. 2016 126 2123 2138 27111235 10.1172/JCI85309 PMC4887159

276. Maus MV T cells expressing chimeric antigen receptors can cause anaphylaxis in humans Cancer Immunol. Res. 2013 1 26 31 24777247 10.1158/2326-6066.CIR-13-0006 PMC3888798

277. Gu R Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia J. Hematol. Oncol. 2020 13 122 32894185 10.1186/s13045-020-00953-8 PMC7487702

278. Wang D A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma Blood 2021 137 2890 2901 33512480 10.1182/blood.2020008936

279. Song F Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL J. Immunother. Cancer 2023 11 e005701 36808074 10.1136/jitc-2022-005701 PMC9944646

280. Depil S ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges Nat. Rev. Drug Discov. 2020 19 185 199 31900462 10.1038/s41573-019-0051-2

281. Hu Y Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study Cell Res. 2022 32 995 1007 36151216 10.1038/s41422-022-00721-y PMC9652391

282. Parikh, R. H., Lonial, S. Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice. CA: A Cancer J. Clin. 73 , 275–285 (2023). 10.3322/caac.21771 36627265

283. Hay KA Turtle CJ Chimeric antigen receptor (CAR) T Cells: lessons learned from targeting of CD19 in B-cell malignancies Drugs 2017 77 237 245 28110394 10.1007/s40265-017-0690-8 PMC5603178

284. Pan J Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial J. Clin. Oncol. 2021 39 3340 3351 34324392 10.1200/JCO.21.00389

285. Zhang M Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia/lymphoma Clin. Cancer Res. 2022 28 2830 2843 35435984 10.1158/1078-0432.CCR-21-4097

286. Freiwan A Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies Blood 2022 140 2684 2696 35914226 10.1182/blood.2021015020 PMC9935551

287. Gruss HJ Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines Blood 1994 83 2045 2056 8161776

288. Walter RB Appelbaum FR Estey EH Bernstein ID Acute myeloid leukemia stem cells and CD33-targeted immunotherapy Blood 2012 119 6198 6208 22286199 10.1182/blood-2011-11-325050 PMC3383202

289. Cui Q CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation J. Hematol. Oncol. 2021 14 82 34034795 10.1186/s13045-021-01092-4 PMC8152118

290. Zhang M GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial Lancet Haematol. 2023 10 e107 e116 36725117 10.1016/S2352-3026(22)00372-6

291. Mei H A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma J. Hematol. Oncol. 2021 14 161 34627333 10.1186/s13045-021-01170-7 PMC8501733

292. Zhang Z Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy J. Immunother. Cancer 2020 8 e001150 33023981 10.1136/jitc-2020-001150 PMC7539592

293. Samur MK Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma Nat. Commun. 2021 12 868 33558511 10.1038/s41467-021-21177-5 PMC7870932

294. Ruella M Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell Nat. Med. 2018 24 1499 1503 30275568 10.1038/s41591-018-0201-9 PMC6511988

295. Hamieh M CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape Nature 2019 568 112 116 30918399 10.1038/s41586-019-1054-1 PMC6707377

296. Nian Z Rapamycin pretreatment rescues the bone marrow AML cell elimination capacity of CAR-T cells Clin. Cancer Res. 2021 27 6026 6038 34233960 10.1158/1078-0432.CCR-21-0452 PMC9401534

297. Jain MD Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma Blood 2021 137 2621 2633 33512407 10.1182/blood.2020007445 PMC8120145

298. Shen Y Serum soluble BCMA can be used to monitor relapse of multiple myeloma patients after chimeric antigen receptor T-cell immunotherapy Curr. Res. Transl. Med. 2023 71 103378 36720180 10.1016/j.retram.2023.103378

299. Mailankody S GPRC5D-targeted CAR T cells for myeloma N. Engl. J. Med. 2022 387 1196 1206 36170501 10.1056/NEJMoa2209900 PMC10309537

300. Smith EL GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells Sci. Transl. Med. 2019 11 eaau7746 30918115 10.1126/scitranslmed.aau7746 PMC7508042

301. Hu Y CRISPR/Cas9-engineered universal CD19/CD22 dual-targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia Clin. Cancer Res. 2021 27 2764 2772 33627493 10.1158/1078-0432.CCR-20-3863

302. Tong C Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma Blood 2020 136 1632 1644 32556247 10.1182/blood.2020005278 PMC7596761

303. He X Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia Blood 2020 135 713 723 31951650 10.1182/blood.2019002779 PMC7059518

304. Li KX A novel approach for relapsed/refractory FLT3(mut+) acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib Mol. Cancer 2022 21 66 35246156 10.1186/s12943-022-01541-9 PMC8896098

305. Fousek K CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression Leukemia 2021 35 75 89 32205861 10.1038/s41375-020-0792-2 PMC7519582

306. Han X Wang Y Wei J Han W Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy J. Hematol. Oncol. 2019 12 128 31783889 10.1186/s13045-019-0813-7 PMC6884912

307. Rabilloud T Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy Nat. Commun. 2021 12 865 33558546 10.1038/s41467-021-21168-6 PMC7870924

308. Shao L Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell products J. Transl. Med. 2022 20 514 36348415 10.1186/s12967-022-03729-5 PMC9644589

309. Xie G CAR-NK cells: a promising cellular immunotherapy for cancer EBioMedicine 2020 59 102975 32853984 10.1016/j.ebiom.2020.102975 PMC7452675

310. Pan K CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy J. Exp. Clin. Cancer Res. 2022 41 119 35361234 10.1186/s13046-022-02327-z PMC8969382

311. Pao SC Chu MT Hung SI Therapeutic vaccines targeting neoantigens to induce T-cell immunity against cancers Pharmaceutics 2022 14 867 35456701 10.3390/pharmaceutics14040867 PMC9029780

312. Keilholz U A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS Blood 2009 113 6541 6548 19389880 10.1182/blood-2009-02-202598

313. Van Tendeloo VF Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination Proc. Natl Acad. Sci. USA 2010 107 13824 13829 20631300 10.1073/pnas.1008051107 PMC2922237

314. Saxena M van der Burg SH Melief CJM Bhardwaj N Therapeutic cancer vaccines Nat. Rev. Cancer 2021 21 360 378 33907315 10.1038/s41568-021-00346-0

315. Smith C Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregation Blood 2009 113 6148 6152 19372256 10.1182/blood-2009-02-203687

316. Frank MJ Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial J. Exp. Med. 2020 217 e20191712 32558897 10.1084/jem.20191712 PMC7478738

317. Neelapu SS Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma Nat. Med. 2005 11 986 991 16116429 10.1038/nm1290

318. Maslak PG Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia Blood Adv. 2018 2 224 234 29386195 10.1182/bloodadvances.2017014175 PMC5812332

319. Hu Z Ott PA Wu CJ Towards personalized, tumour-specific, therapeutic vaccines for cancer Nat. Rev. Immunol. 2018 18 168 182 29226910 10.1038/nri.2017.131 PMC6508552

320. Tay, B. Q. et al. Evolution of cancer vaccines-challenges, achievements, and future directions. Vaccines (Basel) . 9 (2021). 10.3390/vaccines9050535 PMC8160852 34065557

321. French RR Chan HT Tutt AL Glennie MJ CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help Nat. Med. 1999 5 548 553 10229232 10.1038/8426

322. Sotomayor EM Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40 Nat. Med. 1999 5 780 787 10395323 10.1038/10503

323. Nagorsen D Baeuerle PA Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab Exp. Cell Res. 2011 317 1255 1260 21419116 10.1016/j.yexcr.2011.03.010

324. Lu J Jiang G The journey of CAR-T therapy in hematological malignancies Mol. Cancer 2022 21 194 36209106 10.1186/s12943-022-01663-0 PMC9547409

325. Pardoll DM The blockade of immune checkpoints in cancer immunotherapy Nat. Rev. Cancer 2012 12 252 264 22437870 10.1038/nrc3239 PMC4856023

326. Postow MA Callahan MK Wolchok JD Immune checkpoint blockade in cancer therapy J. Clin. Oncol. 2015 33 1974 1982 25605845 10.1200/JCO.2014.59.4358 PMC4980573

327. Baker KS Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin’s disease in children and adolescents J. Clin. Oncol. 1999 17 825 831 10071273 10.1200/JCO.1999.17.3.825

328. Eckert C Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group J. Clin. Oncol. 2013 31 2736 2742 23775972 10.1200/JCO.2012.48.5680

329. Pession A Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia Blood 2013 122 170 178 23673857 10.1182/blood-2013-03-491621

330. Vose JM Autologous transplantation for aggressive non-Hodgkin’s lymphoma: results of a randomized trial evaluating graft source and minimal residual disease J. Clin. Oncol. 2002 20 2344 2352 11981006 10.1200/JCO.2002.09.138

331. Majolino I Pearce R Taghipour G Goldstone AH Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin’s and non-Hodgkin’s lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation J. Clin. Oncol. 1997 15 509 517 9053472 10.1200/JCO.1997.15.2.509

332. Bertz H Illerhaus G Veelken H Finke J Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens Ann. Oncol. 2002 13 135 139 11863095 10.1093/annonc/mdf010

333. Anderlini P Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma: the updated M.D. Anderson Cancer Center experience Haematologica 2008 93 257 264 18223284 10.3324/haematol.11828 PMC4238917

334. Sureda A Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation Haematologica 2012 97 310 317 21993674 10.3324/haematol.2011.045757 PMC3269494

335. Beelen DW Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: final analysis of a prospective randomized trial Am. J. Hematol. 2022 97 1023 1034 35617104 10.1002/ajh.26620

336. Russell NH Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial Haematologica 2022 107 1518 1527 34647442 10.3324/haematol.2021.279010 PMC9244837

337. Nakamura R Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50–75 years of age with advanced myelodysplastic syndrome J. Clin. Oncol. 2021 39 3328 3339 34106753 10.1200/JCO.20.03380 PMC8791814

338. Wang Y Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study Blood 2015 125 3956 3962 25940714 10.1182/blood-2015-02-627786

339. Wang Y Haploidentical versus matched-sibling transplant in adults with Philadelphia-negative high-risk acute lymphoblastic leukemia: a biologically phase III randomized study Clin. Cancer Res. 2016 22 3467 3476 26927664 10.1158/1078-0432.CCR-15-2335

340. Lu Y Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status Ann. Hematol. 2020 99 2911 2925 33000361 10.1007/s00277-020-04283-0

341. Zheng FM Haploidentical- versus identical-sibling transplant for high-risk pediatric AML: a multi-center study Cancer Commun. 2020 40 93 104 10.1002/cac2.12014 PMC7144412 32175698

342. Zhou X Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene Blood 2014 123 3895 3905 24753538 10.1182/blood-2014-01-551671 PMC4064331

343. Martelli MF HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse Blood 2014 124 638 644 24923299 10.1182/blood-2014-03-564401

344. McLaughlin P Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J. Clin. Oncol. 1998 16 2825 2833 9704735 10.1200/JCO.1998.16.8.2825

345. Foran JM European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma J. Clin. Oncol. 2000 18 317 324 10637245 10.1200/JCO.2000.18.2.317

346. Lenz G Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) J. Clin. Oncol. 2005 23 1984 1992 15668467 10.1200/JCO.2005.08.133

347. Mounier N Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL) Blood 2003 101 4279 4284 12576316 10.1182/blood-2002-11-3442

348. Eichhorst B Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann. Oncol. 2021 32 23 33 33091559 10.1016/j.annonc.2020.09.019

349. Hallek M Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial Lancet 2010 376 1164 1174 20888994 10.1016/S0140-6736(10)61381-5

350. Hagenbeek A First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial Blood 2008 111 5486 5495 18390837 10.1182/blood-2007-10-117671

351. Cheson BD Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study J. Clin. Oncol. 2018 36 2259 2266 29584548 10.1200/JCO.2017.76.3656

352. Jurczak W Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma Ann. Oncol. 2018 29 1266 1272 29444231 10.1093/annonc/mdy056 PMC5961010

353. Tilly H Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study Lancet Oncol. 2019 20 998 1010 31101489 10.1016/S1470-2045(19)30091-9

354. Sharman JP Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial Lancet Haematol. 2021 8 e254 e266 33631112 10.1016/S2352-3026(20)30433-6

355. Bargou R Tumor regression in cancer patients by very low doses of a T cell-engaging antibody Science 2008 321 974 977 18703743 10.1126/science.1158545

356. Topp MS Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival J. Clin. Oncol. 2011 29 2493 2498 21576633 10.1200/JCO.2010.32.7270

357. Topp MS Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia J. Clin. Oncol. 2014 32 4134 4140 25385737 10.1200/JCO.2014.56.3247

358. Klinger M Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab Blood 2012 119 6226 6233 22592608 10.1182/blood-2012-01-400515

359. Brown PA Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial JAMA 2021 325 833 842 33651090 10.1001/jama.2021.0669 PMC7926290

360. Locatelli F Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial JAMA 2021 325 843 854 33651091 10.1001/jama.2021.0987 PMC7926287

361. Jabbour E Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial Lancet Haematol. 2022 9 e878 e885 36279879 10.1016/S2352-3026(22)00285-X

362. Jabbour E Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial Lancet Haematol. 2023 10 e24 e34 36402146 10.1016/S2352-3026(22)00319-2

363. Foà R Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults N. Engl. J. Med. 2020 383 1613 1623 33085860 10.1056/NEJMoa2016272

364. Coyle L Open-label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma Leuk. Lymphoma 2020 61 2103 2112 32546071 10.1080/10428194.2020.1759055

365. Katz DA Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL Leuk. Lymphoma 2022 63 2063 2073 35503708 10.1080/10428194.2022.2064981

366. Grosicki S Elranatamab in combination with daratumumab for patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the phase 3 magnetismm-5 study safety lead-in cohort Blood 2022 140 4407 4408

367. Lesokhin A Magnetismm-3: an open-label, multicenter, non-randomized phase 2 study of elranatamab (PF-06863135) in patients with relapsed or refractory multiple myeloma Blood 2021 138 1674

368. Mateos MV MagnetisMM-7: an open label, randomized, phase 3 study of elranatamab versus lenalidomide in patients with newly diagnosed multiple myeloma who are minimal residual disease-positive after transplant Clin. Lymphoma Myeloma Leuk. 2022 22 S45 S45

369. Sievers EL Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse J. Clin. Oncol. 2001 19 3244 3254 11432892 10.1200/JCO.2001.19.13.3244

370. Petersdorf SH A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia Blood 2013 121 4854 4860 23591789 10.1182/blood-2013-01-466706 PMC3682338

371. Löwenberg B Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study Blood 2010 115 2586 2591 20103782 10.1182/blood-2009-10-246470

372. Hasle H Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004 Blood 2012 120 978 984 22730539 10.1182/blood-2012-03-416701

373. Amadori S Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17) J. Clin. Oncol. 2013 31 4424 4430 24127442 10.1200/JCO.2013.49.0771

374. Castaigne S Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study Lancet 2012 379 1508 1516 22482940 10.1016/S0140-6736(12)60485-1

375. Burnett AK Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia J. Clin. Oncol. 2012 30 3924 3931 22851554 10.1200/JCO.2012.42.2964

376. Gamis AS Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531 J. Clin. Oncol. 2014 32 3021 3032 25092781 10.1200/JCO.2014.55.3628 PMC4162498

377. Olombel G The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia Blood 2016 127 2157 2160 26929274 10.1182/blood-2016-01-689976

378. Fournier E Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia Blood 2020 135 542 546 31880804 10.1182/blood.2019003471

379. Schlenk RF Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: early results from the prospective randomized AMLSG 09-09 phase III study J. Clin. Oncol. 2020 38 623 632 31851556 10.1200/JCO.19.01406 PMC7030890

380. Borthakur G Retrospective comparison of survival and responses to fludarabine, cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients Am. J. Hematol. 2022 97 1427 1434 36053747 10.1002/ajh.26700

381. Kantarjian H Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study Lancet Oncol. 2012 13 403 411 22357140 10.1016/S1470-2045(11)70386-2

382. Jabbour E Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: a phase 2 clinical trial JAMA Oncol. 2018 4 230 234 28859185 10.1001/jamaoncol.2017.2380 PMC5838597

383. Kantarjian H Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study Lancet Oncol. 2018 19 240 248 29352703 10.1016/S1470-2045(18)30011-1 PMC11537312

384. Kreitman RJ Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial J. Hematol. Oncol. 2021 14 35 33627164 10.1186/s13045-020-01004-y PMC7905554

385. Trudel S Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial Lancet Oncol. 2018 19 1641 1653 30442502 10.1016/S1470-2045(18)30576-X PMC6328058

386. Quach H Safety and clinical activity of belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-6 arm-A interim analysis Clin. Lymphoma Myeloma Leuk. 2022 22 S423 S424

387. Ansell SM PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma N. Engl. J. Med. 2015 372 311 319 25482239 10.1056/NEJMoa1411087 PMC4348009

388. Younes A Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial Lancet Oncol. 2016 17 1283 1294 27451390 10.1016/S1470-2045(16)30167-X PMC5541855

389. Schnorfeil FM T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment J. Hematol. Oncol. 2015 8 93 26219463 10.1186/s13045-015-0189-2 PMC4518596

390. Armand P Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial J. Clin. Oncol. 2013 31 4199 4206 24127452 10.1200/JCO.2012.48.3685 PMC4878008

391. Armand P Immune checkpoint blockade in hematologic malignancies Blood 2015 125 3393 3400 25833961 10.1182/blood-2015-02-567453

392. Green MR Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma Blood 2010 116 3268 3277 20628145 10.1182/blood-2010-05-282780 PMC2995356

393. Roemer MG PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome J. Clin. Oncol. 2016 34 2690 2697 27069084 10.1200/JCO.2016.66.4482 PMC5019753

394. Green MR Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy Clin. Cancer Res. 2012 18 1611 1618 22271878 10.1158/1078-0432.CCR-11-1942 PMC3321508

395. Merryman RW Armand P Wright KT Rodig SJ Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma Blood Adv. 2017 1 2643 2654 29296917 10.1182/bloodadvances.2017012534 PMC5728646

396. Bashey A CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation Blood 2009 113 1581 1588 18974373 10.1182/blood-2008-07-168468 PMC2644086

397. Ansell SM Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma Clin. Cancer Res. 2009 15 6446 6453 19808874 10.1158/1078-0432.CCR-09-1339 PMC2763019

398. Diefenbach CS Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial Lancet Haematol. 2020 7 e660 e670 32853585 10.1016/S2352-3026(20)30221-0 PMC7737486

399. Armand P A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies Leukemia 2021 35 777 786 32601377 10.1038/s41375-020-0939-1 PMC7932914

400. Mei MG Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE Blood 2022 139 3605 3616 35316328 10.1182/blood.2022015423 PMC9227101

401. Deng Q Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas Nat. Med. 2020 26 1878 1887 33020644 10.1038/s41591-020-1061-7 PMC8446909

402. Nayak L PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma Blood 2017 129 3071 3073 28356247 10.1182/blood-2017-01-764209 PMC5766844

403. Zinzani PL Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II checkMate 436 study J. Clin. Oncol. 2019 37 3081 3089 31398081 10.1200/JCO.19.01492 PMC6864847

404. Ansell SM Nivolumab for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study J. Clin. Oncol. 2019 37 481 489 30620669 10.1200/JCO.18.00766 PMC6528729

405. Chen R Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma J. Clin. Oncol. 2017 35 2125 2132 28441111 10.1200/JCO.2016.72.1316 PMC5791843

406. Westin JR Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial Lancet Oncol. 2014 15 69 77 24332512 10.1016/S1470-2045(13)70551-5 PMC3922714

407. Advani R CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma N. Engl. J. Med. 2018 379 1711 1721 30380386 10.1056/NEJMoa1807315 PMC8058634

408. Armand P Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure J. Clin. Oncol. 2016 34 3733 3739 27354476 10.1200/JCO.2016.67.3467 PMC5791838

409. Younes A Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study Lancet Haematol. 2019 6 e67 e78 30642819 10.1016/S2352-3026(18)30217-5

410. Ding W Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL Blood 2017 129 3419 3427 28424162 10.1182/blood-2017-02-765685 PMC5492091

411. Zinzani PL Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma Blood 2017 130 267 270 28490569 10.1182/blood-2016-12-758383 PMC5766837

412. Berger R Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies Clin. Cancer Res. 2008 14 3044 3051 18483370 10.1158/1078-0432.CCR-07-4079

413. Hawkes E First-in-human (FIH) study of the fully-human kappa-lambda CD19/CD47 bispecific antibody TG-1801 in patients (pts) with B-cell lymphoma Blood 2022 140 6599 6601

414. Mehta A Lemzoparlimab, a differentiated anti-CD47 antibody in combination with rituximab in relapsed and refractory non- Hodgkin’s lymphoma: initial clinical results Blood 2021 138 3542

415. Qi JY A phase I/IIa study of lemzoparlimab, a monoclonal antibody targeting CD47, in patients with relapsed and/or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): initial phase I results Blood 2020 136 30 31

416. Stadtmauer E Lemzoparlimab (TJ011133), an anti-CD47 antibody, with/without dexamethasone plus anti myeloma regimens for relapsed/refractory multiple myeloma: a phase 1b dose escalation and expansion study J. Immunother. Cancer 2021 9 A476

417. Garcia-Manero G Evorpacept (ALX148), a CD47-blocking myeloid checkpoint inhibitor, in combination with azacitidine: a phase 1 / 2 study in patients with myelodysplastic syndrome (ASPEN-02) Blood 2021 138 2601

418. Maude SL Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia N. Engl. J. Med. 2018 378 439 448 29385370 10.1056/NEJMoa1709866 PMC5996391

419. Schuster SJ Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma N. Engl. J. Med. 2019 380 45 56 30501490 10.1056/NEJMoa1804980

420. Bishop MR Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma N. Engl. J. Med. 2022 386 629 639 34904798 10.1056/NEJMoa2116596

421. Fowler NH Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial Nat. Med. 2022 28 325 332 34921238 10.1038/s41591-021-01622-0

422. Locke FL Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial Lancet Oncol. 2019 20 31 42 30518502 10.1016/S1470-2045(18)30864-7 PMC6733402

423. Wang M KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma N. Engl. J. Med. 2020 382 1331 1342 32242358 10.1056/NEJMoa1914347 PMC7731441

424. Shah BD KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study Lancet 2021 398 491 502 34097852 10.1016/S0140-6736(21)01222-8 PMC11613962

425. Jacobson CA Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial Lancet Oncol. 2022 23 91 103 34895487 10.1016/S1470-2045(21)00591-X

426. Locke FL Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma N. Engl. J. Med. 2022 386 640 654 34891224 10.1056/NEJMoa2116133

427. Neelapu SS Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial Nat. Med. 2022 28 735 742 35314842 10.1038/s41591-022-01731-4 PMC9018426

428. Siddiqi T Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL Blood 2022 139 1794 1806 34699592 10.1182/blood.2021011895 PMC10652916

429. Kamdar M Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial Lancet 2022 399 2294 2308 35717989 10.1016/S0140-6736(22)00662-6

430. Sehgal A Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study Lancet Oncol. 2022 23 1066 1077 35839786 10.1016/S1470-2045(22)00339-4

431. Cheng Q CD20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory/relapsed B-cell non-Hodgkin lymphoma Cytotherapy 2022 24 1026 1034 35691818 10.1016/j.jcyt.2022.05.001

432. Fry TJ CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy Nat. Med. 2018 24 20 28 29155426 10.1038/nm.4441 PMC5774642

433. Spiegel JY CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial Nat. Med. 2021 27 1419 1431 34312556 10.1038/s41591-021-01436-0 PMC8363505

434. Shah NN Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial Nat. Med. 2020 26 1569 1575 33020647 10.1038/s41591-020-1081-3

435. Ramos CA Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma J. Clin. Oncol. 2020 38 3794 3804 32701411 10.1200/JCO.20.01342 PMC7655020

436. Ramos CA Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes J. Clin. Investig. 2017 127 3462 3471 28805662 10.1172/JCI94306 PMC5669573

437. Wang CM Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial Clin. Cancer Res. 2017 23 1156 1166 27582488 10.1158/1078-0432.CCR-16-1365

438. Raje N Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma N. Engl. J. Med. 2019 380 1726 1737 31042825 10.1056/NEJMoa1817226 PMC8202968

439. Munshi NC Idecabtagene vicleucel in relapsed and refractory multiple myeloma N. Engl. J. Med. 2021 384 705 716 33626253 10.1056/NEJMoa2024850

440. Rodriguez-Otero P Ide-cel or standard regimens in relapsed and refractory multiple myeloma N. Engl. J. Med. 2023 388 1002 1014 36762851 10.1056/NEJMoa2213614

441. Raje N Updated clinical and correlative results from the Phase I CRB-402 study of the BCMA-targeted CAR T cell therapy bb21217 in patients with relapsed and/or refractory multiple myeloma Clin. Lymphoma Myeloma Leuk. 2022 22 S4 S5

442. Berdeja JG Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study Lancet 2021 398 314 324 34175021 10.1016/S0140-6736(21)00933-8

443. Costello CL Phase 2 study of the response and safety of P-Bcma-101 CAR-T cells in patients with relapsed/refractory (r/r) multiple myeloma (MM) (PRIME) Blood 2019 134 3184

444. Mailankody S Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study ( NCT03430011 ) J. Clin. Oncol. 2020 38 8504

445. Kumar SK Results from Lummicar-2: a phase 1b/2 study of fully human B-cell maturation antigen-specific CAR T cells (CT053) in patients with relapsed and/or refractory multiple myeloma Blood 2020 136 28 29

446. Mailankody S Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results Nat. Med. 2023 29 422 429 36690811 10.1038/s41591-022-02182-7

447. Zhao WH A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma J. Hematol. Oncol. 2018 11 141 30572922 10.1186/s13045-018-0681-6 PMC6302465

448. Bal S Clinical activity of BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T cell therapy, in patients with relapsed and/or refractory (R/R) multiple myeloma (MM): first results from a phase 1, multicenter, open-label study Blood 2022 140 883 885

449. Shi D USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer Nat. Commun. 2022 13 5644 36163134 10.1038/s41467-022-33285-x PMC9513055

450. Yan Z A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial Lancet Haematol. 2019 6 e521 e529 31378662 10.1016/S2352-3026(19)30115-2

451. Baumeister SH Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML/MDS and multiple myeloma Cancer Immunol. Res. 2019 7 100 112 30396908 10.1158/2326-6066.CIR-18-0307 PMC7814996

452. Jin X First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia J. Hematol. Oncol. 2022 15 88 35799191 10.1186/s13045-022-01308-1 PMC9264641

453. Sallman DA Ameli-01: a phase I trial of UCART123v1.2, an anti-CD123 allogeneic CAR-T cell product, in adult patients with relapsed or refractory (R/R) CD123+acute myeloid leukemia (AML) Blood 2022 140 2371 2373

454. Lu P Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial Blood 2022 140 321 334 35500125 10.1182/blood.2021014498

455. Zhang Y Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies Blood Cancer J. 2023 13 61 37095094 10.1038/s41408-023-00822-w PMC10125858

456. Lekakis LJ ALPHA2 Study: ALLO-501A allogeneic CAR T in LBCL, updated results continue to show encouraging safety and efficacy with consolidation dosing Blood 2021 138 649

457. Jain N Preliminary results from the Flu/Cy/alemtuzumab arm of the phase I BALLI-01 trial of UCART22, an antiCD22 allogeneic CAR-T cell product, in adult patients with relapsed or refractory (R/R) CD22+B-cell acute lymphoblastic leukemia (B-ALL) Blood 2021 138 1764

458. Ni JJ Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights Acta Pharmacol. Sin. 2022 44 288 307 35927312 10.1038/s41401-022-00953-z PMC9889774

459. McGuirk JP CTX110 allogeneic CRISPR-Cas9-engineered CAR T cells in patients (pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): results from the phase 1 dose escalation carbon study Blood 2022 140 10303 10306

460. Shah BD Preliminary safety and efficacy of PBCAR0191, an allogeneic, off-the-shelf CD19-targeting CAR-T product, in relapsed/refractory (r/r) CD19+NHL J. Clin. Oncol. 2021 39 7516

461. Jain N Preliminary safety and efficacy of PBCAR0191, an allogeneic ‘off-the-shelf’ CD19-directed CAR-T for patients with relapsed/refractory (R/R) CD19+B-ALL Blood 2021 138 650

462. Scott DW Gascoyne RD The tumour microenvironment in B cell lymphomas Nat. Rev. Cancer 2014 14 517 534 25008267 10.1038/nrc3774

463. Sang W Anti-PD-1 therapy enhances the efficacy of CD30-directed chimeric antigen receptor T cell therapy in patients with relapsed/refractory CD30+ lymphoma Front. Immunol. 2022 13 858021 35432352 10.3389/fimmu.2022.858021 PMC9010867

464. Chen X A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma Immunotherapy 2020 12 681 696 32580597 10.2217/imt-2020-0022

465. Zhang J Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL Nature 2022 609 369 374 36045296 10.1038/s41586-022-05140-y PMC9452296

466. Liu H CD19-specific CAR T Cells that express a PD-1/CD28 chimeric switch-receptor are effective in patients with PD-L1-positive B-cell lymphoma Clin. Cancer Res. 2021 27 473 484 33028589 10.1158/1078-0432.CCR-20-1457

467. Cruz CR Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study Blood 2013 122 2965 2973 24030379 10.1182/blood-2013-06-506741 PMC3811171

468. Wang X Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL Blood 2016 127 2980 2990 27118452 10.1182/blood-2015-12-686725 PMC4911862

469. Zhao H Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study J. Hematol. Oncol. 2020 13 42 32366260 10.1186/s13045-020-00873-7 PMC7199358

470. Jiang H Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial Am. J. Hematol. 2019 94 1113 1122 31321805 10.1002/ajh.25582

471. Liu E Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors N. Engl. J. Med. 2020 382 545 553 32023374 10.1056/NEJMoa1910607 PMC7101242

472. Mickinso M A phase 1 study of NKX019, a CD19 chimeric antigen receptor natural killer (CAR NK) cell therapy, in subjects with B-cell malignancies Blood 2021 138 3868

473. Bachier C A phase 1 study of NKX101, an allogeneic CAR natural killer (NK) cell therapy, in subjects with relapsed/refractory (R/R) acute myeloid leukemia (AML) or higher-risk myelodysplastic syndrome (MDS) Blood 2020 136 42 43

474. Dhakal B Interim phase I clinical data of FT576 as monotherapy and in combination with daratumumab in subjects with relapsed/refractory multiple myeloma Blood 2022 140 4586 4587

475. Roex G Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells J. Transl. Med. 2022 20 124 35287669 10.1186/s12967-022-03326-6 PMC8919645

476. Christodoulou I Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities J. Immunother. Cancer 2021 9 e003894 34896980 10.1136/jitc-2021-003894 PMC8655609

477. Gong Y Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy J. Hematol. Oncol. 2021 14 73 33933160 10.1186/s13045-021-01083-5 PMC8088725

478. Kennedy LB Salama AKS A review of cancer immunotherapy toxicity CA Cancer J. Clin. 2020 70 86 104 31944278 10.3322/caac.21596

479. Fontana L Strasfeld L Respiratory virus infections of the stem cell transplant recipient and the hematologic malignancy patient Infect. Dis. Clin. North Am. 2019 33 523 544 30940462 10.1016/j.idc.2019.02.004 PMC7126949

480. Misch EA Andes DR Bacterial infections in the stem cell transplant recipient and hematologic malignancy patient Infect. Dis. Clin. North Am. 2019 33 399 445 31005135 10.1016/j.idc.2019.02.011

481. Nathan S Ustun C Complications of stem cell transplantation that affect infections in stem cell transplant recipients, with analogies to patients with hematologic malignancies Infect. Dis. Clin. North Am. 2019 33 331 359 30940464 10.1016/j.idc.2019.01.002

482. Renaghan AD Acute kidney injury and CKD associated with hematopoietic stem cell transplantation Clin. J. Am. Soc. Nephrol. 2020 15 289 297 31836598 10.2215/CJN.08580719 PMC7015091

483. Kemmner S Verbeek M Heemann U Renal dysfunction following bone marrow transplantation J. Nephrol. 2017 30 201 209 27589851 10.1007/s40620-016-0345-y

484. Abramson MH Acute kidney injury in the modern era of allogeneic hematopoietic stem cell transplantation Clin. J. Am. Soc. Nephrol. 2021 16 1318 1327 34135023 10.2215/CJN.19801220 PMC8729581

485. Mahadeo KM Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement Lancet Haematol. 2020 7 e61 e72 31818728 10.1016/S2352-3026(19)30201-7

486. Bonifazi F Diagnosis and treatment of VOD/SOS after allogeneic hematopoietic stem cell transplantation Front. Immunol. 2020 11 489 32318059 10.3389/fimmu.2020.00489 PMC7147118

487. Kammersgaard MB Assessment of the proposed EBMT pediatric criteria for diagnosis and severity grading of sinusoidal obstruction syndrome Bone Marrow Transpl. 2019 54 1406 1418 10.1038/s41409-018-0426-8 PMC6760545 30683907

488. Dignan FL BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation Br. J. Haematol. 2013 163 444 457 24102514 10.1111/bjh.12558

489. Markey KA MacDonald KP Hill GR The biology of graft-versus-host disease: experimental systems instructing clinical practice Blood 2014 124 354 362 24914137 10.1182/blood-2014-02-514745 PMC4102708

490. Ferrara JL Deeg HJ Graft-versus-host disease N. Engl. J. Med. 1991 324 667 674 1994250 10.1056/NEJM199103073241005

491. Sacirbegovic F Graft-versus-host disease is locally maintained in target tissues by resident progenitor-like T cells Immunity 2023 56 369 385.e366 36720219 10.1016/j.immuni.2023.01.003 PMC10182785

492. Khoury HJ Improved survival after acute graft-versus-host disease diagnosis in the modern era Haematologica 2017 102 958 966 28302712 10.3324/haematol.2016.156356 PMC5477615

493. Zhao XS Huang XJ Seeking biomarkers for acute graft-versus-host disease: where we are and where we are heading? Biomark. Res. 2019 7 17 31406575 10.1186/s40364-019-0167-x PMC6685226

494. Gooptu M Koreth J Better acute graft-versus-host disease outcomes for allogeneic transplant recipients in the modern era: a tacrolimus effect? Haematologica 2017 102 806 808 28458253 10.3324/haematol.2017.165266 PMC5477598

495. Müller AMS Chronic GVHD on the move Blood 2022 140 2660 2661 36548018 10.1182/blood-2022-160202 PMC9665224

496. Kong X Trafficking between clonally related peripheral T-helper cells and tissue-resident T-helper cells in chronic GVHD Blood 2022 140 2740 2753 36084473 10.1182/blood.2022016581 PMC9935547

497. Nelson AS Second cancers and late mortality in Australian children treated by allogeneic HSCT for haematological malignancy Leukemia 2015 29 441 447 24962016 10.1038/leu.2014.203

498. Goyal A Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides: A Surveillance, Epidemiology, And End Results analysis J. Am. Acad. Dermatol. 2020 83 404 411 31374302 10.1016/j.jaad.2019.07.075 PMC7021276

499. André M Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin’s disease Blood 1998 92 1933 1940 9731050

500. Tichelli A Evaluation of second solid cancers after hematopoietic stem cell transplantation in European patients JAMA Oncol. 2019 5 229 235 30476975 10.1001/jamaoncol.2018.4934 PMC6439555

501. Sirohi B Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma Ann. Oncol. 2008 19 1312 1319 18356139 10.1093/annonc/mdn052

502. Duignan S Post-transplant lymphoproliferative disorder presenting as supraglottitis following pediatric heart transplantation treated with EBV-specific cytotoxic T-lymphocytes J. Heart Lung Transpl. 2022 41 708 711 10.1016/j.healun.2022.02.019 35370033

503. Zimmermann H Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial Leukemia 2022 36 2468 2478 35974101 10.1038/s41375-022-01667-1 PMC9522585

504. Thieme CJ In vitro and in vivo evidence that the switch from calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein-Barr virus-associated post-transplant lymphoproliferative disorder Kidney Int 2022 102 1392 1408 36103953 10.1016/j.kint.2022.08.025

505. Trappe R Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial Lancet Oncol. 2012 13 196 206 22173060 10.1016/S1470-2045(11)70300-X

506. Burns DM Real-world outcomes with rituximab-based therapy for posttransplant lymphoproliferative disease arising after solid organ transplant Transplantation 2020 104 2582 2590 33104308 10.1097/TP.0000000000003183

507. Byrd JC Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance J. Clin. Oncol. 1999 17 791 795 10071268 10.1200/JCO.1999.17.3.791

508. Hansel TT The safety and side effects of monoclonal antibodies Nat. Rev. Drug Discov. 2010 9 325 338 20305665 10.1038/nrd3003

509. Baldo BA Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses Oncoimmunology 2013 2 e26333 24251081 10.4161/onci.26333 PMC3827071

510. Duell J Functionally defective T cells after chemotherapy of B-cell malignancies can be activated by the tetravalent bispecific CD19/CD3 antibody AFM11 J. Immunother. 2019 42 180 188 31090657 10.1097/CJI.0000000000000267

511. Salvaris, R., Ong, J. & Gregory, G. P. Bispecific antibodies: a review of development, clinical efficacy and toxicity in B-cell lymphomas. J. Pers. Med . 11 (2021). 10.3390/jpm11050355 PMC8147062 33946635

512. van Brummelen EM Antidrug antibody formation in oncology: clinical relevance and challenges Oncologist 2016 21 1260 1268 27440064 10.1634/theoncologist.2016-0061 PMC5061540

513. Zhu Y Liu K Wang K Zhu H Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis Cancer 2023 129 283 295 36408673 10.1002/cncr.34507 PMC10099922

514. Nguyen TD Bordeau BM Balthasar JP Mechanisms of ADC toxicity and strategies to increase ADC tolerability Cancers 2023 15 713 36765668 10.3390/cancers15030713 PMC9913659

515. Wolska-Washer A Robak T Safety and tolerability of antibody-drug conjugates in cancer Drug Saf. 2019 42 295 314 30649747 10.1007/s40264-018-0775-7 PMC6399172

516. Thompson JA Management of immunotherapy-related toxicities, version 1.2019 J. Natl Compr. Canc. Netw. 2019 17 255 289 30865922 10.6004/jnccn.2019.0013

517. Haanen J Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann. Oncol. 2017 28 iv119 iv142 28881921 10.1093/annonc/mdx225

518. Thompson JA New NCCN guidelines: recognition and management of immunotherapy-related toxicity J. Natl Compr. Cancer Netw. 2018 16 594 596 10.6004/jnccn.2018.0047 29784734

519. Haanen J Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann. Oncol. 2018 29 iv264 iv266 29917046 10.1093/annonc/mdy162

520. Puzanov I Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group J. Immunother. Cancer 2017 5 95 29162153 10.1186/s40425-017-0300-z PMC5697162

521. Schneider BJ Lacchetti C Bollin K Management of the top 10 most common immune-related adverse events in patients treated with immune checkpoint inhibitor therapy JCO Oncol. Pract. 2022 18 431 444 35061502 10.1200/OP.21.00776

522. Martins F New therapeutic perspectives to manage refractory immune checkpoint-related toxicities Lancet Oncol. 2019 20 e54 e64 30614479 10.1016/S1470-2045(18)30828-3

523. Belum VR Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor Eur. J. Cancer 2016 60 12 25 27043866 10.1016/j.ejca.2016.02.010 PMC4998047

524. Geisler AN Immune checkpoint inhibitor-related dermatologic adverse events J. Am. Acad. Dermatol. 2020 83 1255 1268 32454097 10.1016/j.jaad.2020.03.132 PMC7572894

525. Ellis SR Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features J. Am. Acad. Dermatol. 2020 83 1130 1143 32360716 10.1016/j.jaad.2020.04.105 PMC7492441

526. Kumar V Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy Front. Pharmacol. 2017 8 49 28228726 10.3389/fphar.2017.00049 PMC5296331

527. Villadolid J Amin A Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities Transl. Lung Cancer Res. 2015 4 560 575 26629425 10.3978/j.issn.2218-6751.2015.06.06 PMC4630514

528. Phillips GS Treatment outcomes of immune-related cutaneous adverse events J. Clin. Oncol. 2019 37 2746 2758 31216228 10.1200/JCO.18.02141 PMC7001790

529. de Filette J A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors Horm. Metab. Res. 2019 51 145 156 30861560 10.1055/a-0843-3366

530. Wright JJ Powers AC Johnson DB Endocrine toxicities of immune checkpoint inhibitors Nat. Rev. Endocrinol. 2021 17 389 399 33875857 10.1038/s41574-021-00484-3 PMC8769055

531. Grouthier V Immune checkpoint inhibitor-associated primary adrenal insufficiency: WHO vigiBase report analysis Oncologist 2020 25 696 701 32390168 10.1634/theoncologist.2019-0555 PMC7418341

532. Muir CA Thyroid immune-related adverse events following immune checkpoint inhibitor treatment J. Clin. Endocrinol. Metab. 2021 106 e3704 e3713 33878162 10.1210/clinem/dgab263

533. de Filette JMK Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review Eur. J. Endocrinol. 2019 181 363 374 31330498 10.1530/EJE-19-0291 PMC6709545

534. Reynolds K Thomas M Dougan M Diagnosis and management of hepatitis in patients on checkpoint blockade Oncologist 2018 23 991 997 29853659 10.1634/theoncologist.2018-0174 PMC6192661

535. De Martin E Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors J. Hepatol. 2018 68 1181 1190 29427729 10.1016/j.jhep.2018.01.033

536. Zen Y Yeh MM Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury Mod. Pathol. 2018 31 965 973 29403081 10.1038/s41379-018-0013-y

537. Abdel-Rahman O ElHalawani H Fouad M Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis Immunotherapy 2015 7 1213 1227 26513491 10.2217/imt.15.87

538. Geukes Foppen MH Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management ESMO Open 2018 3 e000278 29387476 10.1136/esmoopen-2017-000278 PMC5786923

539. Collins M Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies Ann. Oncol. 2017 28 2860 2865 29045560 10.1093/annonc/mdx403

540. Samaan MA Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management Nat. Rev. Gastroenterol. Hepatol. 2018 15 222 234 29512649 10.1038/nrgastro.2018.14

541. Naidoo J Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy J. Clin. Oncol. 2017 35 709 717 27646942 10.1200/JCO.2016.68.2005 PMC5559901

542. Nishino M Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis JAMA Oncol. 2016 2 1607 1616 27540850 10.1001/jamaoncol.2016.2453

543. Naidoo J Chronic immune checkpoint inhibitor pneumonitis J. Immunother. Cancer 2020 8 e000840 32554618 10.1136/jitc-2020-000840 PMC7304886

544. Delaunay M Management of pulmonary toxicity associated with immune checkpoint inhibitors Eur. Respir. Rev. 2019 28 190012 31694838 10.1183/16000617.0012-2019 PMC9488507

545. Zhang XT Ge N Xiang ZJ Liu T Immune checkpoint inhibitor-related adverse cardiac events in patients with lung cancer: a systematic review and meta-analysis Cancer Cell Int. 2022 22 363 36402980 10.1186/s12935-022-02760-2 PMC9675058

546. Solimando, A. G. et al. Immune checkpoint inhibitor-related myositis: from biology to bedside. Int. J. Mol. Sci . 21 , 3054 (2020). 10.3390/ijms21093054 PMC7246673 32357515

547. Wu L Unravelling checkpoint inhibitor associated autoimmune diabetes: from bench to bedside Front. Endocrinol. 2021 12 764138 10.3389/fendo.2021.764138 PMC8603930 34803927

548. Kramer R Hematological immune related adverse events after treatment with immune checkpoint inhibitors Eur. J. Cancer 2021 147 170 181 33706206 10.1016/j.ejca.2021.01.013

549. Herrmann SM Perazella MA Immune checkpoint inhibitors and immune-related adverse renal events Kidney Int. Rep. 2020 5 1139 1148 32775813 10.1016/j.ekir.2020.04.018 PMC7403510

550. Sprangers B Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury Nat. Rev. Nephrol. 2022 18 794 805 36168055 10.1038/s41581-022-00630-8

551. Meraz-Muñoz A Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes J. Immunother. Cancer 2020 8 e000467 32601079 10.1136/jitc-2019-000467 PMC7326260

552. Awadalla M Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis J. Am. Coll. Cardiol. 2020 75 467 478 32029128 10.1016/j.jacc.2019.11.049 PMC7067226

553. Leaf RK Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors Am. J. Hematol. 2019 94 563 574 30790338 10.1002/ajh.25448 PMC9552038

554. Haanen J Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy J. Immunother. Cancer 2020 8 e000604 32532839 10.1136/jitc-2020-000604 PMC7295425

555. Schneider BJ Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update J. Clin. Oncol. 2021 39 4073 4126 34724392 10.1200/JCO.21.01440

556. Norelli M Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells Nat. Med. 2018 24 739 748 29808007 10.1038/s41591-018-0036-4

557. Sandler RD Diagnosis and management of secondary HLH/MAS folowing HSCT and CAR-T cell therapy in adults; a review of the literature and a survey of practice within EBMT centres on behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP) Front. Immunol. 2020 11 524 32296434 10.3389/fimmu.2020.00524 PMC7137396

558. Lichtenstein DA Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells Blood 2021 138 2469 2484 34525183 10.1182/blood.2021011898 PMC8832442

559. Schubert ML Side-effect management of chimeric antigen receptor (CAR) T-cell therapy Ann. Oncol. 2021 32 34 48 33098993 10.1016/j.annonc.2020.10.478

560. Si X Hematologic cytopenia post CAR T cell therapy: etiology, potential mechanisms and perspective Cancer Lett. 2022 550 215920 36122628 10.1016/j.canlet.2022.215920

561. Morgan RA Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 Mol. Ther. 2010 18 843 851 20179677 10.1038/mt.2010.24 PMC2862534

562. Gust J Taraseviciute A Turtle CJ Neurotoxicity associated with CD19-targeted CAR-T cell therapies CNS Drugs 2018 32 1091 1101 30387077 10.1007/s40263-018-0582-9 PMC7295115

563. Santomasso BD Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia Cancer Discov. 2018 8 958 971 29880584 10.1158/2159-8290.CD-17-1319 PMC6385599

564. Brudno JN Kochenderfer JN Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management Blood Rev. 2019 34 45 55 30528964 10.1016/j.blre.2018.11.002 PMC6628697

565. Thompson JA Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology J. Natl Compr. Canc. Netw. 2022 20 387 405 35390769 10.6004/jnccn.2022.0020

566. Morris EC Neelapu SS Giavridis T Sadelain M Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy Nat. Rev. Immunol. 2022 22 85 96 34002066 10.1038/s41577-021-00547-6 PMC8127450

567. Freyer CW Porter DL Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies J. Allergy Clin. Immunol. 2020 146 940 948 32771558 10.1016/j.jaci.2020.07.025

568. Schmidts A Wehrli M Maus MV Toward better understanding and management of CAR-T cell-associated toxicity Annu. Rev. Med. 2021 72 365 382 32776808 10.1146/annurev-med-061119-015600

569. Santomasso BD Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline J. Clin. Oncol. 2021 39 3978 3992 34724386 10.1200/JCO.21.01992

570. Jain, M. D., Smith, M., Shah, N. N. How I treat refractory CRS and ICANS following CAR T-cell therapy. Blood . 141 , 2430–2442 (2023). 10.1182/blood.2022017414 PMC10329191 36989488

571. Frey N Porter D Cytokine release syndrome with chimeric antigen receptor T cell therapy Biol. Blood Marrow Transplant. 2019 25 e123 e127 30586620 10.1016/j.bbmt.2018.12.756

572. Giavridis T CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade Nat. Med. 2018 24 731 738 29808005 10.1038/s41591-018-0041-7 PMC6410714

573. Staedtke V Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome Nature 2018 564 273 277 30542164 10.1038/s41586-018-0774-y PMC6512810

574. Teachey DT Identification of predictive biomarkers for cytokine release syndrome after chimeric sntigen receptor T-cell therapy for acute lymphoblastic leukemia Cancer Discov. 2016 6 664 679 27076371 10.1158/2159-8290.CD-16-0040 PMC5448406

575. Lee DW Current concepts in the diagnosis and management of cytokine release syndrome Blood 2014 124 188 195 24876563 10.1182/blood-2014-05-552729 PMC4093680

576. Boyiadzis MM Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance J. Immunother. Cancer 2018 6 137 30514386 10.1186/s40425-018-0460-5 PMC6278156

577. Neelapu SS Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma N. Engl. J. Med. 2017 377 2531 2544 29226797 10.1056/NEJMoa1707447 PMC5882485

578. Mueller KT Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia Clin. Cancer Res 2018 24 6175 6184 30190371 10.1158/1078-0432.CCR-18-0758 PMC7433345

579. Wei J The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma Signal Transduct. Target Ther. 2020 5 134 32728035 10.1038/s41392-020-00256-x PMC7388484

580. Grupp SA Chimeric antigen receptor-modified T cells for acute lymphoid leukemia N. Engl. J. Med. 2013 368 1509 1518 23527958 10.1056/NEJMoa1215134 PMC4058440

581. Maude SL Chimeric antigen receptor T cells for sustained remissions in leukemia N. Engl. J. Med. 2014 371 1507 1517 25317870 10.1056/NEJMoa1407222 PMC4267531

582. Le RQ FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome Oncologist 2018 23 943 947 29622697 10.1634/theoncologist.2018-0028 PMC6156173

583. Chen H Management of cytokine release syndrome related to CAR-T cell therapy Front. Med. 2019 13 610 617 31571160 10.1007/s11684-019-0714-8

584. Neelapu SS Chimeric antigen receptor T-cell therapy - assessment and management of toxicities Nat. Rev. Clin. Oncol. 2018 15 47 62 28925994 10.1038/nrclinonc.2017.148 PMC6733403

585. Gust J Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells Cancer Discov. 2017 7 1404 1419 29025771 10.1158/2159-8290.CD-17-0698 PMC5718945

586. Taraseviciute A Chimeric antigen receptor T cell-mediated neurotoxicity in nonhuman primates Cancer Discov. 2018 8 750 763 29563103 10.1158/2159-8290.CD-17-1368 PMC6058704

587. Lee DW ASTCT consensus grading for cytokine release syndrome and nurologic toxicity associated with immune efector clls Biol. Blood Marrow Transpl. 2019 25 625 638 10.1016/j.bbmt.2018.12.758 PMC12180426 30592986

588. Santomasso BD Gust J Perna F How I treat unique and difficult to manage cases of CAR T-cell therapy associated neurotoxicity Blood 2023 141 2443 2451 36877916 10.1182/blood.2022017604 PMC10329188

589. Major A Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature Leuk. Lymphoma 2021 62 1765 1769 33559517 10.1080/10428194.2021.1881507 PMC8282706

590. Schram AM Berliner N How I treat hemophagocytic lymphohistiocytosis in the adult patient Blood 2015 125 2908 2914 25758828 10.1182/blood-2015-01-551622

591. Sandler RD Diagnosis and management of secondary HLH/MAS following HSCT and CAR-T cell therapy in adults; a review of the literature and a survey of practice within EBMT centres on behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP) Front. Immunol. 2020 11 524 32296434 10.3389/fimmu.2020.00524 PMC7137396

592. Doan, A. & Pulsipher, M. A. Hypogammaglobulinemia due to CAR T-cell therapy. Pediatr. Blood Cancer 10.1002/pbc.26914 (2018). 10.1002/pbc.26914 PMC7477537 29230962

593. Wat J Barmettler S Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions J. Allergy Clin. Immunol. Pract. 2022 10 460 466 34757064 10.1016/j.jaip.2021.10.037 PMC8837681

594. Garcia-Lloret M McGhee S Chatila TA Immunoglobulin replacement therapy in children Immunol. Allergy Clin. North Am. 2008 28 833 849 18940577 10.1016/j.iac.2008.07.001 PMC2585601

595. Radinsky S Bonagura VR Subcutaneous immunoglobulin infusion as an alternative to intravenous immunoglobulin J. Allergy Clin. Immunol. 2003 112 630 633 13679829 10.1016/s0091-6749(03)01781-0

596. Rejeski K CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma Blood 2021 138 2499 2513 34166502 10.1182/blood.2020010543 PMC8893508

597. Jain, T., Olson, T. S., Locke, F. L. How I treat cytopenias after CAR T-cell therapy. Blood 141 , 2460–2469 (2023). 10.1182/blood.2022017415 PMC10646792 36800563

598. Du M Case report: ITP treatment after CAR-T cell therapy in patients with multiple myeloma Front. Immunol. 2022 13 898341 35784357 10.3389/fimmu.2022.898341 PMC9244693

599. Fried S Early and late hematologic toxicity following CD19 CAR-T cells Bone Marrow Transpl. 2019 54 1643 1650 10.1038/s41409-019-0487-3 30809033

600. Nahas GR Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT) Leuk. Lymphoma 2020 61 940 943 31793821 10.1080/10428194.2019.1697814

601. Jain T Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies Blood Adv. 2020 4 3776 3787 32780846 10.1182/bloodadvances.2020002509 PMC7422135

602. Baur R Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report J. Immunother. Cancer 2021 9 e002721 34272307 10.1136/jitc-2021-002721 PMC8287610

603. Buechner J Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy Blood Adv. 2021 5 593 601 33496754 10.1182/bloodadvances.2020002757 PMC7839371

604. Gudiol C Lewis RE Strati P Kontoyiannis DP Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection? Lancet Haematol. 2021 8 e216 e228 33460558 10.1016/S2352-3026(20)30376-8

605. Wang Y Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium J. Clin. Oncol. 2023 41 2594 2606 36753699 10.1200/JCO.22.01797 PMC10489553

606. Hill JA Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy Blood 2018 131 121 130 29038338 10.1182/blood-2017-07-793760 PMC5755046

607. Gill S Brudno JN CAR T-cell therapy in hematologic malignancies: clinical role, toxicity, and unanswered questions Am. Soc. Clin. Oncol. Educ. Book 2021 41 1 20 33989023 10.1200/EDBK_320085

608. Shi M Safety and efficacy of a humanized CD19 chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia Am. J. Hematol. 2022 97 711 718 35179242 10.1002/ajh.26506

609. Holland EM Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation J. Immunother. Cancer 2022 10 e004483 35534047 10.1136/jitc-2021-004483 PMC9086629

610. Lamers CH Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells Blood 2011 117 72 82 20889925 10.1182/blood-2010-07-294520

611. Xu J Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma Proc. Natl Acad. Sci. USA 2019 116 9543 9551 30988175 10.1073/pnas.1819745116 PMC6510991

612. Wagner DL Immunogenicity of CAR T cells in cancer therapy Nat. Rev. Clin. Oncol. 2021 18 379 393 33633361 10.1038/s41571-021-00476-2 PMC8923136

613. Herrmann M Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia Blood 2018 132 2484 2494 30275109 10.1182/blood-2018-05-849802

614. Correnti CE Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation Leukemia 2018 32 1239 1243 29588544 10.1038/s41375-018-0014-3 PMC5943151

615. Li X Decitabine priming increases anti-PD-1 antitumor efficacy by promoting CD8+ progenitor exhausted T cell expansion in tumor models J. Clin. Invest. 2023 133 e165673 36853831 10.1172/JCI165673 PMC10065084

616. Wang Y Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming Nat. Commun. 2021 12 409 33462245 10.1038/s41467-020-20696-x PMC7814040

617. Xu Y Epi-immunotherapy for cancers: rationales of epi-drugs in combination with immunotherapy and advances in clinical trials Cancer Commun. 2022 42 493 516 10.1002/cac2.12313 PMC9198339 35642676

618. Short NJ Kantarjian H Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past Lancet Haematol. 2023 10 e382 e388 37003279 10.1016/S2352-3026(23)00064-9

619. Yang J Advancing CAR T cell therapy through the use of multidimensional omics data Nat. Rev. Clin. Oncol. 2023 20 211 228 36721024 10.1038/s41571-023-00729-2 PMC11734589

620. Svensson V Vento-Tormo R Teichmann SA Exponential scaling of single-cell RNA-seq in the past decade Nat. Protoc. 2018 13 599 604 29494575 10.1038/nprot.2017.149

621. Stubbington MJT Rozenblatt-Rosen O Regev A Teichmann SA Single-cell transcriptomics to explore the immune system in health and disease Science 2017 358 58 63 28983043 10.1126/science.aan6828 PMC5654495

622. Horns F Dekker CL Quake SR Memory B cell activation, broad anti-influenza antibodies, and bystander activation revealed by single-cell transcriptomics Cell Rep. 2020 30 905 913.e906 31968262 10.1016/j.celrep.2019.12.063 PMC7891556

623. Bode D Cull AH Rubio-Lara JA Kent DG Exploiting single-cell tools in gene and cell therapy Front. Immunol. 2021 12 702636 34322133 10.3389/fimmu.2021.702636 PMC8312222

624. Castellanos-Rueda R Di Roberto RB Schlatter FS Reddy ST Leveraging single-cell sequencing for chimeric antigen receptor T cell therapies Trends Biotechnol. 2021 39 1308 1320 33832782 10.1016/j.tibtech.2021.03.005

625. Tracy SI Combining nilotinib and PD-L1 blockade reverses CD4+ T-cell dysfunction and prevents relapse in acute B-cell leukemia Blood 2022 140 335 348 35275990 10.1182/blood.2021015341 PMC9335501

626. Jiang P Single-cell ATAC-seq maps the comprehensive and dynamic chromatin accessibility landscape of CAR-T cell dysfunction Leukemia 2022 36 2656 2668 35962059 10.1038/s41375-022-01676-0

627. Charitidis FT Monitoring CAR T cell generation with a CD8-targeted lentiviral vector by single-cell transcriptomics Mol. Ther. Methods Clin. Dev. 2022 24 207 209 35141349 10.1016/j.omtm.2022.01.010 PMC8800011

628. Bai Z Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells J. Immunother. Cancer 2021 9 e002328 34006631 10.1136/jitc-2020-002328 PMC8137188

629. Yan C Single-cell imaging of T cell immunotherapy responses in vivo J. Exp. Med. 2021 218 e20210314 34415995 10.1084/jem.20210314 PMC8383813

630. Cazaux M Single-cell imaging of CAR T cell activity in vivo reveals extensive functional and anatomical heterogeneity J. Exp. Med. 2019 216 1038 1049 30936262 10.1084/jem.20182375 PMC6504219

631. Tian M An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma J. Clin. Invest. 2022 132 e155621 35852863 10.1172/JCI155621 PMC9374382

632. Pfeifer R A multimodal imaging workflow for monitoring CAR T cell therapy against solid tumor from whole-body to single-cell level Theranostics 2022 12 4834 4850 35836798 10.7150/thno.68966 PMC9274742